Origil raw file me,Converted file me,Re-annotated raw file me (userme_date_PI_Country_sampletag),NumReplicates,Organism,In Vivo or In vitro Process,Tissue type,Cell type,Culture conditions,Disease state,Comments,MHC class I or II,MHC Allele,PMID,SYSMHCID,Peptide,isolation method,antibody,"sample amount (cell number, weight of tissue)",fraction of sample measured,mass spectrometer,LC system,iRT peptides ,Acquisition mode,Fragmentation method,Gradient ,Gradient lenght (min),Flow rate,Column,Statiory Phase,Gradient details
SYSMHC00001_C1R1_Mosh_RS_20141103_B2702_IDA.wiff,SYSMHC00001_C1R1_Mosh_RS_20141103_B2702_IDA.mzXML,SYSMHC00001_schittenhelmr_160207_Purcell_Australia_C1R,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"B27,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_C1R1_Mosh_RS_20141103_B2703_IDA.wiff,SYSMHC00001_C1R1_Mosh_RS_20141103_B2703_IDA.mzXML,SYSMHC00001_schittenhelmr_160207_Purcell_Australia_C1R,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"B27,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_C1R1_Mosh_RS_20141103_B2704_IDA.wiff,SYSMHC00001_C1R1_Mosh_RS_20141103_B2704_IDA.mzXML,SYSMHC00001_schittenhelmr_160207_Purcell_Australia_C1R,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"B27,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_C1R1_Mosh_RS_20141103_B2705_IDA.wiff,SYSMHC00001_C1R1_Mosh_RS_20141103_B2705_IDA.mzXML,SYSMHC00001_schittenhelmr_160207_Purcell_Australia_C1R,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"B27,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_C1R1_Mosh_RS_20141103_B2706_IDA.wiff,SYSMHC00001_C1R1_Mosh_RS_20141103_B2706_IDA.mzXML,SYSMHC00001_schittenhelmr_160207_Purcell_Australia_C1R,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"B27,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_C1R1_Mosh_RS_20141103_B2707_IDA.wiff,SYSMHC00001_C1R1_Mosh_RS_20141103_B2707_IDA.mzXML,SYSMHC00001_schittenhelmr_160207_Purcell_Australia_C1R,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"B27,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_C1R1_Mosh_RS_20141103_B2708_IDA.wiff,SYSMHC00001_C1R1_Mosh_RS_20141103_B2708_IDA.mzXML,SYSMHC00001_schittenhelmr_160207_Purcell_Australia_C1R,7,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"B27,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_C1R1_Mosh_RS_20141103_B2709_IDA.wiff,SYSMHC00001_C1R1_Mosh_RS_20141103_B2709_IDA.mzXML,SYSMHC00001_schittenhelmr_160207_Purcell_Australia_C1R,8,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"B27,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_C1R2_Mosh_RS_20150125_B2705_IDA_1.wiff,SYSMHC00001_C1R2_Mosh_RS_20150125_B2705_IDA_1.mzXML,SYSMHC00001_schittenhelmr_160207_Purcell_Australia_C1R,9,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"B27,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,,2-32% ACN,120,,,,
SYSMHC00001_C1R2_Mosh_RS_20150128_B2705_IDA_1.wiff,SYSMHC00001_C1R2_Mosh_RS_20150128_B2705_IDA_1.mzXML,SYSMHC00001_schittenhelmr_160207_Purcell_Australia_C1R,10,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"B27,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,,2-32% ACN,120,,,,
SYSMHC00001_C1R3_Madrid_B3901_iRT_rep1.wiff,SYSMHC00001_C1R3_Madrid_B3901_iRT_rep1.mzXML,SYSMHC00001_marcillam_160207_marcilla_Spain_C1R_B39,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"B39,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,,2-32% ACN,120,,,,
SYSMHC00001_C1R3_Madrid_B3901_iRT_rep2.wiff,SYSMHC00001_C1R3_Madrid_B3901_iRT_rep2.mzXML,SYSMHC00001_marcillam_160207_marcilla_Spain_C1R_B39,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"B39,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,,2-32% ACN,120,,,,
SYSMHC00001_C1R4_Madrid_B4002_iRT_rep1.wiff,SYSMHC00001_C1R4_Madrid_B4002_iRT_rep1.mzXML,SYSMHC00001_marcillam_160207_marcilla_Spain_C1R_B40,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"B40,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,,2-32% ACN,120,,,,
SYSMHC00001_C1R4_Madrid_B4002_iRT_rep2.wiff,SYSMHC00001_C1R4_Madrid_B4002_iRT_rep2.mzXML,SYSMHC00001_marcillam_160207_marcilla_Spain_C1R_B40,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"B40,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,,2-32% ACN,120,,,,
SYSMHC00001_Jurkat_Oxford_TT0236a_DDA_MHC-I_Jurkat_iRT.wiff,SYSMHC00001_Jurkat_Oxford_TT0236a_DDA_MHC-I_Jurkat_iRT.mzXML,SYSMHC00001_ternetten_160207_Ternette_UK_Jurkat,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A03,B07,B35",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,Ultimate3000 RSLCno,yes,DDA,,2-32% ACN,120,,,,
SYSMHC00001_JY_EBV1_Tubingen_120706_AR_CoOpNO_JY_Normal_W_10_Rep1_msms14.RAW,SYSMHC00001_JY_EBV1_Tubingen_120706_AR_CoOpNO_JY_Normal_W_10_Rep1_msms14_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_JY,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A02,B07,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_JY_EBV1_Tubingen_120706_AR_CoOpNO_JY_Normal_W_10_Rep2_msms15.RAW,SYSMHC00001_JY_EBV1_Tubingen_120706_AR_CoOpNO_JY_Normal_W_10_Rep2_msms15_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_JY,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A02,B07,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_JY_EBV1_Tubingen_120706_AR_CoOpNO_JY_Normal_W_10_Rep3_msms16.RAW,SYSMHC00001_JY_EBV1_Tubingen_120706_AR_CoOpNO_JY_Normal_W_10_Rep3_msms16_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_JY,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A02,B07,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_JY_EBV1_Tubingen_120706_AR_CoOpNO_JY_Normal_W_10_Rep4_msms17.RAW,SYSMHC00001_JY_EBV1_Tubingen_120706_AR_CoOpNO_JY_Normal_W_10_Rep4_msms17_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_JY,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A02,B07,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_JY_EBV1_Tubingen_120706_AR_CoOpNO_JY_Normal_W_10_Rep5_msms18.RAW,SYSMHC00001_JY_EBV1_Tubingen_120706_AR_CoOpNO_JY_Normal_W_10_Rep5_msms18_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_JY,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A02,B07,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_JY_EBV2_Zurich_carone_L130209_001.wiff,SYSMHC00001_JY_EBV2_Zurich_carone_L130209_001.mzXML,SYSMHC00001_carone_160207_Aebersold_Switzerland_JY,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A02,B07,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,,2-32% ACN,120,,,,
SYSMHC00001_JY_EBV2_Zurich_carone_L130326_001_pMHC_1ug.wiff,SYSMHC00001_JY_EBV2_Zurich_carone_L130326_001_pMHC_1ug.mzXML,SYSMHC00001_carone_160207_Aebersold_Switzerland_JY,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A02,B07,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,,2-32% ACN,120,,,,
SYSMHC00001_JY_EBV2_Zurich_carone_L130326_003_pMHC_1-5ug.wiff,SYSMHC00001_JY_EBV2_Zurich_carone_L130326_003_pMHC_1-5ug.mzXML,SYSMHC00001_carone_160207_Aebersold_Switzerland_JY,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A02,B07,C07",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_001.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_001.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_1,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_002.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_002.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_2,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_003.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_003.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_3,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_004.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_004.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_4,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_005.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_005.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_5,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_006.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_006.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_6,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_007.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_007.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_7,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_008.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_008.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_8,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_009.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_009.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_9,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_010.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_010.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_10,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_011.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_011.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_11,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_012.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_012.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_12,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_013.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_013.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_13,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_014.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_014.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_14,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_015.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_015.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_15,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_016.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_016.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_16,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_017.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_017.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_17,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_018.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_018.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_18,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_019.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_019.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_19,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_020.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_020.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_20,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_021.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_021.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_21,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_022.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_022.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_22,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb1_LaJolla_carone_L130911_023.wiff,SYSMHC00001_Mtb1_LaJolla_carone_L130911_023.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_23,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_238.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_238_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_238,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_241.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_241_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_241,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_244.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_244_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_244,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_247.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_247_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_247,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_250.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_250_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_250,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_253.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_253_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_253,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_256.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_256_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_256,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_259.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_259_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_259,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_262.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_262_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_262,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_265.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_265_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_265,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_268.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_268_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_268,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_271.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_271_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_271,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_274.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_274_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_274,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_277.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_277_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_277,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_280.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_280_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_280,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_283.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_283_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_283,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_286.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_286_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_286,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_289.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_289_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_289,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_292.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_292_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_292,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_295.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_295_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_295,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_298.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_298_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_298,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_301.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_301_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_301,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb2_LaJolla_carone_C1309_304.raw,SYSMHC00001_Mtb2_LaJolla_carone_C1309_304_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_304,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_239.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_239_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_239,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_242.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_242_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_242,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_245.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_245_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_245,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_248.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_248_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_248,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_251.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_251_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_251,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_254.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_254_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_254,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_257.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_257_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_257,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_260.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_260_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_260,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_263.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_263_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_263,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_266.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_266_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_266,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_269.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_269_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_269,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_272.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_272_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_272,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_275.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_275_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_275,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_278.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_278_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_278,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_281.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_281_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_281,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_284.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_284_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_284,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_287.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_287_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_287,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_290.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_290_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_290,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_293.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_293_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_293,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_296.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_296_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_296,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_299.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_299_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_299,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_302.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_302_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_302,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_Mtb3_LaJolla_carone_C1309_305.raw,SYSMHC00001_Mtb3_LaJolla_carone_C1309_305_c.mzXML,SYSMHC00001_carone_161024_aebersold_switzerland_Mtb_305,1,Mycobacterium tuberculosis,,,,,,predicted to bind class II,class II,"DR,DP,DQ",26154972,SYSMHC00001,synthetic,,,,,Orbitrap ELITE,EASY-nLC 1000,yes,DDA,HCD,2-32% ACN,120,,,,
SYSMHC00001_PBMC1_Tubingen_120724_CB_Buffy18_W_20_Rep1_msms1.RAW,SYSMHC00001_PBMC1_Tubingen_120724_CB_Buffy18_W_20_Rep1_msms1_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy18,1,Human,In vivo,Blood,PBMC,,,,class I,"A03,A24,B07,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC1_Tubingen_120724_CB_Buffy18_W_20_Rep2_msms2.RAW,SYSMHC00001_PBMC1_Tubingen_120724_CB_Buffy18_W_20_Rep2_msms2_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy18,2,Human,In vivo,Blood,PBMC,,,,class I,"A03,A24,B07,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC1_Tubingen_120724_CB_Buffy18_W_20_Rep3_msms3.RAW,SYSMHC00001_PBMC1_Tubingen_120724_CB_Buffy18_W_20_Rep3_msms3_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy18,3,Human,In vivo,Blood,PBMC,,,,class I,"A03,A24,B07,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC1_Tubingen_120724_CB_Buffy18_W_20_Rep4_msms4.RAW,SYSMHC00001_PBMC1_Tubingen_120724_CB_Buffy18_W_20_Rep4_msms4_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy18,4,Human,In vivo,Blood,PBMC,,,,class I,"A03,A24,B07,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC1_Tubingen_120724_CB_Buffy18_W_20_Rep5_msms5.RAW,SYSMHC00001_PBMC1_Tubingen_120724_CB_Buffy18_W_20_Rep5_msms5_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy18,5,Human,In vivo,Blood,PBMC,,,,class I,"A03,A24,B07,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC10_Tubingen_130429_SKUG_Buffy83_W_1p25ug_20_50umx15cmColumn_60min3sDynExcl_3_msms4.RAW,SYSMHC00001_PBMC10_Tubingen_130429_SKUG_Buffy83_W_1p25ug_20_50umx15cmColumn_60min3sDynExcl_3_msms4_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy83,1,Human,In vivo,Blood,PBMC,,,,class I,"A03,A25,B44,B57",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC10_Tubingen_130430_SKUG_Buffy83_W_1p25ug_20_15cm60min3sDynExcl_4_msms27.RAW,SYSMHC00001_PBMC10_Tubingen_130430_SKUG_Buffy83_W_1p25ug_20_15cm60min3sDynExcl_4_msms27_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy83,2,Human,In vivo,Blood,PBMC,,,,class I,"A03,A25,B44,B57",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC11_Tubingen_130510_SKUG_Buffy85_W_2p00ug_20_Rep_1_msms6.RAW,SYSMHC00001_PBMC11_Tubingen_130510_SKUG_Buffy85_W_2p00ug_20_Rep_1_msms6_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy85,1,Human,In vivo,Blood,PBMC,,,,class I,"A11,A30,B08,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC11_Tubingen_130510_SKUG_Buffy85_W_2p00ug_20_Rep_2_msms7.RAW,SYSMHC00001_PBMC11_Tubingen_130510_SKUG_Buffy85_W_2p00ug_20_Rep_2_msms7_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy85,2,Human,In vivo,Blood,PBMC,,,,class I,"A11,A30,B08,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC11_Tubingen_130510_SKUG_Buffy85_W_2p00ug_20_Rep_3_msms8.RAW,SYSMHC00001_PBMC11_Tubingen_130510_SKUG_Buffy85_W_2p00ug_20_Rep_3_msms8_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy85,3,Human,In vivo,Blood,PBMC,,,,class I,"A11,A30,B08,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC11_Tubingen_130510_SKUG_Buffy85_W_2p00ug_20_Rep_4_msms9.RAW,SYSMHC00001_PBMC11_Tubingen_130510_SKUG_Buffy85_W_2p00ug_20_Rep_4_msms9_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy85,4,Human,In vivo,Blood,PBMC,,,,class I,"A11,A30,B08,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC11_Tubingen_130510_SKUG_Buffy85_W_2p00ug_20_Rep_5_msms10.RAW,SYSMHC00001_PBMC11_Tubingen_130510_SKUG_Buffy85_W_2p00ug_20_Rep_5_msms10_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy85,5,Human,In vivo,Blood,PBMC,,,,class I,"A11,A30,B08,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC12_Tubingen_130426_SKUG_Buffy89_W_1p75ug_20_Rep_1_msms8.RAW,SYSMHC00001_PBMC12_Tubingen_130426_SKUG_Buffy89_W_1p75ug_20_Rep_1_msms8_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy89,1,Human,In vivo,Blood,PBMC,,,,class I,"A01,A23,B08,B44",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC12_Tubingen_130426_SKUG_Buffy89_W_1p75ug_20_Rep_2_msms9.RAW,SYSMHC00001_PBMC12_Tubingen_130426_SKUG_Buffy89_W_1p75ug_20_Rep_2_msms9_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy89,2,Human,In vivo,Blood,PBMC,,,,class I,"A01,A23,B08,B44",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC12_Tubingen_130430_SKUG_Buffy89_W_1p75ug_20_15cm60min3sDynExcl_4_msms25.RAW,SYSMHC00001_PBMC12_Tubingen_130430_SKUG_Buffy89_W_1p75ug_20_15cm60min3sDynExcl_4_msms25_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy89,3,Human,In vivo,Blood,PBMC,,,,class I,"A01,A23,B08,B44",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC13_Tubingen_130314_CB_Buffy54_W_20_Rep_1_msms7.RAW,SYSMHC00001_PBMC13_Tubingen_130314_CB_Buffy54_W_20_Rep_1_msms7_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy54,1,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B35",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC13_Tubingen_130314_CB_Buffy54_W_20_Rep_2_msms8.RAW,SYSMHC00001_PBMC13_Tubingen_130314_CB_Buffy54_W_20_Rep_2_msms8_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy54,2,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B35",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC13_Tubingen_130314_CB_Buffy54_W_20_Rep_3_msms9.RAW,SYSMHC00001_PBMC13_Tubingen_130314_CB_Buffy54_W_20_Rep_3_msms9_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy54,3,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B35",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC13_Tubingen_130314_CB_Buffy54_W_20_Rep_4_msms10.RAW,SYSMHC00001_PBMC13_Tubingen_130314_CB_Buffy54_W_20_Rep_4_msms10_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy54,4,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B35",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC13_Tubingen_130314_CB_Buffy54_W_20_Rep_5_msms11.RAW,SYSMHC00001_PBMC13_Tubingen_130314_CB_Buffy54_W_20_Rep_5_msms11_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy54,5,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B35",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC14_Tubingen_130513_SKUG_Buffy94_W_XpXXg_20_Rep_1_msms26.RAW,SYSMHC00001_PBMC14_Tubingen_130513_SKUG_Buffy94_W_XpXXg_20_Rep_1_msms26_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy94,1,Human,In vivo,Blood,PBMC,,,,class I,"A02,B44,B57",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC14_Tubingen_130513_SKUG_Buffy94_W_XpXXg_20_Rep_2_msms27.RAW,SYSMHC00001_PBMC14_Tubingen_130513_SKUG_Buffy94_W_XpXXg_20_Rep_2_msms27_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy94,2,Human,In vivo,Blood,PBMC,,,,class I,"A02,B44,B57",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC14_Tubingen_130513_SKUG_Buffy94_W_XpXXg_20_Rep_3_msms28.RAW,SYSMHC00001_PBMC14_Tubingen_130513_SKUG_Buffy94_W_XpXXg_20_Rep_3_msms28_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy94,3,Human,In vivo,Blood,PBMC,,,,class I,"A02,B44,B57",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC14_Tubingen_130513_SKUG_Buffy94_W_XpXXg_20_Rep_4_msms29.RAW,SYSMHC00001_PBMC14_Tubingen_130513_SKUG_Buffy94_W_XpXXg_20_Rep_4_msms29_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy94,4,Human,In vivo,Blood,PBMC,,,,class I,"A02,B44,B57",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC14_Tubingen_130513_SKUG_Buffy94_W_XpXXg_20_Rep_5_msms30.RAW,SYSMHC00001_PBMC14_Tubingen_130513_SKUG_Buffy94_W_XpXXg_20_Rep_5_msms30_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy94,5,Human,In vivo,Blood,PBMC,,,,class I,"A02,B44,B57",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC15_Zurich_carone_J130709_001.wiff,SYSMHC00001_PBMC15_Zurich_carone_J130709_001.mzXML,SYSMHC00001_carone_160207_Aebersold_Switzerland_PBMC,1,Human,In vivo,Blood,PBMC,,,,class I,"A03,A26,B51,B57",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC2_Tubingen_120720_CB_Buffy19_W_20_Rep1_msms1.RAW,SYSMHC00001_PBMC2_Tubingen_120720_CB_Buffy19_W_20_Rep1_msms1_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy19,1,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B35,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC2_Tubingen_120720_CB_Buffy19_W_20_Rep2_msms2.RAW,SYSMHC00001_PBMC2_Tubingen_120720_CB_Buffy19_W_20_Rep2_msms2_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy19,2,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B35,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC2_Tubingen_120720_CB_Buffy19_W_20_Rep3_msms3.RAW,SYSMHC00001_PBMC2_Tubingen_120720_CB_Buffy19_W_20_Rep3_msms3_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy19,3,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B35,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC2_Tubingen_120720_CB_Buffy19_W_20_Rep4_msms4.RAW,SYSMHC00001_PBMC2_Tubingen_120720_CB_Buffy19_W_20_Rep4_msms4_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy19,4,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B35,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC2_Tubingen_120720_CB_Buffy19_W_20_Rep5_msms5.RAW,SYSMHC00001_PBMC2_Tubingen_120720_CB_Buffy19_W_20_Rep5_msms5_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy19,5,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B35,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC3_Tubingen_120712_CB_Buffy21_W_ReZipTipped_20_Rep_1_msms1.RAW,SYSMHC00001_PBMC3_Tubingen_120712_CB_Buffy21_W_ReZipTipped_20_Rep_1_msms1_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy21,1,Human,In vivo,Blood,PBMC,,,,class I,"A01,A32,B08,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC3_Tubingen_120712_CB_Buffy21_W_ReZipTipped_20_Rep_2_msms3.RAW,SYSMHC00001_PBMC3_Tubingen_120712_CB_Buffy21_W_ReZipTipped_20_Rep_2_msms3_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy21,2,Human,In vivo,Blood,PBMC,,,,class I,"A01,A32,B08,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC3_Tubingen_120712_CB_Buffy21_W_ReZipTipped_20_Rep_3_msms4.RAW,SYSMHC00001_PBMC3_Tubingen_120712_CB_Buffy21_W_ReZipTipped_20_Rep_3_msms4_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy21,3,Human,In vivo,Blood,PBMC,,,,class I,"A01,A32,B08,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC3_Tubingen_120712_CB_Buffy21_W_ReZipTipped_20_Rep_4_msms5.RAW,SYSMHC00001_PBMC3_Tubingen_120712_CB_Buffy21_W_ReZipTipped_20_Rep_4_msms5_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy21,4,Human,In vivo,Blood,PBMC,,,,class I,"A01,A32,B08,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC3_Tubingen_120713_CB_Buffy21_W_ReZipTipped_20_Rep_5_msms2.RAW,SYSMHC00001_PBMC3_Tubingen_120713_CB_Buffy21_W_ReZipTipped_20_Rep_5_msms2_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy21,5,Human,In vivo,Blood,PBMC,,,,class I,"A01,A32,B08,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC4_Tubingen_120827_CB_Buffy29_W_20_Rep_1_msms1.RAW,SYSMHC00001_PBMC4_Tubingen_120827_CB_Buffy29_W_20_Rep_1_msms1_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy29,1,Human,In vivo,Blood,PBMC,,,,class I,"A03,A29,B44,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC4_Tubingen_120827_CB_Buffy29_W_20_Rep_2_msms2.RAW,SYSMHC00001_PBMC4_Tubingen_120827_CB_Buffy29_W_20_Rep_2_msms2_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy29,2,Human,In vivo,Blood,PBMC,,,,class I,"A03,A29,B44,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC4_Tubingen_120827_CB_Buffy29_W_20_Rep_3_msms3.RAW,SYSMHC00001_PBMC4_Tubingen_120827_CB_Buffy29_W_20_Rep_3_msms3_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy29,3,Human,In vivo,Blood,PBMC,,,,class I,"A03,A29,B44,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC4_Tubingen_120827_CB_Buffy29_W_20_Rep_4_msms4.RAW,SYSMHC00001_PBMC4_Tubingen_120827_CB_Buffy29_W_20_Rep_4_msms4_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy29,4,Human,In vivo,Blood,PBMC,,,,class I,"A03,A29,B44,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC4_Tubingen_120827_CB_Buffy29_W_20_Rep_5_msms5.RAW,SYSMHC00001_PBMC4_Tubingen_120827_CB_Buffy29_W_20_Rep_5_msms5_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy29,5,Human,In vivo,Blood,PBMC,,,,class I,"A03,A29,B44,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC5_Tubingen_120830_CB_Buffy30_W_20_Rep_1_msms1.RAW,SYSMHC00001_PBMC5_Tubingen_120830_CB_Buffy30_W_20_Rep_1_msms1_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy30,1,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B07,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC5_Tubingen_120830_CB_Buffy30_W_20_Rep_2_msms2.RAW,SYSMHC00001_PBMC5_Tubingen_120830_CB_Buffy30_W_20_Rep_2_msms2_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy30,2,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B07,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC5_Tubingen_120830_CB_Buffy30_W_20_Rep_3_msms3.RAW,SYSMHC00001_PBMC5_Tubingen_120830_CB_Buffy30_W_20_Rep_3_msms3_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy30,3,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B07,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC5_Tubingen_120903_CB_Buffy30_ReRun_W_20_Rep_4_msms2.RAW,SYSMHC00001_PBMC5_Tubingen_120903_CB_Buffy30_ReRun_W_20_Rep_4_msms2_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy30,4,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B07,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC5_Tubingen_120903_CB_Buffy30_ReRun_W_20_Rep_5_msms3.RAW,SYSMHC00001_PBMC5_Tubingen_120903_CB_Buffy30_ReRun_W_20_Rep_5_msms3_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy30,5,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B07,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC6_Tubingen_120903_CB_Buffy32_W_20_Rep_1_msms4.RAW,SYSMHC00001_PBMC6_Tubingen_120903_CB_Buffy32_W_20_Rep_1_msms4_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy32,1,Human,In vivo,Blood,PBMC,,,,class I,"A01,A03,B07,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC6_Tubingen_120903_CB_Buffy32_W_20_Rep_2_msms5.RAW,SYSMHC00001_PBMC6_Tubingen_120903_CB_Buffy32_W_20_Rep_2_msms5_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy32,2,Human,In vivo,Blood,PBMC,,,,class I,"A01,A03,B07,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC6_Tubingen_120903_CB_Buffy32_W_20_Rep_3_msms6.RAW,SYSMHC00001_PBMC6_Tubingen_120903_CB_Buffy32_W_20_Rep_3_msms6_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy32,3,Human,In vivo,Blood,PBMC,,,,class I,"A01,A03,B07,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC6_Tubingen_120903_CB_Buffy32_W_20_Rep_4_msms7.RAW,SYSMHC00001_PBMC6_Tubingen_120903_CB_Buffy32_W_20_Rep_4_msms7_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy32,4,Human,In vivo,Blood,PBMC,,,,class I,"A01,A03,B07,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC6_Tubingen_120903_CB_Buffy32_W_20_Rep_5_msms8.RAW,SYSMHC00001_PBMC6_Tubingen_120903_CB_Buffy32_W_20_Rep_5_msms8_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy32,5,Human,In vivo,Blood,PBMC,,,,class I,"A01,A03,B07,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC7_Tubingen_120903_CB_Buffy33_W_20_Rep_1_msms10.RAW,SYSMHC00001_PBMC7_Tubingen_120903_CB_Buffy33_W_20_Rep_1_msms10_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy33,1,Human,In vivo,Blood,PBMC,,,,class I,"A02,A24,B35,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC7_Tubingen_120903_CB_Buffy33_W_20_Rep_2_msms11.RAW,SYSMHC00001_PBMC7_Tubingen_120903_CB_Buffy33_W_20_Rep_2_msms11_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy33,2,Human,In vivo,Blood,PBMC,,,,class I,"A02,A24,B35,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC7_Tubingen_120903_CB_Buffy33_W_20_Rep_3_msms12.RAW,SYSMHC00001_PBMC7_Tubingen_120903_CB_Buffy33_W_20_Rep_3_msms12_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy33,3,Human,In vivo,Blood,PBMC,,,,class I,"A02,A24,B35,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC7_Tubingen_120903_CB_Buffy33_W_20_Rep_4_msms13.RAW,SYSMHC00001_PBMC7_Tubingen_120903_CB_Buffy33_W_20_Rep_4_msms13_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy33,4,Human,In vivo,Blood,PBMC,,,,class I,"A02,A24,B35,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC7_Tubingen_120903_CB_Buffy33_W_20_Rep_5_msms14.RAW,SYSMHC00001_PBMC7_Tubingen_120903_CB_Buffy33_W_20_Rep_5_msms14_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy33,5,Human,In vivo,Blood,PBMC,,,,class I,"A02,A24,B35,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC8_Tubingen_120914_CB_Buffy34_W_20_Rep_1_msms1.RAW,SYSMHC00001_PBMC8_Tubingen_120914_CB_Buffy34_W_20_Rep_1_msms1_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy34,1,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B27,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC8_Tubingen_120914_CB_Buffy34_W_20_Rep_2_msms4.RAW,SYSMHC00001_PBMC8_Tubingen_120914_CB_Buffy34_W_20_Rep_2_msms4_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy34,2,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B27,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC8_Tubingen_120914_CB_Buffy34_W_20_Rep_3_msms5.RAW,SYSMHC00001_PBMC8_Tubingen_120914_CB_Buffy34_W_20_Rep_3_msms5_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy34,3,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B27,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC8_Tubingen_120914_CB_Buffy34_W_20_Rep_4_msms6.RAW,SYSMHC00001_PBMC8_Tubingen_120914_CB_Buffy34_W_20_Rep_4_msms6_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy34,4,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B27,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC8_Tubingen_120914_CB_Buffy34_W_20_Rep_5_msms7.RAW,SYSMHC00001_PBMC8_Tubingen_120914_CB_Buffy34_W_20_Rep_5_msms7_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy34,5,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B27,B39",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC9_Tubingen_130311_CB_Buffy48_W_20_Rep_1_msms2.RAW,SYSMHC00001_PBMC9_Tubingen_130311_CB_Buffy48_W_20_Rep_1_msms2_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy48,1,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B44,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC9_Tubingen_130311_CB_Buffy48_W_20_Rep_2_msms3.RAW,SYSMHC00001_PBMC9_Tubingen_130311_CB_Buffy48_W_20_Rep_2_msms3_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy48,2,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B44,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC9_Tubingen_130313_CB_Buffy48_W_20_Rep_3_msms3.RAW,SYSMHC00001_PBMC9_Tubingen_130313_CB_Buffy48_W_20_Rep_3_msms3_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy48,3,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B44,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00001_PBMC9_Tubingen_130313_CB_Buffy48_W_20_Rep_4_msms4.RAW,SYSMHC00001_PBMC9_Tubingen_130313_CB_Buffy48_W_20_Rep_4_msms4_c.mzXML,SYSMHC00001_Kowalewskid_160207_Rammensee_Germany_PBMC_Buffy48,4,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B44,B51",26154972,SYSMHC00001,native,Immunoaffinity,W6/32,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00002_carone_20150801_QEp7_MiBa_SA_iRT_BCG_1.raw,SYSMHC00002_carone_20150801_QEp7_MiBa_SA_iRT_BCG_1.mzXML,SYSMHC00002_bassanim_160330_Mann_Germany_THP1_BCG_001,1,Human,In vitro,Blood,THP1,adherent macrophage cell line,,infected with BCG ∆ureC::hly ∆nuoG,class I,"A0201,A2402,B1511,B3501,C0303",not published,SYSMHC00002,native,Immunoaffinity,W6/32,,25%,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",yes,DDA,,2-30% ACN,90,,,,
SYSMHC00002_carone_20150801_QEp7_MiBa_SA_iRT_BCG_2.raw,SYSMHC00002_carone_20150801_QEp7_MiBa_SA_iRT_BCG_2.mzXML,SYSMHC00002_bassanim_160330_Mann_Germany_THP1_BCG_002,2,Human,In vitro,Blood,THP1,adherent macrophage cell line,,infected with BCG ∆ureC::hly ∆nuoG,class I,"A0201,A2402,B1511,B3501,C0303",not published,SYSMHC00002,native,Immunoaffinity,W6/32,,25%,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",yes,DDA,,2-30% ACN,90,,,,
SYSMHC00002_carone_20150801_QEp7_MiBa_SA_iRT_THP_1.raw,SYSMHC00002_carone_20150801_QEp7_MiBa_SA_iRT_THP_1.mzXML,SYSMHC00002_bassanim_160330_Mann_Germany_THP1_001,1,Human,In vitro,Blood,THP1,adherent macrophage cell line,,uninfected,class I,"A0201,A2402,B1511,B3501,C0303",not published,SYSMHC00002,native,Immunoaffinity,W6/32,,25%,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",yes,DDA,,2-30% ACN,90,,,,
SYSMHC00002_carone_20150801_QEp7_MiBa_SA_iRT_THP_2.raw,SYSMHC00002_carone_20150801_QEp7_MiBa_SA_iRT_THP_2.mzXML,SYSMHC00002_bassanim_160330_Mann_Germany_THP1_002,2,Human,In vitro,Blood,THP1,adherent macrophage cell line,,uninfected,class I,"A0201,A2402,B1511,B3501,C0303",not published,SYSMHC00002,native,Immunoaffinity,W6/32,,25%,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",yes,DDA,,2-30% ACN,90,,,,
SYSMHC00002_carone_Y150824_001_THP1_DDA.wiff,SYSMHC00002_carone_Y150824_001_THP1_DDA.mzXML,SYSMHC00002_carone_160330_Aebersold_Switzerland_THP1_001,1,Human,In vitro,Blood,THP1,adherent macrophage cell line,,uninfected,class I,"A0201,A2402,B1511,B3501,C0303",not published,SYSMHC00002,native,Immunoaffinity,W6/32,,25%,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,,2-32% ACN,120,,,,
SYSMHC00002_carone_Y150824_001_THP1_rBCG_DDA.wiff,SYSMHC00002_carone_Y150824_001_THP1_rBCG_DDA.mzXML,SYSMHC00002_carone_160330_Aebersold_Switzerland_THP1_BCG_001,1,Human,In vitro,Blood,THP1,adherent macrophage cell line,,infected with BCG ∆ureC::hly ∆nuoG,class I,"A0201,A2402,B1511,B3501,C0303",not published,SYSMHC00002,native,Immunoaffinity,W6/32,,25%,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120410_CB_Buffy3_W_20of10ZTPool_1stReplicates_msms5.RAW,SYSMHC00003_120410_CB_Buffy3_W_20of10ZTPool_1stReplicates_msms5_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy03,1,Human,In vivo,Blood,PBMC,,,,class I,"A02,A28,B07,B38",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120412_CB_Buffy3_W_20of10ZTPool_2ndReplicate_msms15.RAW,SYSMHC00003_120412_CB_Buffy3_W_20of10ZTPool_2ndReplicate_msms15_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy03,2,Human,In vivo,Blood,PBMC,,,,class I,"A02,A28,B07,B38",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120412_CB_Buffy3_W_20of10ZTPool_3rdReplicate_msms16.RAW,SYSMHC00003_120412_CB_Buffy3_W_20of10ZTPool_3rdReplicate_msms16_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy03,3,Human,In vivo,Blood,PBMC,,,,class I,"A02,A28,B07,B38",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120412_CB_Buffy3_W_20of10ZTPool_4thReplicate_msms17.RAW,SYSMHC00003_120412_CB_Buffy3_W_20of10ZTPool_4thReplicate_msms17_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy03,4,Human,In vivo,Blood,PBMC,,,,class I,"A02,A28,B07,B38",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120412_CB_Buffy3_W_20of10ZTPool_5thReplicate_msms18.RAW,SYSMHC00003_120412_CB_Buffy3_W_20of10ZTPool_5thReplicate_msms18_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy03,5,Human,In vivo,Blood,PBMC,,,,class I,"A02,A28,B07,B38",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120718_CB_Buffy22_W_20_Rep_1_msms1.RAW,SYSMHC00003_120718_CB_Buffy22_W_20_Rep_1_msms1_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy22,1,Human,In vivo,Blood,PBMC,,,,class I,"A28,A32,B52,B71",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120718_CB_Buffy22_W_20_Rep_2_msms2.RAW,SYSMHC00003_120718_CB_Buffy22_W_20_Rep_2_msms2_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy22,2,Human,In vivo,Blood,PBMC,,,,class I,"A28,A32,B52,B71",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120718_CB_Buffy22_W_20_Rep_3_msms3.RAW,SYSMHC00003_120718_CB_Buffy22_W_20_Rep_3_msms3_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy22,3,Human,In vivo,Blood,PBMC,,,,class I,"A28,A32,B52,B71",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120718_CB_Buffy22_W_20_Rep_4_msms4.RAW,SYSMHC00003_120718_CB_Buffy22_W_20_Rep_4_msms4_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy22,4,Human,In vivo,Blood,PBMC,,,,class I,"A28,A32,B52,B71",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120718_CB_Buffy22_W_20_Rep_5_msms5.RAW,SYSMHC00003_120718_CB_Buffy22_W_20_Rep_5_msms5_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy22,5,Human,In vivo,Blood,PBMC,,,,class I,"A28,A32,B52,B71",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120720_CB_Buffy23_W_20_Rep_1_msms6.RAW,SYSMHC00003_120720_CB_Buffy23_W_20_Rep_1_msms6_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy23,1,Human,In vivo,Blood,PBMC,,,,class I,"A02,A32,B13,B60",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120720_CB_Buffy23_W_20_Rep_2_msms7.RAW,SYSMHC00003_120720_CB_Buffy23_W_20_Rep_2_msms7_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy23,2,Human,In vivo,Blood,PBMC,,,,class I,"A02,A32,B13,B60",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120720_CB_Buffy23_W_20_Rep_3_msms8.RAW,SYSMHC00003_120720_CB_Buffy23_W_20_Rep_3_msms8_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy23,3,Human,In vivo,Blood,PBMC,,,,class I,"A02,A32,B13,B60",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120720_CB_Buffy23_W_20_Rep_4_msms9.RAW,SYSMHC00003_120720_CB_Buffy23_W_20_Rep_4_msms9_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy23,4,Human,In vivo,Blood,PBMC,,,,class I,"A02,A32,B13,B60",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120720_CB_Buffy23_W_20_Rep_5_msms10.RAW,SYSMHC00003_120720_CB_Buffy23_W_20_Rep_5_msms10_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy23,5,Human,In vivo,Blood,PBMC,,,,class I,"A02,A32,B13,B60",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120831_CB_Buffy31_W_20_Rep_1_msms4.RAW,SYSMHC00003_120831_CB_Buffy31_W_20_Rep_1_msms4_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy31,1,Human,In vivo,Blood,PBMC,,,,class I,"A11,A31,B27,B52",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120831_CB_Buffy31_W_20_Rep_2_msms5.RAW,SYSMHC00003_120831_CB_Buffy31_W_20_Rep_2_msms5_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy31,2,Human,In vivo,Blood,PBMC,,,,class I,"A11,A31,B27,B52",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120831_CB_Buffy31_W_20_Rep_3_msms6.RAW,SYSMHC00003_120831_CB_Buffy31_W_20_Rep_3_msms6_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy31,3,Human,In vivo,Blood,PBMC,,,,class I,"A11,A31,B27,B52",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120831_CB_Buffy31_W_20_Rep_4_msms7.RAW,SYSMHC00003_120831_CB_Buffy31_W_20_Rep_4_msms7_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy31,4,Human,In vivo,Blood,PBMC,,,,class I,"A11,A31,B27,B52",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120903_CB_Buffy31_W_20_Rep_5_msms1.RAW,SYSMHC00003_120903_CB_Buffy31_W_20_Rep_5_msms1_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy31,5,Human,In vivo,Blood,PBMC,,,,class I,"A11,A31,B27,B52",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_120928_CBDKPraktis_Buffy40_W_20_Rep_1_msms18.RAW,SYSMHC00003_120928_CBDKPraktis_Buffy40_W_20_Rep_1_msms18_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy40,1,Human,In vivo,Blood,PBMC,,,,class I,"A02,A31,B27,B60",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_121002_CBDK_Buffy40_W_165minTweakedLP_msms3.RAW,SYSMHC00003_121002_CBDK_Buffy40_W_165minTweakedLP_msms3_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy40,2,Human,In vivo,Blood,PBMC,,,,class I,"A02,A31,B27,B60",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_121002_CBDK_Buffy40_W_180minTweakedLP_ReRun_msms4.RAW,SYSMHC00003_121002_CBDK_Buffy40_W_180minTweakedLP_ReRun_msms4_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy40,3,Human,In vivo,Blood,PBMC,,,,class I,"A02,A31,B27,B60",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_121002_CBDK_Buffy40_W_210minStandardSteeper_msms1.RAW,SYSMHC00003_121002_CBDK_Buffy40_W_210minStandardSteeper_msms1_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy40,4,Human,In vivo,Blood,PBMC,,,,class I,"A02,A31,B27,B60",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_121012_CB_Buffy46_W_20_195minLP5ulFlow6mins0Iso_msms3.RAW,SYSMHC00003_121012_CB_Buffy46_W_20_195minLP5ulFlow6mins0Iso_msms3_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy46,1,Human,In vivo,Blood,PBMC,,,,class I,"A24,A31,B27,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_121012_CB_Buffy46_W_20_210minLP2p5ulFlow9mins1Iso_msms2_121012174155.RAW,SYSMHC00003_121012_CB_Buffy46_W_20_210minLP2p5ulFlow9mins1Iso_msms2_121012174155_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy46,2,Human,In vivo,Blood,PBMC,,,,class I,"A24,A31,B27,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_121012_CB_Buffy46_W_20_210minStandard_msms1.RAW,SYSMHC00003_121012_CB_Buffy46_W_20_210minStandard_msms1_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy46,3,Human,In vivo,Blood,PBMC,,,,class I,"A24,A31,B27,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_121212_DK_Buffy61_W_20_Rep_1_msms2.RAW,SYSMHC00003_121212_DK_Buffy61_W_20_Rep_1_msms2_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy61,1,Human,In vivo,Blood,PBMC,,,,class I,"A01,A28,B08,B38",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_121219_DK_Buffy61_W_20_Rep_2_msms15.RAW,SYSMHC00003_121219_DK_Buffy61_W_20_Rep_2_msms15_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy61,2,Human,In vivo,Blood,PBMC,,,,class I,"A01,A28,B08,B38",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_121221_DK_Buffy61_W_60_msms2.RAW,SYSMHC00003_121221_DK_Buffy61_W_60_msms2_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy61,3,Human,In vivo,Blood,PBMC,,,,class I,"A01,A28,B08,B38",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130201_CB_Buffy45_W_20_Rep_1_msms5.RAW,SYSMHC00003_130201_CB_Buffy45_W_20_Rep_1_msms5_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy45,1,Human,In vivo,Blood,PBMC,,,,class I,"A03,A68,B49,B51",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130201_CB_Buffy45_W_20_Rep_2_msms6.RAW,SYSMHC00003_130201_CB_Buffy45_W_20_Rep_2_msms6_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy45,2,Human,In vivo,Blood,PBMC,,,,class I,"A03,A68,B49,B51",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130201_CB_Buffy45_W_20_Rep_3_msms7.RAW,SYSMHC00003_130201_CB_Buffy45_W_20_Rep_3_msms7_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy45,3,Human,In vivo,Blood,PBMC,,,,class I,"A03,A68,B49,B51",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130201_CB_Buffy45_W_20_Rep_4_msms8.RAW,SYSMHC00003_130201_CB_Buffy45_W_20_Rep_4_msms8_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy45,4,Human,In vivo,Blood,PBMC,,,,class I,"A03,A68,B49,B51",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130201_CB_Buffy45_W_20_Rep_5_msms9.RAW,SYSMHC00003_130201_CB_Buffy45_W_20_Rep_5_msms9_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy45,5,Human,In vivo,Blood,PBMC,,,,class I,"A03,A68,B49,B51",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130208_CB_Buffy52_W_20_Rep_1_msms1.RAW,SYSMHC00003_130208_CB_Buffy52_W_20_Rep_1_msms1_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy52,1,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B44,B60",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130208_CB_Buffy52_W_20_Rep_2_msms2.RAW,SYSMHC00003_130208_CB_Buffy52_W_20_Rep_2_msms2_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy52,2,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B44,B60",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130208_CB_Buffy52_W_20_Rep_3_msms3.RAW,SYSMHC00003_130208_CB_Buffy52_W_20_Rep_3_msms3_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy52,3,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B44,B60",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130208_CB_Buffy52_W_20_Rep_4_msms4.RAW,SYSMHC00003_130208_CB_Buffy52_W_20_Rep_4_msms4_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy52,4,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B44,B60",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130208_CB_Buffy52_W_20_Rep_5_msms5.RAW,SYSMHC00003_130208_CB_Buffy52_W_20_Rep_5_msms5_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy52,5,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B44,B60",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130221_DK_Buffy65_W_20_Rep_1_msms4.RAW,SYSMHC00003_130221_DK_Buffy65_W_20_Rep_1_msms4_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy65,1,Human,In vivo,Blood,PBMC,,,,class I,"A23,A28,B35,B39",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130222_DK_Buffy65_W_20_Rep_2_msms5.RAW,SYSMHC00003_130222_DK_Buffy65_W_20_Rep_2_msms5_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy65,2,Human,In vivo,Blood,PBMC,,,,class I,"A23,A28,B35,B39",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130222_DK_Buffy65_W_20_Rep_3_msms6.RAW,SYSMHC00003_130222_DK_Buffy65_W_20_Rep_3_msms6_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy65,3,Human,In vivo,Blood,PBMC,,,,class I,"A23,A28,B35,B39",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130222_DK_Buffy65_W_20_Rep_4_msms7.RAW,SYSMHC00003_130222_DK_Buffy65_W_20_Rep_4_msms7_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy65,4,Human,In vivo,Blood,PBMC,,,,class I,"A23,A28,B35,B39",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130222_DK_Buffy65_W_20_Rep_5_msms8.RAW,SYSMHC00003_130222_DK_Buffy65_W_20_Rep_5_msms8_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy65,5,Human,In vivo,Blood,PBMC,,,,class I,"A23,A28,B35,B39",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130228_DK_Buffy42_W_20_Rep_1_msms6.RAW,SYSMHC00003_130228_DK_Buffy42_W_20_Rep_1_msms6_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy42,1,Human,In vivo,Blood,PBMC,,,,class I,"A24,A28,B39,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130229_DK_Buffy42_W_20_Rep_2_msms4.RAW,SYSMHC00003_130229_DK_Buffy42_W_20_Rep_2_msms4_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy42,2,Human,In vivo,Blood,PBMC,,,,class I,"A24,A28,B39,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130229_DK_Buffy42_W_20_Rep_3_msms5.RAW,SYSMHC00003_130229_DK_Buffy42_W_20_Rep_3_msms5_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy42,3,Human,In vivo,Blood,PBMC,,,,class I,"A24,A28,B39,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130229_DK_Buffy42_W_20_Rep_4_msms6.RAW,SYSMHC00003_130229_DK_Buffy42_W_20_Rep_4_msms6_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy42,4,Human,In vivo,Blood,PBMC,,,,class I,"A24,A28,B39,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130229_DK_Buffy42_W_20_Rep_5_msms7.RAW,SYSMHC00003_130229_DK_Buffy42_W_20_Rep_5_msms7_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy42,5,Human,In vivo,Blood,PBMC,,,,class I,"A24,A28,B39,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130410_SKUG_Buffy67_W_20_Rep_1_msms1.RAW,SYSMHC00003_130410_SKUG_Buffy67_W_20_Rep_1_msms1_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy53,1,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B51,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130410_SKUG_Buffy67_W_20_Rep_2_msms2.RAW,SYSMHC00003_130410_SKUG_Buffy67_W_20_Rep_2_msms2_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy53,2,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B51,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130410_SKUG_Buffy67_W_20_Rep_3_msms3.RAW,SYSMHC00003_130410_SKUG_Buffy67_W_20_Rep_3_msms3_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy53,3,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B51,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130410_SKUG_Buffy67_W_20_Rep_4_msms4.RAW,SYSMHC00003_130410_SKUG_Buffy67_W_20_Rep_4_msms4_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy53,4,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B51,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130410_SKUG_Buffy67_W_20_Rep_5_msms5.RAW,SYSMHC00003_130410_SKUG_Buffy67_W_20_Rep_5_msms5_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy53,5,Human,In vivo,Blood,PBMC,,,,class I,"A02,A03,B51,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130412_SKUG_Buffy63_W_20_Rep_1_msms18.RAW,SYSMHC00003_130412_SKUG_Buffy63_W_20_Rep_1_msms18_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy63,1,Human,In vivo,Blood,PBMC,,,,class I,"A02,A32,B44,B55",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130412_SKUG_Buffy64_W_20_Rep_1_msms18.RAW,SYSMHC00003_130412_SKUG_Buffy64_W_20_Rep_1_msms18_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy64,1,Human,In vivo,Blood,PBMC,,,,class I,"A02,A32,B44,B56",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130413_SKUG_Buffy63_W_20_Rep_2_msms1.RAW,SYSMHC00003_130413_SKUG_Buffy63_W_20_Rep_2_msms1_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy63,2,Human,In vivo,Blood,PBMC,,,,class I,"A02,A32,B44,B55",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130413_SKUG_Buffy63_W_20_Rep_3_msms2.RAW,SYSMHC00003_130413_SKUG_Buffy63_W_20_Rep_3_msms2_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy63,3,Human,In vivo,Blood,PBMC,,,,class I,"A02,A32,B44,B55",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130413_SKUG_Buffy63_W_20_Rep_4_msms3.RAW,SYSMHC00003_130413_SKUG_Buffy63_W_20_Rep_4_msms3_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy63,4,Human,In vivo,Blood,PBMC,,,,class I,"A02,A32,B44,B55",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130413_SKUG_Buffy63_W_20_Rep_5_msms4.RAW,SYSMHC00003_130413_SKUG_Buffy63_W_20_Rep_5_msms4_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy63,5,Human,In vivo,Blood,PBMC,,,,class I,"A02,A32,B44,B55",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130413_SKUG_Buffy64_W_20_Rep_2_msms1.RAW,SYSMHC00003_130413_SKUG_Buffy64_W_20_Rep_2_msms1_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy64,2,Human,In vivo,Blood,PBMC,,,,class I,"A02,A32,B44,B56",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130413_SKUG_Buffy64_W_20_Rep_3_msms2.RAW,SYSMHC00003_130413_SKUG_Buffy64_W_20_Rep_3_msms2_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy64,3,Human,In vivo,Blood,PBMC,,,,class I,"A02,A32,B44,B56",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130413_SKUG_Buffy64_W_20_Rep_4_msms3.RAW,SYSMHC00003_130413_SKUG_Buffy64_W_20_Rep_4_msms3_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy64,4,Human,In vivo,Blood,PBMC,,,,class I,"A02,A32,B44,B56",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130413_SKUG_Buffy64_W_20_Rep_5_msms4.RAW,SYSMHC00003_130413_SKUG_Buffy64_W_20_Rep_5_msms4_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy64,5,Human,In vivo,Blood,PBMC,,,,class I,"A02,A32,B44,B56",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130505_SKUG_Buffy74_W_NoZipTip_11p6ug_50_Rep_2_15cm90min3sDynExcl_msms4.RAW,SYSMHC00003_130505_SKUG_Buffy74_W_NoZipTip_11p6ug_50_Rep_2_15cm90min3sDynExcl_msms4_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy74,1,Human,In vivo,Blood,PBMC,,,,class I,"A02,A29,B44,B60",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130505_SKUG_Buffy74_W_ZipTip_0p9ug_50_Rep_2_15cm90min3sDynExcl_msms3.RAW,SYSMHC00003_130505_SKUG_Buffy74_W_ZipTip_0p9ug_50_Rep_2_15cm90min3sDynExcl_msms3_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy74,2,Human,In vivo,Blood,PBMC,,,,class I,"A02,A29,B44,B60",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130505_SKUG_Buffy75_W_NoZipTip_7p9ug_50_Rep_1_15cm90min3sDynExcl_msms6.RAW,SYSMHC00003_130505_SKUG_Buffy75_W_NoZipTip_7p9ug_50_Rep_1_15cm90min3sDynExcl_msms6_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy75,1,Human,In vivo,Blood,PBMC,,,,class I,"A01,A30,B08,B61",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130505_SKUG_Buffy75_W_ZipTip_1p0ug_50_Rep_1_15cm90min3sDynExcl_msms5.RAW,SYSMHC00003_130505_SKUG_Buffy75_W_ZipTip_1p0ug_50_Rep_1_15cm90min3sDynExcl_msms5_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy75,2,Human,In vivo,Blood,PBMC,,,,class I,"A01,A30,B08,B61",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy82_W_XpXXg_20_Rep_1_msms5.RAW,SYSMHC00003_130513_SKUG_Buffy82_W_XpXXg_20_Rep_1_msms5_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy82,1,Human,In vivo,Blood,PBMC,,,,class I,"A01,B08,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy82_W_XpXXg_20_Rep_2_msms6.RAW,SYSMHC00003_130513_SKUG_Buffy82_W_XpXXg_20_Rep_2_msms6_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy82,2,Human,In vivo,Blood,PBMC,,,,class I,"A01,B08,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy82_W_XpXXg_20_Rep_3_msms7.RAW,SYSMHC00003_130513_SKUG_Buffy82_W_XpXXg_20_Rep_3_msms7_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy82,3,Human,In vivo,Blood,PBMC,,,,class I,"A01,B08,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy82_W_XpXXg_20_Rep_4_msms8.RAW,SYSMHC00003_130513_SKUG_Buffy82_W_XpXXg_20_Rep_4_msms8_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy82,4,Human,In vivo,Blood,PBMC,,,,class I,"A01,B08,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy82_W_XpXXg_20_Rep_5_msms9.RAW,SYSMHC00003_130513_SKUG_Buffy82_W_XpXXg_20_Rep_5_msms9_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy82,5,Human,In vivo,Blood,PBMC,,,,class I,"A01,B08,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy88_W_XpXXg_20_Rep_1_msms40.RAW,SYSMHC00003_130513_SKUG_Buffy88_W_XpXXg_20_Rep_1_msms40_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy88,1,Human,In vivo,Blood,PBMC,,,,class I,"A01,A26,B61,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy88_W_XpXXg_20_Rep_2_msms41.RAW,SYSMHC00003_130513_SKUG_Buffy88_W_XpXXg_20_Rep_2_msms41_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy88,2,Human,In vivo,Blood,PBMC,,,,class I,"A01,A26,B61,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy88_W_XpXXg_20_Rep_3_msms42.RAW,SYSMHC00003_130513_SKUG_Buffy88_W_XpXXg_20_Rep_3_msms42_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy88,3,Human,In vivo,Blood,PBMC,,,,class I,"A01,A26,B61,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy88_W_XpXXg_20_Rep_4_msms43.RAW,SYSMHC00003_130513_SKUG_Buffy88_W_XpXXg_20_Rep_4_msms43_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy88,4,Human,In vivo,Blood,PBMC,,,,class I,"A01,A26,B61,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy88_W_XpXXg_20_Rep_5_msms44.RAW,SYSMHC00003_130513_SKUG_Buffy88_W_XpXXg_20_Rep_5_msms44_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy88,5,Human,In vivo,Blood,PBMC,,,,class I,"A01,A26,B61,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy92_W_XpXXg_20_Rep_1_msms19.RAW,SYSMHC00003_130513_SKUG_Buffy92_W_XpXXg_20_Rep_1_msms19_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy92,1,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B44,B55",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy92_W_XpXXg_20_Rep_2_msms20.RAW,SYSMHC00003_130513_SKUG_Buffy92_W_XpXXg_20_Rep_2_msms20_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy92,2,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B44,B55",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy92_W_XpXXg_20_Rep_3_msms21.RAW,SYSMHC00003_130513_SKUG_Buffy92_W_XpXXg_20_Rep_3_msms21_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy92,3,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B44,B55",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy92_W_XpXXg_20_Rep_4_msms22.RAW,SYSMHC00003_130513_SKUG_Buffy92_W_XpXXg_20_Rep_4_msms22_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy92,4,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B44,B55",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy92_W_XpXXg_20_Rep_5_msms23.RAW,SYSMHC00003_130513_SKUG_Buffy92_W_XpXXg_20_Rep_5_msms23_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy92,5,Human,In vivo,Blood,PBMC,,,,class I,"A02,A11,B44,B55",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy95_W_XpXXg_20_Rep_1_msms33.RAW,SYSMHC00003_130513_SKUG_Buffy95_W_XpXXg_20_Rep_1_msms33_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy95,1,Human,In vivo,Blood,PBMC,,,,class I,"A02,A24,B57,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy95_W_XpXXg_20_Rep_2_msms34.RAW,SYSMHC00003_130513_SKUG_Buffy95_W_XpXXg_20_Rep_2_msms34_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy95,2,Human,In vivo,Blood,PBMC,,,,class I,"A02,A24,B57,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy95_W_XpXXg_20_Rep_3_msms35.RAW,SYSMHC00003_130513_SKUG_Buffy95_W_XpXXg_20_Rep_3_msms35_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy95,3,Human,In vivo,Blood,PBMC,,,,class I,"A02,A24,B57,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy95_W_XpXXg_20_Rep_4_msms36.RAW,SYSMHC00003_130513_SKUG_Buffy95_W_XpXXg_20_Rep_4_msms36_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy95,4,Human,In vivo,Blood,PBMC,,,,class I,"A02,A24,B57,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130513_SKUG_Buffy95_W_XpXXg_20_Rep_5_msms37.RAW,SYSMHC00003_130513_SKUG_Buffy95_W_XpXXg_20_Rep_5_msms37_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy95,5,Human,In vivo,Blood,PBMC,,,,class I,"A02,A24,B57,B62",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130712_AX_Buffy102_W_20_Rep_1_msms1.RAW,SYSMHC00003_130712_AX_Buffy102_W_20_Rep_1_msms1_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy102,1,Human,In vivo,Blood,PBMC,,,,class I,"A03,A26,B51,B51",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130712_AX_Buffy102_W_20_Rep_2_msms2.RAW,SYSMHC00003_130712_AX_Buffy102_W_20_Rep_2_msms2_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy102,2,Human,In vivo,Blood,PBMC,,,,class I,"A03,A26,B51,B51",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130712_AX_Buffy102_W_20_Rep_3_msms3.RAW,SYSMHC00003_130712_AX_Buffy102_W_20_Rep_3_msms3_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy102,3,Human,In vivo,Blood,PBMC,,,,class I,"A03,A26,B51,B51",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130712_AX_Buffy102_W_20_Rep_4_msms4.RAW,SYSMHC00003_130712_AX_Buffy102_W_20_Rep_4_msms4_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy102,4,Human,In vivo,Blood,PBMC,,,,class I,"A03,A26,B51,B51",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00003_130712_AX_Buffy102_W_20_Rep_5_msms5.RAW,SYSMHC00003_130712_AX_Buffy102_W_20_Rep_5_msms5_c.mzXML,SYSMHC00003_Kowalewskid_160817_Rammensee_Germany_PBMC_Buffy102,5,Human,In vivo,Blood,PBMC,,,,class I,"A03,A26,B51,B51",not published,SYSMHC00003,native,Immunoaffinity,,,25%,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,,2-32% ACN,120,,,,
SYSMHC00004_carone_20150801_QEp7_MiBa_SA_iRT_HLA_I_JY_1.raw,SYSMHC00004_carone_20150801_QEp7_MiBa_SA_iRT_HLA_I_JY_1.mzXML,SYSMHC00004_bassanim_160817_Mann_Germany_JY,1,Human,In vitro,Blood,JY,suspension,,EBV transformed,class I,"A0201,B0702,C0702",not published,SYSMHC00004,native,Immunoaffinity,,,25%,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",yes,DDA,,2-30% ACN,90,,,,
SYSMHC00004_carone_20150801_QEp7_MiBa_SA_iRT_HLA_I_JY_2.raw,SYSMHC00004_carone_20150801_QEp7_MiBa_SA_iRT_HLA_I_JY_2.mzXML,SYSMHC00004_bassanim_160817_Mann_Germany_JY,2,Human,In vitro,Blood,JY,suspension,,EBV transformed,class I,"A0201,B0702,C0702",not published,SYSMHC00004,native,Immunoaffinity,,,25%,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",yes,DDA,,2-30% ACN,90,,,,
SYSMHC00004_carone_20150801_QEp7_MiBa_SA_iRT_HLA_I_JY_3.raw,SYSMHC00004_carone_20150801_QEp7_MiBa_SA_iRT_HLA_I_JY_3.mzXML,SYSMHC00004_bassanim_160817_Mann_Germany_JY,3,Human,In vitro,Blood,JY,suspension,,EBV transformed,class I,"A0201,B0702,C0702",not published,SYSMHC00004,native,Immunoaffinity,,,25%,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",yes,DDA,,2-30% ACN,90,,,,
SYSMHC00004_carone_20150802_QEp7_MiBa_SA_iRT_HLA_I_Fib_1.raw,SYSMHC00004_carone_20150802_QEp7_MiBa_SA_iRT_HLA_I_Fib_1.mzXML,SYSMHC00004_bassanim_160817_Mann_Germany_Fib,1,Human,In vitro,,Fibroblast,adherent,,,class I,"A0301,A2301,B0801,B1518,C0702,C0704",not published,SYSMHC00004,native,Immunoaffinity,,,25%,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",yes,DDA,,2-30% ACN,90,,,,
SYSMHC00004_carone_20150802_QEp7_MiBa_SA_iRT_HLA_I_Fib_2.raw,SYSMHC00004_carone_20150802_QEp7_MiBa_SA_iRT_HLA_I_Fib_2.mzXML,SYSMHC00004_bassanim_160817_Mann_Germany_Fib,2,Human,In vitro,,Fibroblast,adherent,,,class I,"A0301,A2301,B0801,B1518,C0702,C0704",not published,SYSMHC00004,native,Immunoaffinity,,,25%,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",yes,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120321_EXQ1_MiBa_SA_HCC1143_1.raw,SYSMHC00005_20120321_EXQ1_MiBa_SA_HCC1143_1_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_HCC1143,1,Human,In vitro,Breast,HCC1143,adherent,,Basal like breast cancer,class I,"A3101,B3508,B3701,C0401,C0602",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120321_EXQ1_MiBa_SA_HCC1143_2.raw,SYSMHC00005_20120321_EXQ1_MiBa_SA_HCC1143_2_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_HCC1143,2,Human,In vitro,Breast,HCC1143,adherent,,Basal like breast cancer,class I,"A3101,B3508,B3701,C0401,C0602",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120321_EXQ1_MiBa_SA_HCC1937_1.raw,SYSMHC00005_20120321_EXQ1_MiBa_SA_HCC1937_1_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_HCC1937,1,Human,In vitro,Breast,HCC1937,adherent,,Basal like breast cancer,class I,"A2301,A2402,B0702,B4001,C0304,C0702",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120321_EXQ1_MiBa_SA_HCC1937_2.raw,SYSMHC00005_20120321_EXQ1_MiBa_SA_HCC1937_2_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_HCC1937,2,Human,In vitro,Breast,HCC1937,adherent,,Basal like breast cancer,class I,"A2301,A2402,B0702,B4001,C0304,C0702",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120322_EXQ1_MiBa_SA_HCC1143_1_A.raw,SYSMHC00005_20120322_EXQ1_MiBa_SA_HCC1143_1_A_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_HCC1143,3,Human,In vitro,Breast,HCC1143,adherent,,Basal like breast cancer,class I,"A3101,B3508,B3701,C0401,C0602",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120322_EXQ1_MiBa_SA_HCC1937_1_A.raw,SYSMHC00005_20120322_EXQ1_MiBa_SA_HCC1937_1_A_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_HCC1937,3,Human,In vitro,Breast,HCC1937,adherent,,Basal like breast cancer,class I,"A2301,A2402,B0702,B4001,C0304,C0702",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120322_EXQ1_MiBa_SA_HCC1937_2_A.raw,SYSMHC00005_20120322_EXQ1_MiBa_SA_HCC1937_2_A_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_HCC1937,4,Human,In vitro,Breast,HCC1937,adherent,,Basal like breast cancer,class I,"A2301,A2402,B0702,B4001,C0304,C0702",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120403_EXQ1_MiBa_SA_JY_mHLA_19.raw,SYSMHC00005_20120403_EXQ1_MiBa_SA_JY_mHLA_19_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_JY,1,Human,In vitro,Blood,JY,suspension,,EBV transformed,class I,"A0201,B0702,C0702",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120411_EXQ1_MiBa_SA_JY_mHLA_15-10-250.raw,SYSMHC00005_20120411_EXQ1_MiBa_SA_JY_mHLA_15-10-250_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_JY,3,Human,In vitro,Blood,JY,suspension,,EBV transformed,class I,"A0201,B0702,C0702",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120411_EXQ1_MiBa_SA_JY_mHLA_5_15-10-250.raw,SYSMHC00005_20120411_EXQ1_MiBa_SA_JY_mHLA_5_15-10-250_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_JY,2,Human,In vitro,Blood,JY,suspension,,EBV transformed,class I,"A0201,B0702,C0702",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120515_EXQ3_MiBa_SA_HCT116_mHLA-1.raw,SYSMHC00005_20120515_EXQ3_MiBa_SA_HCT116_mHLA-1_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_HCT116,1,Human,In vitro,Colon,HCT116,adherent,,Colon carcinoma,class I,"A0101,A0201,B4501,B1801,C0501,C0701",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120518_EXQ0_MiBa_SA_HCT116_mHLA-2.raw,SYSMHC00005_20120518_EXQ0_MiBa_SA_HCT116_mHLA-2_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_HCT116,2,Human,In vitro,Colon,HCT116,adherent,,Colon carcinoma,class I,"A0101,A0201,B4501,B1801,C0501,C0701",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120617_EXQ0_MiBa_SA_HCT116_1_mHLA_2hr.raw,SYSMHC00005_20120617_EXQ0_MiBa_SA_HCT116_1_mHLA_2hr_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_HCT116,3,Human,In vitro,Colon,HCT116,adherent,,Colon carcinoma,class I,"A0101,A0201,B4501,B1801,C0501,C0701",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120619_EXQ6_MiBa_SA_HCT116_2_mHLA_2hr.raw,SYSMHC00005_20120619_EXQ6_MiBa_SA_HCT116_2_mHLA_2hr_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_HCT116,4,Human,In vitro,Colon,HCT116,adherent,,Colon carcinoma,class I,"A0101,A0201,B4501,B1801,C0501,C0701",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120726_EXQ1_MiBa_SA_SupB15-RT_mHLA-1.raw,SYSMHC00005_20120726_EXQ1_MiBa_SA_SupB15-RT_mHLA-1_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_SupB15-RT,1,Human,In vitro,Blood,SupB15-RT,suspension,,B-cell leukemia,class I,"A03,A11,B51,B52,C1204,C1402",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120726_EXQ1_MiBa_SA_SupB15-RT_mHLA-3.raw,SYSMHC00005_20120726_EXQ1_MiBa_SA_SupB15-RT_mHLA-3_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_SupB15-RT,2,Human,In vitro,Blood,SupB15-RT,suspension,,B-cell leukemia,class I,"A03,A11,B51,B52,C1204,C1402",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120726_EXQ1_MiBa_SA_SupB15-RT_mHLA-4.raw,SYSMHC00005_20120726_EXQ1_MiBa_SA_SupB15-RT_mHLA-4_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_SupB15-RT,3,Human,In vitro,Blood,SupB15-RT,suspension,,B-cell leukemia,class I,"A03,A11,B51,B52,C1204,C1402",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120726_EXQ1_MiBa_SA_SupB15-RT_mHLA-5.raw,SYSMHC00005_20120726_EXQ1_MiBa_SA_SupB15-RT_mHLA-5_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_SupB15-RT,4,Human,In vitro,Blood,SupB15-RT,suspension,,B-cell leukemia,class I,"A03,A11,B51,B52,C1204,C1402",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120726_EXQ1_MiBa_SA_SupB15-WT_mHLA-2.raw,SYSMHC00005_20120726_EXQ1_MiBa_SA_SupB15-WT_mHLA-2_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_SupB15-WT,1,Human,In vitro,Blood,SupB15-WT,suspension,,B-cell leukemia,class I,"A03,A11,B51,B52,C1204,C1402",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120726_EXQ1_MiBa_SA_SupB15-WT_mHLA-3.raw,SYSMHC00005_20120726_EXQ1_MiBa_SA_SupB15-WT_mHLA-3_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_SupB15-WT,2,Human,In vitro,Blood,SupB15-WT,suspension,,B-cell leukemia,class I,"A03,A11,B51,B52,C1204,C1402",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120726_EXQ1_MiBa_SA_SupB15-WT_mHLA-4.raw,SYSMHC00005_20120726_EXQ1_MiBa_SA_SupB15-WT_mHLA-4_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_SupB15-WT,3,Human,In vitro,Blood,SupB15-WT,suspension,,B-cell leukemia,class I,"A03,A11,B51,B52,C1204,C1402",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20120726_EXQ1_MiBa_SA_SupB15-WT_mHLA-5.raw,SYSMHC00005_20120726_EXQ1_MiBa_SA_SupB15-WT_mHLA-5_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_SupB15-WT,4,Human,In vitro,Blood,SupB15-WT,suspension,,B-cell leukemia,class I,"A03,A11,B51,B52,C1204,C1402",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20121117_EXQ2_MiBa_SA_mHLA_Fib_1.raw,SYSMHC00005_20121117_EXQ2_MiBa_SA_mHLA_Fib_1_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_Fib,2,Human,In vitro,,Fibroblast,adherent,,,class I,"A0301,A2301,B0801,B1518,C0702,C0704",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20121117_EXQ2_MiBa_SA_mHLA_Fib_2.raw,SYSMHC00005_20121117_EXQ2_MiBa_SA_mHLA_Fib_2_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_Fib,3,Human,In vitro,,Fibroblast,adherent,,,class I,"A0301,A2301,B0801,B1518,C0702,C0704",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20130504_EXQ3_MiBa_SA_Fib-1.raw,SYSMHC00005_20130504_EXQ3_MiBa_SA_Fib-1_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_Fib,4,Human,In vitro,,Fibroblast,adherent,,,class I,"A0301,A2301,B0801,B1518,C0702,C0704",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00005_20130504_EXQ3_MiBa_SA_Fib-2.raw,SYSMHC00005_20130504_EXQ3_MiBa_SA_Fib-2_c.mzXML,SYSMHC00005_bassanim_160817_Mann_Germany_Fib,1,Human,In vitro,,Fibroblast,adherent,,,class I,"A0301,A2301,B0801,B1518,C0702,C0704",25576301,SYSMHC00005,native,Immunoaffinity,,,,Q-Exactive,"no-LC, Proxeon Biosystems, Thermo",no,DDA,,2-30% ACN,90,,,,
SYSMHC00006_s291587.RAW,SYSMHC00006_s291587_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,1,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,A= 95/3/0.1 water/acetonitrile/formic acid,
SYSMHC00006_s291587c.RAW,SYSMHC00006_s291587c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,2,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,B= 10/90/0.1 water/acetonitrile/formic acid,
SYSMHC00006_s291587d.RAW,SYSMHC00006_s291587d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,3,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291588.RAW,SYSMHC00006_s291588_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,4,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291588c.RAW,SYSMHC00006_s291588c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,5,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291588d.RAW,SYSMHC00006_s291588d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,6,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291589.RAW,SYSMHC00006_s291589_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,7,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291589c.RAW,SYSMHC00006_s291589c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,8,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291589d.RAW,SYSMHC00006_s291589d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,9,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291590.RAW,SYSMHC00006_s291590_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,10,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291590c.RAW,SYSMHC00006_s291590c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,11,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291590d.RAW,SYSMHC00006_s291590d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,12,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291591.RAW,SYSMHC00006_s291591_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,13,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291591c.RAW,SYSMHC00006_s291591c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,14,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291591d.RAW,SYSMHC00006_s291591d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,15,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291592.RAW,SYSMHC00006_s291592_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,16,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291592c.RAW,SYSMHC00006_s291592c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,17,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291592d.RAW,SYSMHC00006_s291592d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,18,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291593.RAW,SYSMHC00006_s291593_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,19,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291593c.RAW,SYSMHC00006_s291593c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,20,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291593d.RAW,SYSMHC00006_s291593d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,21,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291594.RAW,SYSMHC00006_s291594_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,22,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291594c.RAW,SYSMHC00006_s291594c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,23,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291594d.RAW,SYSMHC00006_s291594d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,24,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291595.RAW,SYSMHC00006_s291595_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,25,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291595c.RAW,SYSMHC00006_s291595c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,26,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291595d.RAW,SYSMHC00006_s291595d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,27,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291596.RAW,SYSMHC00006_s291596_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,28,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291596c.RAW,SYSMHC00006_s291596c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,29,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291596d.RAW,SYSMHC00006_s291596d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,30,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291597.RAW,SYSMHC00006_s291597_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,31,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291597c.RAW,SYSMHC00006_s291597c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,32,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291597d.RAW,SYSMHC00006_s291597d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,33,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291598.RAW,SYSMHC00006_s291598_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,34,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291598c.RAW,SYSMHC00006_s291598c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,35,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291598d.RAW,SYSMHC00006_s291598d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_IEF,36,Human,In vitro,Blood,HHC,suspension,,HHC IEF,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291638.RAW,SYSMHC00006_s291638_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,1,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291638c.RAW,SYSMHC00006_s291638c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,2,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291638d.RAW,SYSMHC00006_s291638d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,3,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291639.RAW,SYSMHC00006_s291639_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,4,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291639c.RAW,SYSMHC00006_s291639c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,5,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291639d.RAW,SYSMHC00006_s291639d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,6,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291640.RAW,SYSMHC00006_s291640_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,7,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291640c.RAW,SYSMHC00006_s291640c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,8,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291640d.RAW,SYSMHC00006_s291640d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,9,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291641.RAW,SYSMHC00006_s291641_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,10,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291641c.RAW,SYSMHC00006_s291641c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,11,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291641d.RAW,SYSMHC00006_s291641d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,12,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291642.RAW,SYSMHC00006_s291642_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,13,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291642c.RAW,SYSMHC00006_s291642c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,14,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291642d.RAW,SYSMHC00006_s291642d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,15,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291643.RAW,SYSMHC00006_s291643_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,16,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291643c.RAW,SYSMHC00006_s291643c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,17,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291643d.RAW,SYSMHC00006_s291643d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,18,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291644.RAW,SYSMHC00006_s291644_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,19,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291644c.RAW,SYSMHC00006_s291644c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,20,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291644d.RAW,SYSMHC00006_s291644d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,21,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291645.RAW,SYSMHC00006_s291645_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,22,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291645c.RAW,SYSMHC00006_s291645c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,23,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291645d.RAW,SYSMHC00006_s291645d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,24,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291646.RAW,SYSMHC00006_s291646_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,25,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291646c.RAW,SYSMHC00006_s291646c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,26,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291646d.RAW,SYSMHC00006_s291646d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,27,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291647.RAW,SYSMHC00006_s291647_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,28,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291647c.RAW,SYSMHC00006_s291647c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,29,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291647d.RAW,SYSMHC00006_s291647d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,30,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291648.RAW,SYSMHC00006_s291648_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,31,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291648c.RAW,SYSMHC00006_s291648c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,32,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291648d.RAW,SYSMHC00006_s291648d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,33,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291649.RAW,SYSMHC00006_s291649_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,34,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291649c.RAW,SYSMHC00006_s291649c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,35,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291649d.RAW,SYSMHC00006_s291649d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,36,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291650.RAW,SYSMHC00006_s291650_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,37,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291650c.RAW,SYSMHC00006_s291650c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,38,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291650d.RAW,SYSMHC00006_s291650d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,39,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291651.RAW,SYSMHC00006_s291651_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,40,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291651c.RAW,SYSMHC00006_s291651c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,41,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291651d.RAW,SYSMHC00006_s291651d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,42,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291652.RAW,SYSMHC00006_s291652_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,43,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291652c.RAW,SYSMHC00006_s291652c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,44,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291652d.RAW,SYSMHC00006_s291652d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,45,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291653.RAW,SYSMHC00006_s291653_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,46,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291653c.RAW,SYSMHC00006_s291653c_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,47,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s291653d.RAW,SYSMHC00006_s291653d_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_HHC_SCX,48,Human,In vitro,Blood,HHC,suspension,,HHC SCX,class I,"A0201,B0702,B4402,C0501,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292119a.RAW,SYSMHC00006_s292119a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,1,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292119b.RAW,SYSMHC00006_s292119b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,2,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292120a.RAW,SYSMHC00006_s292120a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,3,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292120b.RAW,SYSMHC00006_s292120b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,4,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292121a.RAW,SYSMHC00006_s292121a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,5,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292121b.RAW,SYSMHC00006_s292121b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,6,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292122a.RAW,SYSMHC00006_s292122a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,7,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292122b.RAW,SYSMHC00006_s292122b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,8,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292123a.RAW,SYSMHC00006_s292123a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,9,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292123b.RAW,SYSMHC00006_s292123b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,10,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292124a.RAW,SYSMHC00006_s292124a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,11,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292124b.RAW,SYSMHC00006_s292124b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,12,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292125a.RAW,SYSMHC00006_s292125a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,13,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292125b.RAW,SYSMHC00006_s292125b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,14,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292126a.RAW,SYSMHC00006_s292126a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,15,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292126b.RAW,SYSMHC00006_s292126b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,16,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292127a.RAW,SYSMHC00006_s292127a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,17,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292127b.RAW,SYSMHC00006_s292127b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,18,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292128a.RAW,SYSMHC00006_s292128a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,19,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292128b.RAW,SYSMHC00006_s292128b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,20,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292129a.RAW,SYSMHC00006_s292129a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,21,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292129b.RAW,SYSMHC00006_s292129b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,22,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292130a.RAW,SYSMHC00006_s292130a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,23,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292130b.RAW,SYSMHC00006_s292130b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_IEF,24,Human,In vitro,Blood,JY,suspension,,JY IEF,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292174a.RAW,SYSMHC00006_s292174a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,1,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292174b.RAW,SYSMHC00006_s292174b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,2,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292175a.RAW,SYSMHC00006_s292175a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,3,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292175b.RAW,SYSMHC00006_s292175b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,4,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292176a.RAW,SYSMHC00006_s292176a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,5,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292176b.RAW,SYSMHC00006_s292176b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,6,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292177a.RAW,SYSMHC00006_s292177a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,7,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292177b.RAW,SYSMHC00006_s292177b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,8,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292178a.RAW,SYSMHC00006_s292178a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,9,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292178b.RAW,SYSMHC00006_s292178b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,10,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292179a.RAW,SYSMHC00006_s292179a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,11,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292179b.RAW,SYSMHC00006_s292179b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,12,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292180a.RAW,SYSMHC00006_s292180a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,13,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292180b.RAW,SYSMHC00006_s292180b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,14,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292181a.RAW,SYSMHC00006_s292181a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,15,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292181b.RAW,SYSMHC00006_s292181b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,16,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292182a.RAW,SYSMHC00006_s292182a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,17,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292182b.RAW,SYSMHC00006_s292182b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,18,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292183a.RAW,SYSMHC00006_s292183a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,19,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292183b.RAW,SYSMHC00006_s292183b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,20,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292184a.RAW,SYSMHC00006_s292184a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,21,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292184b.RAW,SYSMHC00006_s292184b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,22,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292185a.RAW,SYSMHC00006_s292185a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,23,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292185b.RAW,SYSMHC00006_s292185b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,24,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292186a.RAW,SYSMHC00006_s292186a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,25,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292186b.RAW,SYSMHC00006_s292186b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,26,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292187a.RAW,SYSMHC00006_s292187a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,27,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292187b.RAW,SYSMHC00006_s292187b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,28,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292188a.RAW,SYSMHC00006_s292188a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,29,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292188b.RAW,SYSMHC00006_s292188b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,30,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292189a.RAW,SYSMHC00006_s292189a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,31,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292189b.RAW,SYSMHC00006_s292189b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,32,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292190a.RAW,SYSMHC00006_s292190a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,33,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292190b.RAW,SYSMHC00006_s292190b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,34,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292191a.RAW,SYSMHC00006_s292191a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,35,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292191b.RAW,SYSMHC00006_s292191b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,36,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292192a.RAW,SYSMHC00006_s292192a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,37,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292192b.RAW,SYSMHC00006_s292192b_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_SCX,38,Human,In vitro,Blood,JY,suspension,,JY SCX,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292296a.RAW,SYSMHC00006_s292296a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,1,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292297a.RAW,SYSMHC00006_s292297a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,2,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292298a.RAW,SYSMHC00006_s292298a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,3,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292299a.RAW,SYSMHC00006_s292299a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,4,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292300a.RAW,SYSMHC00006_s292300a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,5,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292301a.RAW,SYSMHC00006_s292301a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,6,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292302a.RAW,SYSMHC00006_s292302a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,7,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292303a.RAW,SYSMHC00006_s292303a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,8,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292304a.RAW,SYSMHC00006_s292304a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,9,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292305a.RAW,SYSMHC00006_s292305a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,10,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292306a.RAW,SYSMHC00006_s292306a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,11,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292307a.RAW,SYSMHC00006_s292307a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,12,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292308a.RAW,SYSMHC00006_s292308a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,13,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292309a.RAW,SYSMHC00006_s292309a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,14,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292310a.RAW,SYSMHC00006_s292310a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,15,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292311a.RAW,SYSMHC00006_s292311a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,16,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292312a.RAW,SYSMHC00006_s292312a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,17,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292313a.RAW,SYSMHC00006_s292313a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,18,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292314a.RAW,SYSMHC00006_s292314a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,19,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292315a.RAW,SYSMHC00006_s292315a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,20,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292316a.RAW,SYSMHC00006_s292316a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,21,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292317a.RAW,SYSMHC00006_s292317a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,22,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292318a.RAW,SYSMHC00006_s292318a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,23,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292319a.RAW,SYSMHC00006_s292319a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,24,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292320a.RAW,SYSMHC00006_s292320a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,25,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292321a.RAW,SYSMHC00006_s292321a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,26,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292322a.RAW,SYSMHC00006_s292322a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,27,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292323a.RAW,SYSMHC00006_s292323a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,28,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292324a.RAW,SYSMHC00006_s292324a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,29,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292325a.RAW,SYSMHC00006_s292325a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,30,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292326a.RAW,SYSMHC00006_s292326a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,31,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292327a.RAW,SYSMHC00006_s292327a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,32,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292328a.RAW,SYSMHC00006_s292328a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,33,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292329a.RAW,SYSMHC00006_s292329a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,34,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292330a.RAW,SYSMHC00006_s292330a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,35,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292331a.RAW,SYSMHC00006_s292331a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,36,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292333a.RAW,SYSMHC00006_s292333a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,37,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292334a.RAW,SYSMHC00006_s292334a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,38,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292335a.RAW,SYSMHC00006_s292335a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,39,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292336a.RAW,SYSMHC00006_s292336a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,40,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292337a.RAW,SYSMHC00006_s292337a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,41,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292338a.RAW,SYSMHC00006_s292338a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,42,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292339a.RAW,SYSMHC00006_s292339a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,43,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00006_s292340a.RAW,SYSMHC00006_s292340a_c.mzXML,SYSMHC00006_hassanc_160817_vanveelen_netherlands_JY_C18,44,Human,In vitro,Blood,JY,suspension,,JY C18,class I,"A0201,B0702,C0702",23481700,SYSMHC00006,native,Immunoaffinity,,2.00E+10,,LTQ-FT,Agilent 1100 plus flowsplitter,no,DDA,,0-30%B,120,50 um id 15 cm,Dr Maisch reprosil C18-AQ 3 um,,
SYSMHC00007_Seq44762_QE2.raw,SYSMHC00007_Seq44762_QE2_c.mzXML,SYSMHC00007_shraibmanb_160819_admon_Israel_U87,1,Human,In vitro,Brain,U-87,adherent,,Glioblastoma-cultured cells ,class I,"A020101,B4402,C050101",27412690,SYSMHC00007,native,Immunoaffinity,,5*108 cells ,50%,Q-Exactive Plus,UltiMate 3000 RSLC,no,DDA,,5–28% of 100% acetonitrile with 0.1% Formic acid,120,150nl/min,,,
SYSMHC00007_Seq44763_QE2.raw,SYSMHC00007_Seq44763_QE2_c.mzXML,SYSMHC00007_shraibmanb_160819_admon_Israel_U87,2,Human,In vitro,Brain,U-87,adherent,,Glioblastoma-cultured cells ,class I,"A020101,B4402,C050101",27412690,SYSMHC00007,native,Immunoaffinity,,5*108 cells ,50%,Q-Exactive Plus,UltiMate 3000 RSLC,no,DDA,,5–28% of 100% acetonitrile with 0.1% Formic acid,120,150nl/min,,,
SYSMHC00007_Seq44764_QE2.raw,SYSMHC00007_Seq44764_QE2_c.mzXML,SYSMHC00007_shraibmanb_160819_admon_Israel_U87D,1,Human,In vitro,Brain,U-87,adherent treated with Decitabine,,Glioblastoma-cultured cells ,class I,"A020101,B4402,C050101",27412690,SYSMHC00007,native,Immunoaffinity,,5*108 cells ,50%,Q-Exactive Plus,UltiMate 3000 RSLC,no,DDA,,5–28% of 100% acetonitrile with 0.1% Formic acid,120,150nl/min,,,
SYSMHC00007_Seq44765_QE2.raw,SYSMHC00007_Seq44765_QE2_c.mzXML,SYSMHC00007_shraibmanb_160819_admon_Israel_U87D,2,Human,In vitro,Brain,U-87,adherent treated with Decitabine,,Glioblastoma-cultured cells ,class I,"A020101,B4402,C050101",27412690,SYSMHC00007,native,Immunoaffinity,,5*108 cells ,50%,Q-Exactive Plus,UltiMate 3000 RSLC,no,DDA,,5–28% of 100% acetonitrile with 0.1% Formic acid,120,150nl/min,,,
SYSMHC00007_Seq44766_QE2.raw,SYSMHC00007_Seq44766_QE2_c.mzXML,SYSMHC00007_shraibmanb_160819_admon_Israel_T98G,1,Human,In vitro,Brain,T98G,adherent,,Glioblastoma-cultured cells ,class I,"A020101,B390602,C070201",27412690,SYSMHC00007,native,Immunoaffinity,,5*108 cells ,50%,Q-Exactive Plus,UltiMate 3000 RSLC,no,DDA,,5–28% of 100% acetonitrile with 0.1% Formic acid,120,150nl/min,,,
SYSMHC00007_Seq44767_QE2.raw,SYSMHC00007_Seq44767_QE2_c.mzXML,SYSMHC00007_shraibmanb_160819_admon_Israel_T98G,2,Human,In vitro,Brain,T98G,adherent,,Glioblastoma-cultured cells ,class I,"A020101,B390602,C070201",27412690,SYSMHC00007,native,Immunoaffinity,,5*108 cells ,50%,Q-Exactive Plus,UltiMate 3000 RSLC,no,DDA,,5–28% of 100% acetonitrile with 0.1% Formic acid,120,150nl/min,,,
SYSMHC00007_Seq44768_QE2.raw,SYSMHC00007_Seq44768_QE2_c.mzXML,SYSMHC00007_shraibmanb_160819_admon_Israel_T98GD,1,Human,In vitro,Brain,T98G ,adherent treated with Decitabine,,Glioblastoma-cultured cells ,class I,"A020101,B390602,C070201",27412690,SYSMHC00007,native,Immunoaffinity,,5*108 cells ,50%,Q-Exactive Plus,UltiMate 3000 RSLC,no,DDA,,5–28% of 100% acetonitrile with 0.1% Formic acid,120,150nl/min,,,
SYSMHC00007_Seq44769_QE2.raw,SYSMHC00007_Seq44769_QE2_c.mzXML,SYSMHC00007_shraibmanb_160819_admon_Israel_T98GD,2,Human,In vitro,Brain,T98G,adherent treated with Decitabine,,Glioblastoma-cultured cells ,class I,"A020101,B390602,C070201",27412690,SYSMHC00007,native,Immunoaffinity,,5*108 cells ,50%,Q-Exactive Plus,UltiMate 3000 RSLC,no,DDA,,5–28% of 100% acetonitrile with 0.1% Formic acid,120,150nl/min,,,
SYSMHC00007_Seq44770_QE2.raw,SYSMHC00007_Seq44770_QE2_c.mzXML,SYSMHC00007_shraibmanb_160819_admon_Israel_LNT229,1,Human,In vitro,Brain,LNT-229,adherent,,Glioblastoma-cultured cells ,class I,"A030101,B3501,C040101",27412690,SYSMHC00007,native,Immunoaffinity,,5*108 cells ,50%,Q-Exactive Plus,UltiMate 3000 RSLC,no,DDA,,5–28% of 100% acetonitrile with 0.1% Formic acid,120,150nl/min,,,
SYSMHC00007_Seq44771_QE2.raw,SYSMHC00007_Seq44771_QE2_c.mzXML,SYSMHC00007_shraibmanb_160819_admon_Israel_LNT229,2,Human,In vitro,Brain,LNT-229,adherent,,Glioblastoma-cultured cells ,class I,"A030101,B3501,C040101",27412690,SYSMHC00007,native,Immunoaffinity,,5*108 cells ,50%,Q-Exactive Plus,UltiMate 3000 RSLC,no,DDA,,5–28% of 100% acetonitrile with 0.1% Formic acid,120,150nl/min,,,
SYSMHC00007_Seq44772_QE2.raw,SYSMHC00007_Seq44772_QE2_c.mzXML,SYSMHC00007_shraibmanb_160819_admon_Israel_LNT229D,1,Human,In vitro,Brain,LNT-229 ,adherent treated with Decitabine,,Glioblastoma-cultured cells ,class I,"A030101,B3501,C040101",27412690,SYSMHC00007,native,Immunoaffinity,,5*108 cells ,50%,Q-Exactive Plus,UltiMate 3000 RSLC,no,DDA,,5–28% of 100% acetonitrile with 0.1% Formic acid,120,150nl/min,,,
SYSMHC00007_Seq44773_QE2.raw,SYSMHC00007_Seq44773_QE2_c.mzXML,SYSMHC00007_shraibmanb_160819_admon_Israel_LNT229D,2,Human,In vitro,Brain,LNT-229 ,adherent treated with Decitabine,,Glioblastoma-cultured cells ,class I,"A030101,B3501,C040101",27412690,SYSMHC00007,native,Immunoaffinity,,5*108 cells ,50%,Q-Exactive Plus,UltiMate 3000 RSLC,no,DDA,,5–28% of 100% acetonitrile with 0.1% Formic acid,120,150nl/min,,,
SYSMHC00007_Seq44774_QE2.raw,SYSMHC00007_Seq44774_QE2_c.mzXML,SYSMHC00007_shraibmanb_160819_admon_Israel_U87,3,Human,In vitro,Brain,U-87,adherent,,Glioblastoma-cultured cells ,class I,"A020101,B4402,C050101",27412690,SYSMHC00007,native,Immunoaffinity,,5*108 cells ,50%,Q-Exactive Plus,UltiMate 3000 RSLC,no,DDA,,5–28% of 100% acetonitrile with 0.1% Formic acid,120,150nl/min,,,
SYSMHC00007_Seq44775_QE2.raw,SYSMHC00007_Seq44775_QE2_c.mzXML,SYSMHC00007_shraibmanb_160819_admon_Israel_U87D,4,Human,In vitro,Brain,U-87,adherent treated with Decitabine,,Glioblastoma-cultured cells ,class I,"A020101,B4402,C050101",27412690,SYSMHC00007,native,Immunoaffinity,,5*108 cells ,50%,Q-Exactive Plus,UltiMate 3000 RSLC,no,DDA,,5–28% of 100% acetonitrile with 0.1% Formic acid,120,150nl/min,,,
SYSMHC00007_Seq44776_QE2.raw,SYSMHC00007_Seq44776_QE2_c.mzXML,SYSMHC00007_shraibmanb_160819_admon_Israel_T98G,3,Human,In vitro,Brain,T98G,adherent,,Glioblastoma-cultured cells ,class I,"A020101,B390602,C070201",27412690,SYSMHC00007,native,Immunoaffinity,,5*108 cells ,50%,Q-Exactive Plus,UltiMate 3000 RSLC,no,DDA,,5–28% of 100% acetonitrile with 0.1% Formic acid,120,150nl/min,,,
SYSMHC00007_Seq44777_QE2.raw,SYSMHC00007_Seq44777_QE2_c.mzXML,SYSMHC00007_shraibmanb_160819_admon_Israel_T98GD,4,Human,In vitro,Brain,T98G,adherent treated with Decitabine,,Glioblastoma-cultured cells ,class I,"A020101,B390602,C070201",27412690,SYSMHC00007,native,Immunoaffinity,,5*108 cells ,50%,Q-Exactive Plus,UltiMate 3000 RSLC,no,DDA,,5–28% of 100% acetonitrile with 0.1% Formic acid,120,150nl/min,,,
SYSMHC00007_Seq44778_QE2.raw,SYSMHC00007_Seq44778_QE2_c.mzXML,SYSMHC00007_shraibmanb_160819_admon_Israel_LNT229,3,Human,In vitro,Brain,LNT-229,adherent,,Glioblastoma-cultured cells ,class I,"A030101,B3501,C040101",27412690,SYSMHC00007,native,Immunoaffinity,,5*108 cells ,50%,Q-Exactive Plus,UltiMate 3000 RSLC,no,DDA,,5–28% of 100% acetonitrile with 0.1% Formic acid,120,150nl/min,,,
SYSMHC00007_Seq44779_QE2.raw,SYSMHC00007_Seq44779_QE2_c.mzXML,SYSMHC00007_shraibmanb_160819_admon_Israel_LNT229D,4,Human,In vitro,Brain,LNT-229,adherent treated with Decitabine,,Glioblastoma-cultured cells ,class I,"A030101,B3501,C040101",27412690,SYSMHC00007,native,Immunoaffinity,,5*108 cells ,50%,Q-Exactive Plus,UltiMate 3000 RSLC,no,DDA,,5–28% of 100% acetonitrile with 0.1% Formic acid,120,150nl/min,,,
SYSMHC00008_Subject3_rep3_021213_Fx100mM.raw,SYSMHC00008_Subject3_rep3_021213_Fx100mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep3,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject3_rep3_021213_Fx300mM.raw,SYSMHC00008_Subject3_rep3_021213_Fx300mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep3,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject3_rep3_021213_Fx50mM.raw,SYSMHC00008_Subject3_rep3_021213_Fx50mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep3,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject3_rep3_021213_Fx600mM.raw,SYSMHC00008_Subject3_rep3_021213_Fx600mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep3,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject3_rep3_021213_Fx75mM.raw,SYSMHC00008_Subject3_rep3_021213_Fx75mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep3,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject3_rep4_021213_Fx100mM.raw,SYSMHC00008_Subject3_rep4_021213_Fx100mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep4,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject3_rep4_021213_Fx300mM.raw,SYSMHC00008_Subject3_rep4_021213_Fx300mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep4,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject3_rep4_021213_Fx50mM.raw,SYSMHC00008_Subject3_rep4_021213_Fx50mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep4,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject3_rep4_021213_Fx600mM.raw,SYSMHC00008_Subject3_rep4_021213_Fx600mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep4,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject3_rep4_021213_Fx75mM.raw,SYSMHC00008_Subject3_rep4_021213_Fx75mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep4,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject3_rep5_021213_Fx100mM.raw,SYSMHC00008_Subject3_rep5_021213_Fx100mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep5,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject3_rep5_021213_Fx300mM.raw,SYSMHC00008_Subject3_rep5_021213_Fx300mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep5,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject3_rep5_021213_Fx50mM.raw,SYSMHC00008_Subject3_rep5_021213_Fx50mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep5,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject3_rep5_021213_Fx600mM.raw,SYSMHC00008_Subject3_rep5_021213_Fx600mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep5,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject3_rep5_021213_Fx75mM.raw,SYSMHC00008_Subject3_rep5_021213_Fx75mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep5,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep3_021213_Fx100mM.raw,SYSMHC00008_Subject4_rep3_021213_Fx100mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep3,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep3_021213_Fx300mM.raw,SYSMHC00008_Subject4_rep3_021213_Fx300mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep3,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep3_021213_Fx50mM.raw,SYSMHC00008_Subject4_rep3_021213_Fx50mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep3,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep3_021213_Fx600mM.raw,SYSMHC00008_Subject4_rep3_021213_Fx600mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep3,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep3_021213_Fx75mM.raw,SYSMHC00008_Subject4_rep3_021213_Fx75mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep3,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep4_021213_Fx100mM.raw,SYSMHC00008_Subject4_rep4_021213_Fx100mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep4,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep4_021213_Fx300mM.raw,SYSMHC00008_Subject4_rep4_021213_Fx300mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep4,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep4_021213_Fx50mM.raw,SYSMHC00008_Subject4_rep4_021213_Fx50mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep4,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep4_021213_Fx600mM.raw,SYSMHC00008_Subject4_rep4_021213_Fx600mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep4,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep4_021213_Fx75mM.raw,SYSMHC00008_Subject4_rep4_021213_Fx75mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep4,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep5_021213_Fx100mM.raw,SYSMHC00008_Subject4_rep5_021213_Fx100mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep5,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep5_021213_Fx300mM.raw,SYSMHC00008_Subject4_rep5_021213_Fx300mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep5,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep5_021213_Fx50mM.raw,SYSMHC00008_Subject4_rep5_021213_Fx50mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep5,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep5_021213_Fx600mM.raw,SYSMHC00008_Subject4_rep5_021213_Fx600mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep5,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep5_021213_Fx75mM.raw,SYSMHC00008_Subject4_rep5_021213_Fx75mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep5,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep6_021213_Fx100mM.raw,SYSMHC00008_Subject4_rep6_021213_Fx100mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep6,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep6_021213_Fx300mM.raw,SYSMHC00008_Subject4_rep6_021213_Fx300mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep6,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep6_021213_Fx50mM.raw,SYSMHC00008_Subject4_rep6_021213_Fx50mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep6,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep6_021213_Fx600mM.raw,SYSMHC00008_Subject4_rep6_021213_Fx600mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep6,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00008_Subject4_rep6_021213_Fx75mM.raw,SYSMHC00008_Subject4_rep6_021213_Fx75mM_c.mzXML,SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep6,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A0201,B1801,B3924",26728094,SYSMHC00008,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M1_120612_F1.raw,SYSMHC00009_DS_M1_120612_F1.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M1,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M1_120612_F2.raw,SYSMHC00009_DS_M1_120612_F2.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M1,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M1_120612_F3.raw,SYSMHC00009_DS_M1_120612_F3.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M1,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M1_120612_F4.raw,SYSMHC00009_DS_M1_120612_F4.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M1,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M1_120612_F5.raw,SYSMHC00009_DS_M1_120612_F5.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M1,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M1_120612_F6.raw,SYSMHC00009_DS_M1_120612_F6.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M1,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M1_120612_F7.raw,SYSMHC00009_DS_M1_120612_F7.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M1,7,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M2_120628_F1.raw,SYSMHC00009_DS_M2_120628_F1.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M2,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M2_120628_F2.raw,SYSMHC00009_DS_M2_120628_F2.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M2,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M2_120628_F3.raw,SYSMHC00009_DS_M2_120628_F3.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M2,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M2_120628_F4.raw,SYSMHC00009_DS_M2_120628_F4.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M2,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M2_120628_F5.raw,SYSMHC00009_DS_M2_120628_F5.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M2,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M2_120628_F6.raw,SYSMHC00009_DS_M2_120628_F6.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M2,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M2_120628_F7.raw,SYSMHC00009_DS_M2_120628_F7.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M2,7,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M3_120629_F1.raw,SYSMHC00009_DS_M3_120629_F1.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M3,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M3_120629_F2.raw,SYSMHC00009_DS_M3_120629_F2.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M3,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M3_120629_F3.raw,SYSMHC00009_DS_M3_120629_F3.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M3,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M3_120629_F4.raw,SYSMHC00009_DS_M3_120629_F4.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M3,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M3_120629_F5.raw,SYSMHC00009_DS_M3_120629_F5.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M3,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M3_120629_F6.raw,SYSMHC00009_DS_M3_120629_F6.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M3,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M3_120629_F7.raw,SYSMHC00009_DS_M3_120629_F7.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M3,7,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M4_120630_F1.raw,SYSMHC00009_DS_M4_120630_F1.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M4,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M4_120630_F2.raw,SYSMHC00009_DS_M4_120630_F2.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M4,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M4_120630_F3.raw,SYSMHC00009_DS_M4_120630_F3.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M4,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M4_120630_F4.raw,SYSMHC00009_DS_M4_120630_F4.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M4,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M4_120630_F5.raw,SYSMHC00009_DS_M4_120630_F5.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M4,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M4_120630_F6.raw,SYSMHC00009_DS_M4_120630_F6.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M4,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_M4_120630_F7.raw,SYSMHC00009_DS_M4_120630_F7.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_M4,7,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R1_120612_F1.raw,SYSMHC00009_DS_R1_120612_F1.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R1,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R1_120612_F2.raw,SYSMHC00009_DS_R1_120612_F2.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R1,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R1_120612_F3.raw,SYSMHC00009_DS_R1_120612_F3.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R1,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R1_120612_F4.raw,SYSMHC00009_DS_R1_120612_F4.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R1,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R1_120612_F5.raw,SYSMHC00009_DS_R1_120612_F5.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R1,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R1_120612_F6.raw,SYSMHC00009_DS_R1_120612_F6.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R1,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R1_120612_F7.raw,SYSMHC00009_DS_R1_120612_F7.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R1,7,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R2_120628_F1.raw,SYSMHC00009_DS_R2_120628_F1.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R2,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R2_120628_F2.raw,SYSMHC00009_DS_R2_120628_F2.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R2,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R2_120628_F3.raw,SYSMHC00009_DS_R2_120628_F3.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R2,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R2_120628_F4.raw,SYSMHC00009_DS_R2_120628_F4.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R2,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R2_120628_F5.raw,SYSMHC00009_DS_R2_120628_F5.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R2,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R2_120628_F6.raw,SYSMHC00009_DS_R2_120628_F6.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R2,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R2_120628_F7.raw,SYSMHC00009_DS_R2_120628_F7.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R2,7,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R3_120629_F1.raw,SYSMHC00009_DS_R3_120629_F1.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R3,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R3_120629_F2.raw,SYSMHC00009_DS_R3_120629_F2.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R3,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R3_120629_F3.raw,SYSMHC00009_DS_R3_120629_F3.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R3,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R3_120629_F4.raw,SYSMHC00009_DS_R3_120629_F4.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R3,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R3_120629_F5.raw,SYSMHC00009_DS_R3_120629_F5.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R3,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R3_120629_F6.raw,SYSMHC00009_DS_R3_120629_F6.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R3,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R3_120629_F7.raw,SYSMHC00009_DS_R3_120629_F7.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R3,7,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R4_120630_F1.raw,SYSMHC00009_DS_R4_120630_F1.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R4,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R4_120630_F2.raw,SYSMHC00009_DS_R4_120630_F2.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R4,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R4_120630_F3.raw,SYSMHC00009_DS_R4_120630_F3.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R4,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R4_120630_F4.raw,SYSMHC00009_DS_R4_120630_F4.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R4,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R4_120630_F5.raw,SYSMHC00009_DS_R4_120630_F5.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R4,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R4_120630_F6.raw,SYSMHC00009_DS_R4_120630_F6.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R4,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00009_DS_R4_120630_F7.raw,SYSMHC00009_DS_R4_120630_F7.c_mzXML,SYSMHC00009_gradosd_140409_perreault-thibault_cada_LCL_R4,7,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",24714562,SYSMHC00009,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,3-60%,120,,,,
SYSMHC00010_C_rep3_021213_Fx100mM.raw,SYSMHC00010_C_rep3_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep3_021213_Fx300mM.raw,SYSMHC00010_C_rep3_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep3_021213_Fx50mM.raw,SYSMHC00010_C_rep3_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep3_021213_Fx600mM.raw,SYSMHC00010_C_rep3_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep3_021213_Fx75mM.raw,SYSMHC00010_C_rep3_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep4_021213_Fx100mM.raw,SYSMHC00010_C_rep4_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep4_021213_Fx300mM.raw,SYSMHC00010_C_rep4_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,7,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep4_021213_Fx50mM.raw,SYSMHC00010_C_rep4_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,8,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep4_021213_Fx600mM.raw,SYSMHC00010_C_rep4_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,9,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep4_021213_Fx75mM.raw,SYSMHC00010_C_rep4_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,10,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep5_021213_Fx100mM.raw,SYSMHC00010_C_rep5_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,11,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep5_021213_Fx300mM.raw,SYSMHC00010_C_rep5_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,12,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep5_021213_Fx50mM.raw,SYSMHC00010_C_rep5_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,13,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep5_021213_Fx600mM.raw,SYSMHC00010_C_rep5_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,14,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep5_021213_Fx75mM.raw,SYSMHC00010_C_rep5_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,15,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep6_021213_Fx100mM.raw,SYSMHC00010_C_rep6_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,16,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep6_021213_Fx300mM.raw,SYSMHC00010_C_rep6_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,17,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep6_021213_Fx50mM.raw,SYSMHC00010_C_rep6_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,18,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep6_021213_Fx600mM.raw,SYSMHC00010_C_rep6_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,19,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_C_rep6_021213_Fx75mM.raw,SYSMHC00010_C_rep6_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_08,20,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702, C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep3_021213_Fx100mM.raw,SYSMHC00010_CELG_rep3_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep3_021213_Fx300mM.raw,SYSMHC00010_CELG_rep3_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep3_021213_Fx50mM.raw,SYSMHC00010_CELG_rep3_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep3_021213_Fx600mM.raw,SYSMHC00010_CELG_rep3_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep3_021213_Fx75mM.raw,SYSMHC00010_CELG_rep3_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep4_021213_Fx100mM.raw,SYSMHC00010_CELG_rep4_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep4_021213_Fx300mM.raw,SYSMHC00010_CELG_rep4_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,7,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep4_021213_Fx50mM.raw,SYSMHC00010_CELG_rep4_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,8,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep4_021213_Fx600mM.raw,SYSMHC00010_CELG_rep4_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,9,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep4_021213_Fx75mM.raw,SYSMHC00010_CELG_rep4_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,10,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep5_021213_Fx100mM.raw,SYSMHC00010_CELG_rep5_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,11,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep5_021213_Fx300mM.raw,SYSMHC00010_CELG_rep5_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,12,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep5_021213_Fx50mM.raw,SYSMHC00010_CELG_rep5_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,13,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep5_021213_Fx600mM.raw,SYSMHC00010_CELG_rep5_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,14,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep5_021213_Fx75mM.raw,SYSMHC00010_CELG_rep5_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,15,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep6_021213_Fx100mM.raw,SYSMHC00010_CELG_rep6_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,16,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep6_021213_Fx300mM.raw,SYSMHC00010_CELG_rep6_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,17,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep6_021213_Fx50mM.raw,SYSMHC00010_CELG_rep6_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,18,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep6_021213_Fx600mM.raw,SYSMHC00010_CELG_rep6_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,19,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_CELG_rep6_021213_Fx75mM.raw,SYSMHC00010_CELG_rep6_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_11,20,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep3_021213_Fx100mM.raw,SYSMHC00010_J_rep3_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep3_021213_Fx300mM.raw,SYSMHC00010_J_rep3_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep3_021213_Fx50mM.raw,SYSMHC00010_J_rep3_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep3_021213_Fx600mM.raw,SYSMHC00010_J_rep3_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep3_021213_Fx75mM.raw,SYSMHC00010_J_rep3_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep4_021213_Fx100mM.raw,SYSMHC00010_J_rep4_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep4_021213_Fx300mM.raw,SYSMHC00010_J_rep4_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,7,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep4_021213_Fx50mM.raw,SYSMHC00010_J_rep4_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,8,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep4_021213_Fx600mM.raw,SYSMHC00010_J_rep4_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,9,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep4_021213_Fx75mM.raw,SYSMHC00010_J_rep4_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,10,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep5_021213_Fx100mM.raw,SYSMHC00010_J_rep5_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,11,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep5_021213_Fx300mM.raw,SYSMHC00010_J_rep5_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,12,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep5_021213_Fx50mM.raw,SYSMHC00010_J_rep5_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,13,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep5_021213_Fx600mM.raw,SYSMHC00010_J_rep5_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,14,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep5_021213_Fx75mM.raw,SYSMHC00010_J_rep5_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,15,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep6_021213_Fx100mM.raw,SYSMHC00010_J_rep6_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,16,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep6_021213_Fx300mM.raw,SYSMHC00010_J_rep6_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,17,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep6_021213_Fx50mM.raw,SYSMHC00010_J_rep6_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,18,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep6_021213_Fx600mM.raw,SYSMHC00010_J_rep6_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,19,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_J_rep6_021213_Fx75mM.raw,SYSMHC00010_J_rep6_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_09,20,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_MA_rep3_021213_Fx100mM.raw,SYSMHC00010_MA_rep3_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_03,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_MA_rep3_021213_Fx300mM.raw,SYSMHC00010_MA_rep3_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_03,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_MA_rep3_021213_Fx50mM.raw,SYSMHC00010_MA_rep3_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_03,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_MA_rep3_021213_Fx600mM.raw,SYSMHC00010_MA_rep3_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_03,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_MA_rep3_021213_Fx75mM.raw,SYSMHC00010_MA_rep3_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_03,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_MA_rep4_021213_Fx100mM.raw,SYSMHC00010_MA_rep4_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_03,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_MA_rep4_021213_Fx300mM.raw,SYSMHC00010_MA_rep4_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_03,7,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_MA_rep4_021213_Fx50mM.raw,SYSMHC00010_MA_rep4_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_03,8,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_MA_rep4_021213_Fx600mM.raw,SYSMHC00010_MA_rep4_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_03,9,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_MA_rep4_021213_Fx75mM.raw,SYSMHC00010_MA_rep4_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_03,10,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_MA_rep5_021213_Fx100mM.raw,SYSMHC00010_MA_rep5_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_03,11,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_MA_rep5_021213_Fx300mM.raw,SYSMHC00010_MA_rep5_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_03,12,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_MA_rep5_021213_Fx50mM.raw,SYSMHC00010_MA_rep5_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_03,13,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_MA_rep5_021213_Fx600mM.raw,SYSMHC00010_MA_rep5_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_03,14,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_MA_rep5_021213_Fx75mM.raw,SYSMHC00010_MA_rep5_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_03,15,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_pat_AC2_04092014_rep3_2.raw,SYSMHC00010_pat_AC2_04092014_rep3_2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_14,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A3201,B2705,B4501,C01,C16",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_AC2_04092014_rep4.raw,SYSMHC00010_pat_AC2_04092014_rep4_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_14,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A3201,B2705,B4501,C01,C16",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_AC2_22072014_rep1.raw,SYSMHC00010_pat_AC2_22072014_rep1_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_14,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A3201,B2705,B4501,C01,C16",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_AC2_22072014_rep2.raw,SYSMHC00010_pat_AC2_22072014_rep2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_14,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A3201,B2705,B4501,C01,C16",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_C_22072014_rep2.raw,SYSMHC00010_pat_C_22072014_rep2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_C_Subject_08,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_C_22072014_rep3.raw,SYSMHC00010_pat_C_22072014_rep3_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_C_Subject_08,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_C_23072014_rep4.raw,SYSMHC00010_pat_C_23072014_rep4_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_C_Subject_08,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_CELG_14072014_rep1.raw,SYSMHC00010_pat_CELG_14072014_rep1_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_CELG_Subject_11,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_CELG_14072014_rep2.raw,SYSMHC00010_pat_CELG_14072014_rep2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_CELG_Subject_11,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_CELG_14072014_rep3.raw,SYSMHC00010_pat_CELG_14072014_rep3_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_CELG_Subject_11,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2402,B1501,B7301,C0303,C1505",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_CP2_06082014_rep1.raw,SYSMHC00010_pat_CP2_06082014_rep1_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_16,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A1101,B1402,B4402,C05,C08",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_CP2_06082014_rep2.raw,SYSMHC00010_pat_CP2_06082014_rep2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_16,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A1101,B1402,B4402,C05,C08",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_CP2_06082014_rep3.raw,SYSMHC00010_pat_CP2_06082014_rep3_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_16,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A1101,B1402,B4402,C05,C08",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_FL_03062014_rep1.raw,SYSMHC00010_pat_FL_03062014_rep1_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_05,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A1101,B4403,B5001",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_FL_03062014_rep2.raw,SYSMHC00010_pat_FL_03062014_rep2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_05,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A1101,B4403,B5001",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_FL_03062014_rep3.raw,SYSMHC00010_pat_FL_03062014_rep3_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_05,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A1101,B4403,B5001",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_FL_03062014_rep4.raw,SYSMHC00010_pat_FL_03062014_rep4_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_05,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A1101,B4403,B5001",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_FL_13082014_rep6.raw,SYSMHC00010_pat_FL_13082014_rep6_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_05,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A1101,B4403,B5001",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_FL_13082014_rep7.raw,SYSMHC00010_pat_FL_13082014_rep7_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_05,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A1101,B4403,B5001",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_FL_13082014_rep8.raw,SYSMHC00010_pat_FL_13082014_rep8_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_05,7,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A1101,B4403,B5001",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_J_07082014_rep4.raw,SYSMHC00010_pat_J_07082014_rep4_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_J_Subject_09,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_J_07082014_rep5.raw,SYSMHC00010_pat_J_07082014_rep5_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_J_Subject_09,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_J_07082014_rep6.raw,SYSMHC00010_pat_J_07082014_rep6_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_J_Subject_09,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_J_14072014_rep1.raw,SYSMHC00010_pat_J_14072014_rep1_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_J_Subject_09,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_J_14072014_rep2.raw,SYSMHC00010_pat_J_14072014_rep2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_J_Subject_09,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_J_14072014_rep3.raw,SYSMHC00010_pat_J_14072014_rep3_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_J_Subject_09,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0301,B0702,C0702",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_JPB3_24102014_rep1.raw,SYSMHC00010_pat_JPB3_24102014_rep1_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_13,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A1101,B2705,B5601,C01,C02",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_JPB3_24102014_rep2.raw,SYSMHC00010_pat_JPB3_24102014_rep2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_13,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A1101,B2705,B5601,C01,C02",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_JPB3_24102014_rep3.raw,SYSMHC00010_pat_JPB3_24102014_rep3_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_13,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A1101,B2705,B5601,C01,C02",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_JT2_14072014_rep1.raw,SYSMHC00010_pat_JT2_14072014_rep1_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_17,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A1101,B1803,B3501,C04,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_JT2_14072014_rep2.raw,SYSMHC00010_pat_JT2_14072014_rep2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_17,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A1101,B1803,B3501,C04,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_JT2_14072014_rep3.raw,SYSMHC00010_pat_JT2_14072014_rep3_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_17,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A1101,B1803,B3501,C04,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_M_11072014_rep1.raw,SYSMHC00010_pat_M_11072014_rep1_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_01,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_M_11072014_rep2.raw,SYSMHC00010_pat_M_11072014_rep2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_01,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_M_11072014_rep3.raw,SYSMHC00010_pat_M_11072014_rep3_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_01,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_MA_07082014_rep1.raw,SYSMHC00010_pat_MA_07082014_rep1_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_MA_Subject_03,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_MA_07082014_rep2.raw,SYSMHC00010_pat_MA_07082014_rep2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_MA_Subject_03,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_MA_07082014_rep3.raw,SYSMHC00010_pat_MA_07082014_rep3_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_MA_Subject_03,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2902,B5701,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_ML_03062014_rep5.raw,SYSMHC00010_pat_ML_03062014_rep5_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_06,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A1101,B4001,B4403,C03,C16",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_ML_03062014_rep6.raw,SYSMHC00010_pat_ML_03062014_rep6_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_06,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A1101,B4001,B4403,C03,C16",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_ML_13052014_rep1.raw,SYSMHC00010_pat_ML_13052014_rep1_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_06,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A1101,B4001,B4403,C03,C16",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_ML_13052014_rep2.raw,SYSMHC00010_pat_ML_13052014_rep2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_06,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A1101,B4001,B4403,C03,C16",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_ML_16052014_rep3.raw,SYSMHC00010_pat_ML_16052014_rep3_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_06,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A1101,B4001,B4403,C03,C16",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_ML_16052014_rep4.raw,SYSMHC00010_pat_ML_16052014_rep4_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_06,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A1101,B4001,B4403,C03,C16",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_NS2_14072014_rep1.raw,SYSMHC00010_pat_NS2_14072014_rep1_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_12,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,B1302,B4101,C06,C17",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_NS2_14072014_rep2.raw,SYSMHC00010_pat_NS2_14072014_rep2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_12,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,B1302,B4101,C06,C17",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_NS2_14072014_rep3.raw,SYSMHC00010_pat_NS2_14072014_rep3_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_12,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,B1302,B4101,C06,C17",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_NT_03062014_rep5.raw,SYSMHC00010_pat_NT_03062014_rep5_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_15,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A3201,B0801,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_NT_03062014_rep6.raw,SYSMHC00010_pat_NT_03062014_rep6_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_15,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A3201,B0801,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_NT_13052014_rep1.raw,SYSMHC00010_pat_NT_13052014_rep1_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_15,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A3201,B0801,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_NT_13052014_rep2.raw,SYSMHC00010_pat_NT_13052014_rep2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_15,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A3201,B0801,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_NT_15082014_rep7.raw,SYSMHC00010_pat_NT_15082014_rep7_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_15,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A3201,B0801,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_NT_15082014_rep8.raw,SYSMHC00010_pat_NT_15082014_rep8_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_15,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A3201,B0801,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_NT_15082014_rep9.raw,SYSMHC00010_pat_NT_15082014_rep9_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_15,7,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A3201,B0801,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_NT_16052014_rep3.raw,SYSMHC00010_pat_NT_16052014_rep3_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_15,8,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A3201,B0801,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_NT_16052014_rep4.raw,SYSMHC00010_pat_NT_16052014_rep4_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_15,9,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0101,A3201,B0801,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_PF1_22072014_rep1.raw,SYSMHC00010_pat_PF1_22072014_rep1_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_PF1_Subject_04,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_PF1_22072014_rep2.raw,SYSMHC00010_pat_PF1_22072014_rep2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_PF1_Subject_04,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_PF1_22072014_rep3.raw,SYSMHC00010_pat_PF1_22072014_rep3_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_PF1_Subject_04,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_R_11072014_rep1.raw,SYSMHC00010_pat_R_11072014_rep1_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_02,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_R_11072014_rep2.raw,SYSMHC00010_pat_R_11072014_rep2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_02,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_R_11072014_rep3.raw,SYSMHC00010_pat_R_11072014_rep3_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_02,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2902,B0801,B4403,C0701,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_RT_06082014_rep1.raw,SYSMHC00010_pat_RT_06082014_rep1_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_RT_Subject_10,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_RT_06082014_rep2.raw,SYSMHC00010_pat_RT_06082014_rep2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_RT_Subject_10,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_RT_06082014_rep3.raw,SYSMHC00010_pat_RT_06082014_rep3_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_pat_RT_Subject_10,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_SR_03062014_rep5.raw,SYSMHC00010_pat_SR_03062014_rep5_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_07,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2301,B1801,B4403,C04,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_SR_03062014_rep6.raw,SYSMHC00010_pat_SR_03062014_rep6_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_07,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2301,B1801,B4403,C04,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_SR_13052014_rep1.raw,SYSMHC00010_pat_SR_13052014_rep1_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_07,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2301,B1801,B4403,C04,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_SR_13052014_rep2.raw,SYSMHC00010_pat_SR_13052014_rep2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_07,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2301,B1801,B4403,C04,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_SR_15082014_rep7.raw,SYSMHC00010_pat_SR_15082014_rep7_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_07,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2301,B1801,B4403,C04,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_SR_15082014_rep8.raw,SYSMHC00010_pat_SR_15082014_rep8_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_07,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2301,B1801,B4403,C04,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_SR_15082014_rep9_2.raw,SYSMHC00010_pat_SR_15082014_rep9_2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_07,7,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2301,B1801,B4403,C04,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_SR_16052014_rep3.raw,SYSMHC00010_pat_SR_16052014_rep3_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_07,8,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2301,B1801,B4403,C04,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_SR_16052014_rep4.raw,SYSMHC00010_pat_SR_16052014_rep4_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_07,9,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A2301,B1801,B4403,C04,C07",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_ST_13082014_rep1.raw,SYSMHC00010_pat_ST_13082014_rep1_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_18,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2402,B0702,B2705",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_ST_13082014_rep2.raw,SYSMHC00010_pat_ST_13082014_rep2_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_18,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2402,B0702,B2705",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_pat_ST_13082014_rep3.raw,SYSMHC00010_pat_ST_13082014_rep3_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_18,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0301,A2402,B0702,B2705",26857467,SYSMHC00010,native,mild acid elution,,,,Q-Exactive Plus,,no,DDA,,3-40%,151,,,,
SYSMHC00010_PF1_rep3_021213_Fx100mM.raw,SYSMHC00010_PF1_rep3_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep3_021213_Fx300mM.raw,SYSMHC00010_PF1_rep3_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_PF1_Subject_04,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep3_021213_Fx50mM.raw,SYSMHC00010_PF1_rep3_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep3_021213_Fx600mM.raw,SYSMHC00010_PF1_rep3_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep3_021213_Fx75mM.raw,SYSMHC00010_PF1_rep3_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep4_021213_Fx100mM.raw,SYSMHC00010_PF1_rep4_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep4_021213_Fx300mM.raw,SYSMHC00010_PF1_rep4_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,7,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep4_021213_Fx50mM.raw,SYSMHC00010_PF1_rep4_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,8,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep4_021213_Fx600mM.raw,SYSMHC00010_PF1_rep4_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,9,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep4_021213_Fx75mM.raw,SYSMHC00010_PF1_rep4_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,10,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep5_021213_Fx100mM.raw,SYSMHC00010_PF1_rep5_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,11,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep5_021213_Fx300mM.raw,SYSMHC00010_PF1_rep5_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,12,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep5_021213_Fx50mM.raw,SYSMHC00010_PF1_rep5_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,13,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep5_021213_Fx600mM.raw,SYSMHC00010_PF1_rep5_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,14,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep5_021213_Fx75mM.raw,SYSMHC00010_PF1_rep5_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,15,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep6_021213_Fx100mM.raw,SYSMHC00010_PF1_rep6_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,16,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep6_021213_Fx300mM.raw,SYSMHC00010_PF1_rep6_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,17,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep6_021213_Fx50mM.raw,SYSMHC00010_PF1_rep6_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,18,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep6_021213_Fx600mM.raw,SYSMHC00010_PF1_rep6_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,19,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_PF1_rep6_021213_Fx75mM.raw,SYSMHC00010_PF1_rep6_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_04,20,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B0702,B4403,C0702,C1601",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep3_021213_Fx100mM.raw,SYSMHC00010_RT_rep3_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep3_021213_Fx300mM.raw,SYSMHC00010_RT_rep3_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_RT_Subject_10,2,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep3_021213_Fx50mM.raw,SYSMHC00010_RT_rep3_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,3,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep3_021213_Fx600mM.raw,SYSMHC00010_RT_rep3_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,4,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep3_021213_Fx75mM.raw,SYSMHC00010_RT_rep3_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,5,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep4_021213_Fx100mM.raw,SYSMHC00010_RT_rep4_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,6,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep4_021213_Fx300mM.raw,SYSMHC00010_RT_rep4_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,7,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep4_021213_Fx50mM.raw,SYSMHC00010_RT_rep4_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,8,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep4_021213_Fx600mM.raw,SYSMHC00010_RT_rep4_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,9,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep4_021213_Fx75mM.raw,SYSMHC00010_RT_rep4_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,10,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep5_021213_Fx100mM.raw,SYSMHC00010_RT_rep5_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,11,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep5_021213_Fx300mM.raw,SYSMHC00010_RT_rep5_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,12,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep5_021213_Fx50mM.raw,SYSMHC00010_RT_rep5_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,13,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep5_021213_Fx600mM.raw,SYSMHC00010_RT_rep5_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,14,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep5_021213_Fx75mM.raw,SYSMHC00010_RT_rep5_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,15,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep6_021213_Fx100mM.raw,SYSMHC00010_RT_rep6_021213_Fx100mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,16,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep6_021213_Fx300mM.raw,SYSMHC00010_RT_rep6_021213_Fx300mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,17,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep6_021213_Fx50mM.raw,SYSMHC00010_RT_rep6_021213_Fx50mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,18,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep6_021213_Fx600mM.raw,SYSMHC00010_RT_rep6_021213_Fx600mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,19,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00010_RT_rep6_021213_Fx75mM.raw,SYSMHC00010_RT_rep6_021213_Fx75mM_c.mzXML,SYSMHC00010_gradosd_160630_perreault-thibault_cada_LCL_Subject_10,20,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed,class I,"A0201,A0101,B1801,B3924,C0501,C0701",26857467,SYSMHC00010,native,mild acid elution,,,,Orbitrap ELITE,,no,DDA,,5-40%,56,,,,
SYSMHC00011_OTE0089_NT_cone8_neg_13579.raw,SYSMHC00011_OTE0089_NT_cone8_neg_13579_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTE0089_NT_cone8_neg_13579,1,Human,In vitro,Blood,CD4+ PBMC,suspension,,,class I,"A2902,A3004,B4101,B4403,C1601,C1701",26467324,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Elite,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTE0090_NT_cone8_neg_2468.raw,SYSMHC00011_OTE0090_NT_cone8_neg_2468_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTE0090_NT_cone8_neg_2468,1,Human,In vitro,Blood,CD4+ PBMC,suspension,,,class I,"A2902,A3004,B4101,B4403,C1601,C1701",26467324,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Elite,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTE0091_NT_cone8_IIIB_13581.raw,SYSMHC00011_OTE0091_NT_cone8_IIIB_13581_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTE0091_NT_cone8_IIIB_13581,1,Human,In vitro,Blood,CD4+ PBMC,suspension,,HIV-1-infected,class I,"A2902,A3004,B4101,B4403,C1601,C1701",26467324,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Elite,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTE0092_NT_cone8_IIIB_2468.raw,SYSMHC00011_OTE0092_NT_cone8_IIIB_2468_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTE0092_NT_cone8_IIIB_2468,1,Human,In vitro,Blood,CD4+ PBMC,suspension,,HIV-1-infected,class I,"A2902,A3004,B4101,B4403,C1601,C1701",26467324,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Elite,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTV3024a_Jurkat_MVA-HIVconsv_0h_3579_inclusion.raw,SYSMHC00011_OTV3024a_Jurkat_MVA-HIVconsv_0h_3579_inclusion_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTV3024a_Jurkat_MVA-HIVconsv_0h_3579_inclusion,replicate 1,Human,In vitro,Blood,Jurkat,suspension,,,class I,"A0301,A0301,B0702,B3503,C0401,C0702",26467324,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Velos,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTV3024b_Jurkat_MVA-HIVconsv_0h_3579.raw,SYSMHC00011_OTV3024b_Jurkat_MVA-HIVconsv_0h_3579_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTV3024b_Jurkat_MVA-HIVconsv_0h_3579,replicate 2,Human,In vitro,Blood,Jurkat,suspension,,,class I,"A0301,A0301,B0702,B3503,C0401,C0702",25810538,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Velos,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTV3025a_Jurkat_MVA-HIVconsv_0h_2468_inclusion.raw,SYSMHC00011_OTV3025a_Jurkat_MVA-HIVconsv_0h_2468_inclusion_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTV3025a_Jurkat_MVA-HIVconsv_0h_2468_inclusion,replicate 1,Human,In vitro,Blood,Jurkat,suspension,,,class I,"A0301,A0301,B0702,B3503,C0401,C0702",25810538,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Velos,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTV3025b_Jurkat_MVA-HIVconsv_0h_2468.raw,SYSMHC00011_OTV3025b_Jurkat_MVA-HIVconsv_0h_2468_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTV3025b_Jurkat_MVA-HIVconsv_0h_2468,replicate 2,Human,In vitro,Blood,Jurkat,suspension,,,class I,"A0301,A0301,B0702,B3503,C0401,C0702",25810538,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Velos,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTV3026a_Jurkat_MVA-HIVconsv_1-5h_3579_inclusion.raw,SYSMHC00011_OTV3026a_Jurkat_MVA-HIVconsv_1-5h_3579_inclusion_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTV3026a_Jurkat_MVA-HIVconsv_1-5h_3579_inclusion,replicate 1,Human,In vitro,Blood,Jurkat,suspension,,MVA.HIVconsv infected,class I,"A0301,A0301,B0702,B3503,C0401,C0702",25810538,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Velos,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTV3026b_Jurkat_MVA-HIVconsv_1-5h_3579.raw,SYSMHC00011_OTV3026b_Jurkat_MVA-HIVconsv_1-5h_3579_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTV3026b_Jurkat_MVA-HIVconsv_1-5h_3579,replicate 2,Human,In vitro,Blood,Jurkat,suspension,,MVA.HIVconsv infected,class I,"A0301,A0301,B0702,B3503,C0401,C0702",25810538,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Velos,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTV3027a_Jurkat_MVA-HIVconsv_1-5h_2468_inclusion.raw,SYSMHC00011_OTV3027a_Jurkat_MVA-HIVconsv_1-5h_2468_inclusion_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTV3027a_Jurkat_MVA-HIVconsv_1-5h_2468_inclusion,replicate 1,Human,In vitro,Blood,Jurkat,suspension,,MVA.HIVconsv infected,class I,"A0301,A0301,B0702,B3503,C0401,C0702",25810538,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Velos,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTV3027b_Jurkat_MVA-HIVconsv_1-5h_2468.raw,SYSMHC00011_OTV3027b_Jurkat_MVA-HIVconsv_1-5h_2468_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTV3027b_Jurkat_MVA-HIVconsv_1-5h_2468,replicate 2,Human,In vitro,Blood,Jurkat,suspension,,MVA.HIVconsv infected,class I,"A0301,A0301,B0702,B3503,C0401,C0702",25810538,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Velos,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTV3028a_Jurkat_MVA-HIVconsv_2-5h_3579_inclusion.raw,SYSMHC00011_OTV3028a_Jurkat_MVA-HIVconsv_2-5h_3579_inclusion_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTV3028a_Jurkat_MVA-HIVconsv_2-5h_3579_inclusion,replicate 1,Human,In vitro,Blood,Jurkat,suspension,,MVA.HIVconsv infected,class I,"A0301,A0301,B0702,B3503,C0401,C0702",25810538,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Velos,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTV3028b_Jurkat_MVA-HIVconsv_2-5h_3579.raw,SYSMHC00011_OTV3028b_Jurkat_MVA-HIVconsv_2-5h_3579_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTV3028b_Jurkat_MVA-HIVconsv_2-5h_3579,replicate 2,Human,In vitro,Blood,Jurkat,suspension,,MVA.HIVconsv infected,class I,"A0301,A0301,B0702,B3503,C0401,C0702",25810538,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Velos,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTV3029a_Jurkat_MVA-HIVconsv_2-5h_2468_inclusion.raw,SYSMHC00011_OTV3029a_Jurkat_MVA-HIVconsv_2-5h_2468_inclusion_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTV3029a_Jurkat_MVA-HIVconsv_2-5h_2468_inclusion,replicate 1,Human,In vitro,Blood,Jurkat,suspension,,MVA.HIVconsv infected,class I,"A0301,A0301,B0702,B3503,C0401,C0702",25810538,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Velos,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTV3029b_Jurkat_MVA-HIVconsv_2-5h_2468.raw,SYSMHC00011_OTV3029b_Jurkat_MVA-HIVconsv_2-5h_2468_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTV3029b_Jurkat_MVA-HIVconsv_2-5h_2468,replicate 2,Human,In vitro,Blood,Jurkat,suspension,,MVA.HIVconsv infected,class I,"A0301,A0301,B0702,B3503,C0401,C0702",25810538,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Velos,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTV3030a_Jurkat_MVA-HIVconsv_3-5h_3579_inclusion.raw,SYSMHC00011_OTV3030a_Jurkat_MVA-HIVconsv_3-5h_3579_inclusion_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTV3030a_Jurkat_MVA-HIVconsv_3-5h_3579_inclusion,replicate 1,Human,In vitro,Blood,Jurkat,suspension,,MVA.HIVconsv infected,class I,"A0301,A0301,B0702,B3503,C0401,C0702",25810538,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Velos,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTV3030b_Jurkat_MVA-HIVconsv_3-5h_3579.raw,SYSMHC00011_OTV3030b_Jurkat_MVA-HIVconsv_3-5h_3579_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTV3030b_Jurkat_MVA-HIVconsv_3-5h_3579,replicate 2,Human,In vitro,Blood,Jurkat,suspension,,MVA.HIVconsv infected,class I,"A0301,A0301,B0702,B3503,C0401,C0702",25810538,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Velos,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTV3031a_Jurkat_MVA-HIVconsv_3-5h_2468_inclusion.raw,SYSMHC00011_OTV3031a_Jurkat_MVA-HIVconsv_3-5h_2468_inclusion_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTV3031a_Jurkat_MVA-HIVconsv_3-5h_2468_inclusion,replicate 1,Human,In vitro,Blood,Jurkat,suspension,,MVA.HIVconsv infected,class I,"A0301,A0301,B0702,B3503,C0401,C0702",25810538,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Velos,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_OTV3031b_Jurkat_MVA-HIVconsv_3-5h_2468.raw,SYSMHC00011_OTV3031b_Jurkat_MVA-HIVconsv_3-5h_2468_c.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_OTV3031b_Jurkat_MVA-HIVconsv_3-5h_2468,replicate 2,Human,In vitro,Blood,Jurkat,suspension,,MVA.HIVconsv infected,class I,"A0301,A0301,B0702,B3503,C0401,C0702",25810538,SYSMHC00011,native,Immunoaffinity,,,,Orbitrap Velos,no Acquity (Waters),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_TT0024_HLA_MVA-HIVconsv_0h.wiff,SYSMHC00011_TT0024_HLA_MVA-HIVconsv_0h.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TT0024_HLA_MVA-HIVconsv_0h,replicate 1,Human,In vitro,Blood,Jurkat,suspension,,,class I,"A0301,A0301,B0702,B3503,C0401,C0702",,SYSMHC00011,native,Immunoaffinity,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_TT0025_HLA_MVA-HIVconsv_0h.wiff,SYSMHC00011_TT0025_HLA_MVA-HIVconsv_0h.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TT0025_HLA_MVA-HIVconsv_0h,replicate 2,Human,In vitro,Blood,Jurkat,suspension,,,class I,"A0301,A0301,B0702,B3503,C0401,C0702",,SYSMHC00011,native,Immunoaffinity,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_TT0026_HLA_MVA-HIVconsv_1-5h.wiff,SYSMHC00011_TT0026_HLA_MVA-HIVconsv_1-5h.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TT0026_HLA_MVA-HIVconsv_1-5h,replicate 1,Human,In vitro,Blood,Jurkat,suspension,,MVA.HIVconsv infected,class I,"A0301,A0301,B0702,B3503,C0401,C0702",,SYSMHC00011,native,Immunoaffinity,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_TT0027_HLA_MVA-HIVconsv_1-5h.wiff,SYSMHC00011_TT0027_HLA_MVA-HIVconsv_1-5h.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TT0027_HLA_MVA-HIVconsv_1-5h,replicate 2,Human,In vitro,Blood,Jurkat,suspension,,MVA.HIVconsv infected,class I,"A0301,A0301,B0702,B3503,C0401,C0702",,SYSMHC00011,native,Immunoaffinity,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_TT0028_HLA_MVA-HIVconsv_2-5h.wiff,SYSMHC00011_TT0028_HLA_MVA-HIVconsv_2-5h.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TT0028_HLA_MVA-HIVconsv_2-5h,replicate 1,Human,In vitro,Blood,Jurkat,suspension,,MVA.HIVconsv infected,class I,"A0301,A0301,B0702,B3503,C0401,C0702",,SYSMHC00011,native,Immunoaffinity,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_TT0029_HLA_MVA-HIVconsv_2-5h.wiff,SYSMHC00011_TT0029_HLA_MVA-HIVconsv_2-5h.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TT0029_HLA_MVA-HIVconsv_2-5h,replicate 2,Human,In vitro,Blood,Jurkat,suspension,,MVA.HIVconsv infected,class I,"A0301,A0301,B0702,B3503,C0401,C0702",,SYSMHC00011,native,Immunoaffinity,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_TT0030_HLA_MVA-HIVconsv_3-5h.wiff,SYSMHC00011_TT0030_HLA_MVA-HIVconsv_3-5h.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TT0030_HLA_MVA-HIVconsv_3-5h,replicate 1,Human,In vitro,Blood,Jurkat,suspension,,MVA.HIVconsv infected,class I,"A0301,A0301,B0702,B3503,C0401,C0702",,SYSMHC00011,native,Immunoaffinity,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_TT0031_HLA_MVA-HIVconsv_3-5h.wiff,SYSMHC00011_TT0031_HLA_MVA-HIVconsv_3-5h.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TT0031_HLA_MVA-HIVconsv_3-5h,replicate 2,Human,In vitro,Blood,Jurkat,suspension,,MVA.HIVconsv infected,class I,"A0301,A0301,B0702,B3503,C0401,C0702",,SYSMHC00011,native,Immunoaffinity,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_TT0033_C7_HIV-1_3579_201307.wiff,SYSMHC00011_TT0033_C7_HIV-1_3579_201307.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TT0033_C7_HIV-1_3579_201307,1,Human,In vitro,Blood,CD4+ PBMC,suspension,,HIV-1-infected,class I,"A1101,A6801,B0702,B2705,C0102,C0702",26467324,SYSMHC00011,native,Immunoaffinity,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_TT0034_C7_HIV-1_2468_201307.wiff,SYSMHC00011_TT0034_C7_HIV-1_2468_201307.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TT0034_C7_HIV-1_2468_201307,1,Human,In vitro,Blood,CD4+ PBMC,suspension,,HIV-1-infected,class I,"A1101,A6801,B0702,B2705,C0102,C0702",26467324,SYSMHC00011,native,Immunoaffinity,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_TT0035_C6_HIV-1_C6_201307.wiff,SYSMHC00011_TT0035_C6_HIV-1_C6_201307.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TT0035_C6_HIV-1_C6_201307,1,Human,In vitro,Blood,CD4+ PBMC,suspension,,HIV-1-infected,class I,"A2402,A2902,B3503,B4501,C0401,C0602",26467324,SYSMHC00011,native,Immunoaffinity,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_TT0036_CD4_HIV-1_1357_201302.wiff,SYSMHC00011_TT0036_CD4_HIV-1_1357_201302.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TT0036_CD4_HIV-1_1357_201302,1,,,Blood,,,,,class I,,,,,,,,,,,,,,,,,,,
SYSMHC00011_TT0037_CD4_HIV-1_2468_201302.wiff,SYSMHC00011_TT0037_CD4_HIV-1_2468_201302.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TT0037_CD4_HIV-1_2468_201302,1,,,Blood,,,,,class I,,,,,,,,,,,,,,,,,,,
SYSMHC00011_TT0038_C1866_HIV-1_579_201205.wiff,SYSMHC00011_TT0038_C1866_HIV-1_579_201205.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TT0038_C1866_HIV-1_579_201205,1,Human,In vitro,Blood,C8166,suspension,,HIV-1-infected,class I,"A0101,A0101,B0801,B4402,C0501,C0702",26467324,SYSMHC00011,native,Immunoaffinity,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_TT0039_C1866_HIV-1_246_201205.wiff,SYSMHC00011_TT0039_C1866_HIV-1_246_201205.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TT0039_C1866_HIV-1_246_201205,1,Human,In vitro,Blood,C8166,suspension,,HIV-1-infected,class I,"A0101,A0101,B0801,B4402,C0501,C0702",26467324,SYSMHC00011,native,Immunoaffinity,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_TT0040_C1866_neg_all_201305.wiff,SYSMHC00011_TT0040_C1866_neg_all_201305.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TT0040_C1866_neg_all_201305,1,Human,In vitro,Blood,C8166,suspension,,,class I,"A0101,A0101,B0801,B4402,C0501,C0702",26467324,SYSMHC00011,native,Immunoaffinity,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_TTOF0076_NT_cone8_neg_13579.wiff,SYSMHC00011_TTOF0076_NT_cone8_neg_13579.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TTOF0076_NT_cone8_neg_13579,1,Human,In vitro,Blood,CD4+ PBMC,suspension,,,class I,"A2902,A3004,B4101,B4403,C1601,C1701",26467324,SYSMHC00011,native,Immunoaffinity,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_TTOF0077_NT_cone8_neg_2468.wiff,SYSMHC00011_TTOF0077_NT_cone8_neg_2468.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TTOF0077_NT_cone8_neg_2468,1,Human,In vitro,Blood,CD4+ PBMC,suspension,,,class I,"A2902,A3004,B4101,B4403,C1601,C1701",26467324,SYSMHC00011,native,Immunoaffinity,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_TTOF0078_NT_cone8_IIIB_13581.wiff,SYSMHC00011_TTOF0078_NT_cone8_IIIB_13581.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TTOF0078_NT_cone8_IIIB_13581,1,Human,In vitro,Blood,CD4+ PBMC,suspension,,HIV-1-infected,class I,"A2902,A3004,B4101,B4403,C1601,C1701",26467324,SYSMHC00011,native,Immunoaffinity,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,8-35% ACN,60,,,,
SYSMHC00011_TTOF0079_NT_cone8_IIIB_2468.wiff,SYSMHC00011_TTOF0079_NT_cone8_IIIB_2468.mzXML,SYSMHC00011_ternetten_161228_ternetten_UK_TTOF0079_NT_cone8_IIIB_2468,1,Human,In vitro,Blood,CD4+ PBMC,suspension,,HIV-1-infected,class I,"A2902,A3004,B4101,B4403,C1601,C1701",26467324,SYSMHC00011,native,Immunoaffinity,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),no,DDA,,8-35% ACN,60,,,,
SYSMHC00012_B4002_FT_bis.wiff,SYSMHC00012_B4002_FT_bis.mzXML,SYSMHC00012_mmarcilla_140203_Paradela_Spain_C1R-B*40,2,Human,In vitro,Blood,HMy2-C1R ,suspension,,Transfected with HLA-B*40:02; Expression of B35 and C04 is very low compared with that of B40,class I,"B4002,B3503,C0401",24366607,SYSMHC00012,native,Immunoaffinity,,10^10 cells,50%,Triple-TOF 5600,no-LC Ultra (Eksigent),no,DDA,,2-30% AcN,109,,,,
SYSMHC00012_DataB4002_FT.wiff,SYSMHC00012_DataB4002_FT.mzXML,SYSMHC00012_mmarcilla_140203_Paradela_Spain_C1R-B*40,1,Human,In vitro,Blood,HMy2-C1R,suspension,,Transfected with HLA-B*40:02; Expression of B35 and C04 is very low compared with that of B40,class I,"B4002,B3503,C0401",24366607,SYSMHC00012,native,Immunoaffinity,,10^10 cells,50%,Triple-TOF 5600,no-LC Ultra (Eksigent),no,DDA,,2-30% AcN,109,,,,
SYSMHC00013_B27_P2.wiff,,SYSMHC00013_mmarcilla_160913_Paradela_Spain_C1R-B*27,1,Human,In vitro,Blood,HMy2-C1R,suspension,,Transfected with HLA-B*B27:05; Expression of B35 and C04 is very low compared cith that of B27,class I,"B2705,B3503,C0401",26811146,SYSMHC00013,native,Immunoaffinity,,10^10 cells,33%,Triple-TOF 5600,no-LC Ultra (Eksigent),no,DDA,,2-30% AcN,109,,,,
SYSMHC00013_B27_P6_13.wiff,,SYSMHC00013_mmarcilla_160913_Paradela_Spain_C1R-B*27,2,Human,In vitro,Blood,HMy2-C1R ,suspension,,Transfected with HLA-B*B27:05; Expression of B35 and C04 is very low compared cith that of B27,class I,"B2705,B3503,C0401",26811146,SYSMHC00013,native,Immunoaffinity,,10^10 cells,33%,Triple-TOF 5600,no-LC Ultra (Eksigent),no,DDA,,2-30% AcN,182,,,,
SYSMHC00013_B27_P6_23.wiff,,SYSMHC00013_mmarcilla_160913_Paradela_Spain_C1R-B*27,3,Human,In vitro,Blood,HMy2-C1R ,suspension,,Transfected with HLA-B*B27:05; Expression of B35 and C04 is very low compared cith that of B27,class I,"B2705,B3503,C0401",26811146,SYSMHC00013,native,Immunoaffinity,,10^10 cells,33%,Triple-TOF 5600,no-LC Ultra (Eksigent),no,DDA,,2-30% AcN,182,,,,
SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr1_EThcD.raw,SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr1_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_GR_SCX_Fr1_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Fusion,EASY-nLC 1000,no,DDA,EThcD,"3% B to 27 % B in 96 min, 27% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 23 min",125,150 nl/min,"2.7 μm pore size, 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr10_EThcD.raw,SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr10_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_GR_SCX_Fr10_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Fusion,EASY-nLC 1000,no,DDA,EThcD,"3% B to 27 % B in 146 min, 30% B to 100% B in 3 min, 100 B % for 5 min, 100% B to 5 B % in 1 min, 5% B for 25 min",180,150 nl/min,"2.7 μm pore size, 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr2_EThcD.raw,SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr2_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_GR_SCX_Fr2_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Fusion,EASY-nLC 1000,no,DDA,EThcD,"3% B to 27 % B in 96 min, 27% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 23 min",125,150 nl/min,"2.7 μm pore size, 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr3_EThcD.raw,SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr3_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_GR_SCX_Fr3_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Fusion,EASY-nLC 1000,no,DDA,EThcD,"3% B to 27 % B in 96 min, 27% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 23 min",125,150 nl/min,"2.7 μm pore size, 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr4_EThcD.raw,SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr4_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_GR_SCX_Fr4_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Fusion,EASY-nLC 1000,no,DDA,EThcD,"3% B to 27 % B in 96 min, 27% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 23 min",125,150 nl/min,"2.7 μm pore size, 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr5_EThcD.raw,SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr5_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_GR_SCX_Fr5_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Fusion,EASY-nLC 1000,no,DDA,EThcD,"3% B to 27 % B in 96 min, 27% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 23 min",125,150 nl/min,"2.7 μm pore size, 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr6_EThcD.raw,SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr6_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_GR_SCX_Fr6_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Fusion,EASY-nLC 1000,no,DDA,EThcD,"3% B to 27 % B in 96 min, 27% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 23 min",125,150 nl/min,"2.7 μm pore size, 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr7_EThcD.raw,SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr7_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_GR_SCX_Fr7_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Fusion,EASY-nLC 1000,no,DDA,EThcD,"3% B to 27 % B in 96 min, 27% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 23 min",125,150 nl/min,"2.7 μm pore size, 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr8_EThcD.raw,SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr8_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_GR_SCX_Fr8_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Fusion,EASY-nLC 1000,no,DDA,EThcD,"3% B to 27 % B in 96 min, 27% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 23 min",125,150 nl/min,"2.7 μm pore size, 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr9_EThcD.raw,SYSMHC00014_F1_Agilent5_20150504_HLAI_GR_FM_SCX_Fr9_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_GR_SCX_Fr9_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Fusion,EASY-nLC 1000,no,DDA,EThcD,"3% B to 27 % B in 96 min, 27% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 23 min",125,150 nl/min,"2.7 μm pore size, 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_F1_ProxeonB_20150507_HLAI_GR_CNBR.raw,SYSMHC00014_F1_ProxeonB_20150507_HLAI_GR_CNBR_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_GR_CNBR,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\20 unfractioted,Orbitrap Fusion,EASY-nLC 1000,no,DDA,EThcD,"3% B to 27 % B in 146 min, 30% B to 100% B in 3 min, 100 B % for 5 min, 100% B to 5 B % in 1 min, 5% B for 25 min",180,150 nl/min,"2.7 μm pore size, 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_F1_ProxeonB_20150507_HLAI_GR_Separose_ProteiG.raw,SYSMHC00014_F1_ProxeonB_20150507_HLAI_GR_Separose_ProteiG_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_GR_Separose_ProteiG,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\20 unfractioted,Orbitrap Fusion,EASY-nLC 1000,no,DDA,EThcD,"7% B to 30 % B in 151 min, 30% B to 100% B in 3 min, 100 B % for 3 min, 100% B to 7 B % in 2 min, 7% B for 28 min",180,150 nl/min,"2.7 μm pore size, 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_CID_FT.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_CID_FT_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_CID_FT,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\20 unfractioted,Orbitrap Fusion,EASY-nLC 1000,no,DDA,CID,"7% B to 30 % B in 151 min, 30% B to 100% B in 3 min, 100 B % for 3 min, 100% B to 7 B % in 2 min, 7% B for 28 min",185,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr24_26_CID_HCD.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr24_26_CID_HCD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_SCX_fr24_26_CID_HCD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Elite,EASY-nLC 1000,no,DDA,HCD and CID,"6% B to 30 % B in 61 min, 30% B to 100% B in 3 min, 100% B for 3 min, 100% B to 7% B in 1 in, 7% B for 23 min",90,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr24_26_EThcD.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr24_26_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_SCX_fr24_26_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Elite,EASY-nLC 1000,no,DDA,EThcD,"6% B to 30 % B in 61 min, 30% B to 100% B in 3 min, 100% B for 3 min, 100% B to 7% B in 1 in, 7% B for 23 min",90,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr26_28_CID_HCD.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr26_28_CID_HCD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_SCX_fr26_28_CID_HCD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Elite,EASY-nLC 1000,no,DDA,HCD and CID,"6% B to 30 % B in 61 min, 30% B to 100% B in 3 min, 100% B for 3 min, 100% B to 7% B in 1 in, 7% B for 23 min",90,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr26_28_EThcD.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr26_28_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_SCX_fr26_28_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Elite,EASY-nLC 1000,no,DDA,EThcD,"6% B to 30 % B in 61 min, 30% B to 100% B in 3 min, 100% B for 3 min, 100% B to 7% B in 1 in, 7% B for 23 min",90,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr28_30_CID_HCD.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr28_30_CID_HCD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_SCX_fr28_30_CID_HCD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Elite,EASY-nLC 1000,no,DDA,HCD and CID,"6% B to 30 % B in 61 min, 30% B to 100% B in 3 min, 100% B for 3 min, 100% B to 7% B in 1 in, 7% B for 23 min",90,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr28_30_EThcD.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr28_30_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_SCX_fr28_30_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Elite,EASY-nLC 1000,no,DDA,EThcD,"6% B to 30 % B in 61 min, 30% B to 100% B in 3 min, 100% B for 3 min, 100% B to 7% B in 1 in, 7% B for 23 min",90,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr30_32_CID_HCD.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr30_32_CID_HCD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_SCX_fr30_32_CID_HCD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Elite,EASY-nLC 1000,no,DDA,HCD and CID,"6% B to 30 % B in 61 min, 30% B to 100% B in 3 min, 100% B for 3 min, 100% B to 7% B in 1 in, 7% B for 23 min",90,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr30_32_EThcD.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr30_32_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_SCX_fr30_32_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Elite,EASY-nLC 1000,no,DDA,EThcD,"6% B to 30 % B in 61 min, 30% B to 100% B in 3 min, 100% B for 3 min, 100% B to 7% B in 1 in, 7% B for 23 min",90,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr32_34_CID_HCD.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr32_34_CID_HCD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_SCX_fr32_34_CID_HCD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Elite,EASY-nLC 1000,no,DDA,HCD and CID,"6% B to 30 % B in 61 min, 30% B to 100% B in 3 min, 100% B for 3 min, 100% B to 7% B in 1 in, 7% B for 23 min",90,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr32_34_EThcD.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr32_34_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_SCX_fr32_34_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Elite,EASY-nLC 1000,no,DDA,EThcD,"6% B to 30 % B in 61 min, 30% B to 100% B in 3 min, 100% B for 3 min, 100% B to 7% B in 1 in, 7% B for 23 min",90,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr34_36_CID_HCD.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr34_36_CID_HCD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_SCX_fr34_36_CID_HCD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Elite,EASY-nLC 1000,no,DDA,HCD and CID,"6% B to 30 % B in 61 min, 30% B to 100% B in 3 min, 100% B for 3 min, 100% B to 7% B in 1 in, 7% B for 23 min",90,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr34_36_EThcD.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr34_36_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_SCX_fr34_36_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Elite,EASY-nLC 1000,no,DDA,EThcD,"6% B to 30 % B in 61 min, 30% B to 100% B in 3 min, 100% B for 3 min, 100% B to 7% B in 1 in, 7% B for 23 min",90,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr36_38_CID_HCD.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr36_38_CID_HCD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_SCX_fr36_38_CID_HCD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Elite,EASY-nLC 1000,no,DDA,HCD and CID,"6% B to 30 % B in 61 min, 30% B to 100% B in 3 min, 100% B for 3 min, 100% B to 7% B in 1 in, 7% B for 23 min",90,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr36_38_EThcD.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr36_38_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_SCX_fr36_38_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Elite,EASY-nLC 1000,no,DDA,EThcD,"6% B to 30 % B in 61 min, 30% B to 100% B in 3 min, 100% B for 3 min, 100% B to 7% B in 1 in, 7% B for 23 min",90,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr38_40_CID_HCD.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr38_40_CID_HCD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_SCX_fr38_40_CID_HCD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Elite,EASY-nLC 1000,no,DDA,HCD and CID,"6% B to 30 % B in 61 min, 30% B to 100% B in 3 min, 100% B for 3 min, 100% B to 7% B in 1 in, 7% B for 23 min",90,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr38_40_EThcD.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr38_40_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_SCX_fr38_40_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Elite,EASY-nLC 1000,no,DDA,EThcD,"6% B to 30 % B in 61 min, 30% B to 100% B in 3 min, 100% B for 3 min, 100% B to 7% B in 1 in, 7% B for 23 min",90,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr40_42_CID_HCD.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr40_42_CID_HCD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_SCX_fr40_42_CID_HCD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Elite,EASY-nLC 1000,no,DDA,HCD and CID,"6% B to 30 % B in 61 min, 30% B to 100% B in 3 min, 100% B for 3 min, 100% B to 7% B in 1 in, 7% B for 23 min",90,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr40_42_EThcD.raw,SYSMHC00014_OR8_1307012_CF_GM_HLA_SCX_fr40_42_EThcD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_SCX_fr40_42_EThcD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\3 SCX fraction,Orbitrap Elite,EASY-nLC 1000,no,DDA,EThcD,"6% B to 30 % B in 61 min, 30% B to 100% B in 3 min, 100% B for 3 min, 100% B to 7% B in 1 in, 7% B for 23 min",90,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR9_20130604_CF_GM_HLA_CID_HCD_Orbi.raw,SYSMHC00014_OR9_20130604_CF_GM_HLA_CID_HCD_Orbi_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_CID_HCD_Orbi,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\20 unfractioted,Orbitrap Elite,EASY-nLC 1000,no,DDA,HCD and CID,"7% B to 30 % B in 151 min, 30% B to 100% B in 3 min, 100 B % for 3 min, 100% B to 7 B % in 2 min, 7% B for 28 min",185,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR9_20130604_CF_GM_HLA_EThcD_replicate.raw,SYSMHC00014_OR9_20130604_CF_GM_HLA_EThcD_replicate_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_EThcD_replicate,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\20 unfractioted,Orbitrap Elite,EASY-nLC 1000,no,DDA,EThcD,"7% B to 30 % B in 151 min, 30% B to 100% B in 3 min, 100 B % for 3 min, 100% B to 7 B % in 2 min, 7% B for 28 min",185,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00014_OR9_20130604_CF_GM_HLA_HCD.raw,SYSMHC00014_OR9_20130604_CF_GM_HLA_HCD_c.mzXML,SYSMHC00014_Marinof_161005_Heck_Netherlands_HCD,1,Human,In vitro,Blood,B lymphoblastoid cell line GR,,,,class I,"A01,A03,B07,B27,C02,C07",27503676,SYSMHC00014,native,immunoaffinity,W6/32,9.00E+09,1\20 unfractioted,Orbitrap Elite,EASY-nLC 1000,no,DDA,HCD,"7% B to 30 % B in 151 min, 30% B to 100% B in 3 min, 100 B % for 3 min, 100% B to 7 B % in 2 min, 7% B for 28 min",185,300 nl/min,"1.8 μm pore size , 40 length × 0.0075 I.D. cm",Zorbax SB-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr1.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr1_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_ETD_SCX_fr1,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,ETD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr10.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr10_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_ETD_SCX_fr10,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,ETD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr2.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr2_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_ETD_SCX_fr2,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,ETD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr3.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr3_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_ETD_SCX_fr3,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,ETD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr4.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr4_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_ETD_SCX_fr4,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,ETD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr5_1.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr5_1_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_ETD_SCX_fr5,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,ETD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr6.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr6_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_ETD_SCX_fr6,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,ETD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr7.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr7_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_ETD_SCX_fr7,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,ETD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr8.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr8_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_ETD_SCX_fr8,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,ETD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr9.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_ETD_SCX_fr9_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_ETD_SCX_fr9,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,ETD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr1.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr1_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_HCD_SCX_fr1,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,HCD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr10.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr10_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_HCD_SCX_fr10,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,HCD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr2.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr2_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_HCD_SCX_fr2,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,HCD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr3.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr3_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_HCD_SCX_fr3,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,HCD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr4.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr4_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_HCD_SCX_fr4,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,HCD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr5.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr5_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_HCD_SCX_fr5,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,HCD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr6.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr6_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_HCD_SCX_fr6,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,HCD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr7.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr7_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_HCD_SCX_fr7,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,HCD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr8.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr8_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_HCD_SCX_fr8,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,HCD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr9.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_HCD_SCX_fr9_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_HCD_SCX_fr9,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,HCD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr1.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr1_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_SCX_fr1,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,EThcD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr10.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr10_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_SCX_fr10,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,EThcD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr2.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr2_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_SCX_fr2,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,EThcD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr3.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr3_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_SCX_fr3,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,EThcD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr4.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr4_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_SCX_fr4,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,EThcD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr5.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr5_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_SCX_fr5,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,EThcD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr6.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr6_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_SCX_fr6,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,EThcD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr7.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr7_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_SCX_fr7,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,EThcD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr8.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr8_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_SCX_fr8,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,EThcD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr9.raw,SYSMHC00015_OR9_20140407_FM_GM_HLA2_SCX_fr9_c.mzXML,SYSMHC00015_Mommeng_161005_Heck_Netherlands_SCX_fr9,1,Human,In vitro,Blood,MUTZ-3,adherent dendritic cells,,,class II,"DRB1_10,DRB1_11,DRB3_01",26764012,SYSMHC00015,native,immunoaffinity,L243,1.20E+09,1/4 SCX fraction,Orbitrap ELITE,EASY-nLC 1000,no,DDA,EThcD,"7% B to 30 % B in 91 min, 30% B to 100% B in 3 min, 100% B for 5 min, 100% B to 7% B in 1 min, 7% B for 20 min",125,150 nl/min,"2.7 μm pore size , 50 length × 0.005 I.D. cm",Poroshell 120 EC-C18,"A: 99.9% H2O, 0.1% Formic Acid; B: 99.9 % ACN, 0.1% Formic Acid"
SYSMHC00016_20111214_03_V1_PAT1.raw,SYSMHC00016_20111214_03_V1_PAT1_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_03_V1_PAT1,1,Human,In vivo,Bronchoalveolar lavage fluid,Macrophage,,sarcoidosis ,Mainly macrophage,class II,"DRB1_04,DRB1_07",27452731,SYSMHC00016,native,immunoaffinity,L243,85e6 cells,100%,Orbitrap Velos,Easy-nLC (Thermo Fisher Scientific),no,DDA,CID,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 3-35 % B over 89 minutes, followed by a 35-95 % ACN gradient over 5 minutes and 95 % ACN for 8 minutes",94,300 nl/min,10 cm long fused silica tip columns (OD 360 µm and ID 75 µm; SilicaTips™ New Objecnative Inc.) packed in-house. ,3 µm C18-AQ ReproSil-Pur®,
SYSMHC00016_20130301_03_Q3_PAT2.raw,SYSMHC00016_20130301_03_Q3_PAT2_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_03_Q3_PAT2,1,Human,In vivo,Bronchoalveolar lavage fluid,Macrophage,,sarcoidosis ,Mainly macrophage,class II,"DRB1_04,DRB1_13",27452731,SYSMHC00016,native,immunoaffinity,L243,50e6 cells,100%,Q-Exactive,Easy-nLC (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 3-35 % B over 35 min, followed by a 35-95 % ACN gradient over 5 minutes and 95 % ACN for 8 minutes.",40,300 nl/min,10 cm long fused silica tip columns (OD 360 µm and ID 75 µm; SilicaTips™ New Objecnative Inc.) packed in-house. ,3 µm C18-AQ ReproSil-Pur®,
SYSMHC00016_20130301_04_Q3_PAT3.raw,SYSMHC00016_20130301_04_Q3_PAT3_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_04_Q3_PAT3,1,Human,In vivo,Bronchoalveolar lavage fluid,Macrophage,,sarcoidosis ,Mainly macrophage,class II,"DRB1_07,DRB1_13",27452731,SYSMHC00016,native,immunoaffinity,L243,23e6 cells,100%,Q-Exactive,Easy-nLC (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 3-35 % B over 35 min, followed by a 35-95 % ACN gradient over 5 minutes and 95 % ACN for 8 minutes.",40,300 nl/min,10 cm long fused silica tip columns (OD 360 µm and ID 75 µm; SilicaTips™ New Objecnative Inc.) packed in-house. ,3 µm C18-AQ ReproSil-Pur®,
SYSMHC00016_20130301_05_Q3_PAT4.raw,SYSMHC00016_20130301_05_Q3_PAT4_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_05_Q3_PAT4,1,Human,In vivo,Bronchoalveolar lavage fluid,Macrophage,,sarcoidosis ,Mainly macrophage,class II,"DRB1_13,DRB1_14",27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive,Easy-nLC (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 3-35 % B over 35 min, followed by a 35-95 % ACN gradient over 5 minutes and 95 % ACN for 8 minutes.",40,300 nl/min,10 cm long fused silica tip columns (OD 360 µm and ID 75 µm; SilicaTips™ New Objecnative Inc.) packed in-house. ,3 µm C18-AQ ReproSil-Pur®,
SYSMHC00016_20130317_13_Q3_PAT5_rep1.raw,SYSMHC00016_20130317_13_Q3_PAT5_rep1_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_13_Q3_PAT5_rep1,1,Human,In vivo,Bronchoalveolar lavage fluid,Macrophage,,idiopatic pulmory fibrosis ,Mainly macrophage,class II,"DRB1_08,DRB1_13",27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive,Easy-nLC (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 3-35 % B over 35 min, followed by a 35-95 % ACN gradient over 5 minutes and 95 % ACN for 8 minutes.",40,300 nl/min,10 cm long fused silica tip columns (OD 360 µm and ID 75 µm; SilicaTips™ New Objecnative Inc.) packed in-house. ,3 µm C18-AQ ReproSil-Pur®,
SYSMHC00016_20130317_14_Q3_PAT5_rep2.raw,SYSMHC00016_20130317_14_Q3_PAT5_rep2_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_14_Q3_PAT5_rep2,1,Human,In vivo,Bronchoalveolar lavage fluid,Macrophage,,idiopatic pulmory fibrosis ,Mainly macrophage,class II,"DRB1_08,DRB1_13",27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive,Easy-nLC (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 3-35 % B over 35 min, followed by a 35-95 % ACN gradient over 5 minutes and 95 % ACN for 8 minutes.",40,300 nl/min,10 cm long fused silica tip columns (OD 360 µm and ID 75 µm; SilicaTips™ New Objecnative Inc.) packed in-house. ,3 µm C18-AQ ReproSil-Pur®,
SYSMHC00016_20130504_68_Q3_PAT6_10_rep1.raw,SYSMHC00016_20130504_68_Q3_PAT6_10_rep1_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_68_Q3_PAT6_10_rep1,1,Human,In vivo,Bronchoalveolar lavage fluid,Macrophage,,idiopathic interstitial pneumonia,Mainly macrophage,class II,,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive,Easy-nLC (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 3-35 % B over 35 min, followed by a 35-95 % ACN gradient over 5 minutes and 95 % ACN for 8 minutes.",40,300 nl/min,10 cm long fused silica tip columns (OD 360 µm and ID 75 µm; SilicaTips™ New Objecnative Inc.) packed in-house. ,3 µm C18-AQ ReproSil-Pur®,
SYSMHC00016_20130504_68_Q3_PAT6_10_rep2.raw,SYSMHC00016_20130504_68_Q3_PAT6_10_rep2_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_68_Q3_PAT6_10_rep2,1,Human,In vivo,Bronchoalveolar lavage fluid,Macrophage,,idiopathic interstitial pneumonia,Mainly macrophage,class II,,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive,Easy-nLC (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 3-35 % B over 35 min, followed by a 35-95 % ACN gradient over 5 minutes and 95 % ACN for 8 minutes.",40,300 nl/min,10 cm long fused silica tip columns (OD 360 µm and ID 75 µm; SilicaTips™ New Objecnative Inc.) packed in-house. ,3 µm C18-AQ ReproSil-Pur®,
SYSMHC00016_20130504_70_Q3_PAT6_50.raw,SYSMHC00016_20130504_70_Q3_PAT6_50_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_70_Q3_PAT6_50,1,Human,In vivo,Bronchoalveolar lavage fluid,Macrophage,,idiopathic interstitial pneumonia,Mainly macrophage,class II,,27452731,SYSMHC00016,native,immunoaffinity,L243,50e6 cells,100%,Q-Exactive,Easy-nLC (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 3-35 % B over 35 min, followed by a 35-95 % ACN gradient over 5 minutes and 95 % ACN for 8 minutes.",40,300 nl/min,10 cm long fused silica tip columns (OD 360 µm and ID 75 µm; SilicaTips™ New Objecnative Inc.) packed in-house. ,3 µm C18-AQ ReproSil-Pur®,
SYSMHC00016_20151029_04_Qp2_ajy_th_HLA-DR_1.raw,SYSMHC00016_20151029_04_Qp2_ajy_th_HLA-DR_1_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_04_Qp2_ajy_th_HLA-DR_1,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151029_05_Qp2_ajy_th_HLA-DR_3.raw,SYSMHC00016_20151029_05_Qp2_ajy_th_HLA-DR_3_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_05_Qp2_ajy_th_HLA-DR_3,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151029_06_Qp2_ajy_th_HLA-DR_4.raw,SYSMHC00016_20151029_06_Qp2_ajy_th_HLA-DR_4_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_06_Qp2_ajy_th_HLA-DR_4,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151029_07_Qp2_ajy_th_HLA-DR_7.raw,SYSMHC00016_20151029_07_Qp2_ajy_th_HLA-DR_7_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_07_Qp2_ajy_th_HLA-DR_7,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151029_08_Qp2_ajy_th_HLA-DR_11.raw,SYSMHC00016_20151029_08_Qp2_ajy_th_HLA-DR_11_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_08_Qp2_ajy_th_HLA-DR_11,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151029_09_Qp2_ajy_th_HLA-DR_14.raw,SYSMHC00016_20151029_09_Qp2_ajy_th_HLA-DR_14_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_09_Qp2_ajy_th_HLA-DR_14,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151029_10_Qp2_ajy_th_HLA-DR_17.raw,SYSMHC00016_20151029_10_Qp2_ajy_th_HLA-DR_17_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_10_Qp2_ajy_th_HLA-DR_17,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151029_11_Qp2_ajy_th_HLA-DR_18.raw,SYSMHC00016_20151029_11_Qp2_ajy_th_HLA-DR_18_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_11_Qp2_ajy_th_HLA-DR_18,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151029_12_Qp2_ajy_th_HLA-DR_19.raw,SYSMHC00016_20151029_12_Qp2_ajy_th_HLA-DR_19_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_12_Qp2_ajy_th_HLA-DR_19,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151029_13_Qp2_ajy_th_HLA-DR_20.raw,SYSMHC00016_20151029_13_Qp2_ajy_th_HLA-DR_20_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_13_Qp2_ajy_th_HLA-DR_20,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151029_14_Qp2_ajy_th_HLA-DR_21.raw,SYSMHC00016_20151029_14_Qp2_ajy_th_HLA-DR_21_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_14_Qp2_ajy_th_HLA-DR_21,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151029_15_Qp2_ajy_th_HLA-DR_22.raw,SYSMHC00016_20151029_15_Qp2_ajy_th_HLA-DR_22_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_15_Qp2_ajy_th_HLA-DR_22,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151029_16_Qp2_ajy_th_HLA-DR_24.raw,SYSMHC00016_20151029_16_Qp2_ajy_th_HLA-DR_24_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_16_Qp2_ajy_th_HLA-DR_24,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151029_17_Qp2_ajy_th_HLA-DR_26.raw,SYSMHC00016_20151029_17_Qp2_ajy_th_HLA-DR_26_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_17_Qp2_ajy_th_HLA-DR_26,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151029_18_Qp2_ajy_th_HLA-DR_27.raw,SYSMHC00016_20151029_18_Qp2_ajy_th_HLA-DR_27_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_18_Qp2_ajy_th_HLA-DR_27,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151029_19_Qp2_ajy_th_HLA-DR_31.raw,SYSMHC00016_20151029_19_Qp2_ajy_th_HLA-DR_31_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_19_Qp2_ajy_th_HLA-DR_31,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151106_05_Qp2_ajy_th_HLA-DR_2.raw,SYSMHC00016_20151106_05_Qp2_ajy_th_HLA-DR_2_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_05_Qp2_ajy_th_HLA-DR_2,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151106_06_Qp2_ajy_th_HLA-DR_5.raw,SYSMHC00016_20151106_06_Qp2_ajy_th_HLA-DR_5_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_06_Qp2_ajy_th_HLA-DR_5,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151106_07_Qp2_ajy_th_HLA-DR_6.raw,SYSMHC00016_20151106_07_Qp2_ajy_th_HLA-DR_6_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_07_Qp2_ajy_th_HLA-DR_6,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151106_08_Qp2_ajy_th_HLA-DR_9.raw,SYSMHC00016_20151106_08_Qp2_ajy_th_HLA-DR_9_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_08_Qp2_ajy_th_HLA-DR_9,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151106_09_Qp2_ajy_th_HLA-DR_10.raw,SYSMHC00016_20151106_09_Qp2_ajy_th_HLA-DR_10_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_09_Qp2_ajy_th_HLA-DR_10,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151106_10_Qp2_ajy_th_HLA-DR_12.raw,SYSMHC00016_20151106_10_Qp2_ajy_th_HLA-DR_12_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_10_Qp2_ajy_th_HLA-DR_12,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151106_11_Qp2_ajy_th_HLA-DR_13.raw,SYSMHC00016_20151106_11_Qp2_ajy_th_HLA-DR_13_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_11_Qp2_ajy_th_HLA-DR_13,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151106_12_Qp2_ajy_th_HLA-DR_15.raw,SYSMHC00016_20151106_12_Qp2_ajy_th_HLA-DR_15_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_12_Qp2_ajy_th_HLA-DR_15,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151106_13_Qp2_ajy_th_HLA-DR_16.raw,SYSMHC00016_20151106_13_Qp2_ajy_th_HLA-DR_16_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_13_Qp2_ajy_th_HLA-DR_16,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151106_14_Qp2_ajy_th_HLA-DR_23.raw,SYSMHC00016_20151106_14_Qp2_ajy_th_HLA-DR_23_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_14_Qp2_ajy_th_HLA-DR_23,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151106_15_Qp2_ajy_th_HLA-DR_28.raw,SYSMHC00016_20151106_15_Qp2_ajy_th_HLA-DR_28_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_15_Qp2_ajy_th_HLA-DR_28,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20151106_16_Qp2_ajy_th_HLA-DR_30.raw,SYSMHC00016_20151106_16_Qp2_ajy_th_HLA-DR_30_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_16_Qp2_ajy_th_HLA-DR_30,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20160114_03_Qp2_Bcell_38.raw,SYSMHC00016_20160114_03_Qp2_Bcell_38_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_03_Qp2_Bcell_38,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20160114_04_Qp2_Bcell_33.raw,SYSMHC00016_20160114_04_Qp2_Bcell_33_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_04_Qp2_Bcell_33,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20160114_05_Qp2_BAL_6.raw,SYSMHC00016_20160114_05_Qp2_BAL_6_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_05_Qp2_BAL_6,1,Human,In vivo,Bronchoalveolar lavage fluid,Macrophage,,sarcoidosis ,Mainly macrophage,class II,"DRB1_03,DRB1_15",27452731,SYSMHC00016,native,immunoaffinity,L243,11.5e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20160114_06_Qp2_Bcell_36.raw,SYSMHC00016_20160114_06_Qp2_Bcell_36_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_06_Qp2_Bcell_36,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20160114_07_Qp2_BAL_3.raw,SYSMHC00016_20160114_07_Qp2_BAL_3_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_07_Qp2_BAL_3,1,Human,In vivo,Bronchoalveolar lavage fluid,Macrophage,,sarcoidosis ,Mainly macrophage,class II,"DRB1_03,DRB1_15",27452731,SYSMHC00016,native,immunoaffinity,L243,11.5e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20160114_08_Qp2_BAL_1.raw,SYSMHC00016_20160114_08_Qp2_BAL_1_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_08_Qp2_BAL_1,1,Human,In vivo,Bronchoalveolar lavage fluid,Macrophage,,sarcoidosis ,Mainly macrophage,class II,"DRB1_03,DRB1_15",27452731,SYSMHC00016,native,immunoaffinity,L243,11.5e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20160114_09_Qp2_Bcell_34.raw,SYSMHC00016_20160114_09_Qp2_Bcell_34_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_09_Qp2_Bcell_34,1,Human,In vitro,Blood,B lymphoblast,,,EBV transformed,class II,DRB1_0401,27452731,SYSMHC00016,native,immunoaffinity,L243,10e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00016_20160114_10_Qp2_BAL_4.raw,SYSMHC00016_20160114_10_Qp2_BAL_4_c.mzXML,SYSMHC00016_Heydert_161006_Ytterberg_Sweden_10_Qp2_BAL_4,1,Human,In vivo,Bronchoalveolar lavage fluid,Macrophage,,sarcoidosis ,Mainly macrophage,class II,"DRB1_03,DRB1_15",27452731,SYSMHC00016,native,immunoaffinity,L243,11.5e6 cells,100%,Q-Exactive plus,noUltimate 3000 (Thermo Fisher Scientific),no,DDA,HCD,"The separation was achieved using ACN/water gradients (buffer A: 2 % ACN, 0.1 % FA; buffer B: 98 % ACN, 0.1 % FA) of 4-26 % B over 60 min, followed by 26-95 % over 5 min. ",65,300 nl/min,"Acclaim® PepMap100 C18, 3 µm, 100 Å precolumn (Thermo Scientific) together with a heated (55°C) 25 cm long PicoFrit® self-pack alytical column (360 µm OD, 75 µm ID, 10 µm tip, non-coated; New Objecnative Inc.). ",Reprosil-pur AQ C18 1.9 µm (Dr. Maisch GmbH),
SYSMHC00017_1001.raw,SYSMHC00017_1001_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1001,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_S9037,class II,DQ7.5,25502872,SYSMHC00017,native,immunoaffinity,SPV-L3 (anti-DQ),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1002.raw,SYSMHC00017_1002_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1002,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_S9037,class II,DQ7.5,25502872,SYSMHC00017,native,immunoaffinity,SPV-L3 (anti-DQ),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1003.raw,SYSMHC00017_1003_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1003,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_S9037,class II,DQ7.5,25502872,SYSMHC00017,native,immunoaffinity,SPV-L3 (anti-DQ),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1204.raw,SYSMHC00017_1204_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1204,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_S9087,class II,DQ2.5,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1205.raw,SYSMHC00017_1205_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1205,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_S9087,class II,DQ2.5,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1206.raw,SYSMHC00017_1206_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1206,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_S9087,class II,DQ2.5,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1207.raw,SYSMHC00017_1207_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1207,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_P9047,class II,DQ2.2,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1208.raw,SYSMHC00017_1208_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1208,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_P9047,class II,DQ2.2,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1209.raw,SYSMHC00017_1209_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1209,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_P9047,class II,DQ2.2,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1210.raw,SYSMHC00017_1210_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1210,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_S9037,class II,DQ7.5,25502872,SYSMHC00017,native,immunoaffinity,SPV-L3 (anti-DQ),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1212.raw,SYSMHC00017_1212_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1212,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_S9037,class II,DQ7.5,25502872,SYSMHC00017,native,immunoaffinity,SPV-L3 (anti-DQ),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1216.raw,SYSMHC00017_1216_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1216,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_P9047,class II,DQ2.2,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1217.raw,SYSMHC00017_1217_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1217,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_P9047,class II,DQ2.2,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1218.raw,SYSMHC00017_1218_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1218,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_P9047,class II,DQ2.2,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1401.raw,SYSMHC00017_1401_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1401,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_M9050,class II,DQ2.2,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1402.raw,SYSMHC00017_1402_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1402,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_M9050,class II,DQ2.2,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1403.raw,SYSMHC00017_1403_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1403,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_M9050,class II,DQ2.2,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1405.raw,SYSMHC00017_1405_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1405,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_CD114,class II,DQ2.5,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1406.raw,SYSMHC00017_1406_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1406,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_CD114,class II,DQ2.5,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1407.raw,SYSMHC00017_1407_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1407,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_CD114,class II,DQ2.5,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1409.raw,SYSMHC00017_1409_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1409,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_A9064,class II,DQ7.5,25502872,SYSMHC00017,native,immunoaffinity,SPV-L3 (anti-DQ),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1410.raw,SYSMHC00017_1410_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1410,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_A9064,class II,DQ7.5,25502872,SYSMHC00017,native,immunoaffinity,SPV-L3 (anti-DQ),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1411.raw,SYSMHC00017_1411_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1411,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_A9064,class II,DQ7.5,25502872,SYSMHC00017,native,immunoaffinity,SPV-L3 (anti-DQ),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1413.raw,SYSMHC00017_1413_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1413,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_P9088,class II,DQ2.5,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1414.raw,SYSMHC00017_1414_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1414,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_P9088,class II,DQ2.5,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1415.raw,SYSMHC00017_1415_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1415,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_P9088,class II,DQ2.5,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1417.raw,SYSMHC00017_1417_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1417,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_P9051,class II,DQ2.2,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1418.raw,SYSMHC00017_1418_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1418,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_P9051,class II,DQ2.2,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1419.raw,SYSMHC00017_1419_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1419,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_P9051,class II,DQ2.2,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1421.raw,SYSMHC00017_1421_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1421,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_B9089,class II,DQ7.5,25502872,SYSMHC00017,native,immunoaffinity,SPV-L3 (anti-DQ),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1422.raw,SYSMHC00017_1422_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1422,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_B9089,class II,DQ7.5,25502872,SYSMHC00017,native,immunoaffinity,SPV-L3 (anti-DQ),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1423.raw,SYSMHC00017_1423_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1423,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_B9089,class II,DQ7.5,25502872,SYSMHC00017,native,immunoaffinity,SPV-L3 (anti-DQ),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1492.raw,SYSMHC00017_1492_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1492,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_P9088,class II,DQ2.5,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1493.raw,SYSMHC00017_1493_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1493,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_P9088,class II,DQ2.5,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1494.raw,SYSMHC00017_1494_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1494,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_P9088,class II,DQ2.5,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1858.raw,SYSMHC00017_1858_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1858,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_B9089,class II,DQ7.5,25502872,SYSMHC00017,native,immunoaffinity,SPV-L3 (anti-DQ),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1859.raw,SYSMHC00017_1859_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1859,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_B9089,class II,DQ7.5,25502872,SYSMHC00017,native,immunoaffinity,SPV-L3 (anti-DQ),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1860.raw,SYSMHC00017_1860_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1860,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_B9089,class II,DQ7.5,25502872,SYSMHC00017,native,immunoaffinity,SPV-L3 (anti-DQ),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1862.raw,SYSMHC00017_1862_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1862,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_A9064,class II,DQ7.5,25502872,SYSMHC00017,native,immunoaffinity,SPV-L3 (anti-DQ),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1863.raw,SYSMHC00017_1863_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1863,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_A9064,class II,DQ7.5,25502872,SYSMHC00017,native,immunoaffinity,SPV-L3 (anti-DQ),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1864.raw,SYSMHC00017_1864_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1864,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_A9064,class II,DQ7.5,25502872,SYSMHC00017,native,immunoaffinity,SPV-L3 (anti-DQ),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1866.raw,SYSMHC00017_1866_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1866,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_P9051,class II,DQ2.2,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1867.raw,SYSMHC00017_1867_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1867,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_P9051,class II,DQ2.2,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_1868.raw,SYSMHC00017_1868_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_1868,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_P9051,class II,DQ2.2,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_2019.raw,SYSMHC00017_2019_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_2019,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_S9087,class II,DQ2.5,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_2020.raw,SYSMHC00017_2020_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_2020,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_S9087,class II,DQ2.5,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_2021.raw,SYSMHC00017_2021_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_2021,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_S9087,class II,DQ2.5,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_831.raw,SYSMHC00017_831_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_831,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_CD114,class II,DQ2.5,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_832.raw,SYSMHC00017_832_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_832,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_CD114,class II,DQ2.5,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_833.raw,SYSMHC00017_833_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_833,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_CD114,class II,DQ2.5,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_997.raw,SYSMHC00017_997_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_997,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_M9050,class II,DQ2.2,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_998.raw,SYSMHC00017_998_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_998,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_M9050,class II,DQ2.2,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00017_999.raw,SYSMHC00017_999_c.mzXML,SYSMHC00017_Bergsenge_161006_Sollid_Norway_999,1,Human,In vitro,Blood,B lymphoblast,suspension,,EBV transformed_M9050,class II,DQ2.2,25502872,SYSMHC00017,native,immunoaffinity,2.12.E11 (anti-DQ2),7x10e7 cells,,Q-Exactive,Dionex Ultimate 3000 no-LC,no,DDA,,"5-50% B in 45 min, 90% B for 15 min",60 min,300 nL/min,Acclaim PepMap100 RSLC,C18," (A - 0.1% FA in H20, B - 90% ACN 0.1% FA in H20)"
SYSMHC00019_LA2SF_1_Orbitrap.raw,SYSMHC00019_LA2SF_1_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA2SF,1,Human ,in vivo,,synovial fluid mononuclear cells,,Lyme arthritis,disease duration 1.6 years,class II,"DRB1_1001,DRB1_1101",27726376,SYSMHC00019,native,immunoaffinity,L243,6.4×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA2SF_2_Orbitrap.raw,SYSMHC00019_LA2SF_2_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA2SF,2,Human ,in vivo,,synovial fluid mononuclear cells,,Lyme arthritis,disease duration 1.6 years,class II,"DRB1_1001,DRB1_1101",27726376,SYSMHC00019,native,immunoaffinity,L243,6.4×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA2SF_3_Orbitrap.raw,SYSMHC00019_LA2SF_3_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA2SF,3,Human ,in vivo,,synovial fluid mononuclear cells,,Lyme arthritis,disease duration 1.6 years,class II,"DRB1_1001,DRB1_1101",27726376,SYSMHC00019,native,immunoaffinity,L243,6.4×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA2SF_4_Orbitrap.raw,SYSMHC00019_LA2SF_4_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA2SF,4,Human ,in vivo,,synovial fluid mononuclear cells,,Lyme arthritis,disease duration 1.6 years,class II,"DRB1_1001,DRB1_1101",27726376,SYSMHC00019,native,immunoaffinity,L243,6.4×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA3ST_1_Orbitrap.RAW,SYSMHC00019_LA3ST_1_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA3ST,1,Human ,in vivo,Synovium,,,Lyme arthritis,disease duration 0.5 year,class II,"DRB1_0301,DRB1_1501",27726376,SYSMHC00019,native,immunoaffinity,L243,7-10 grams ,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA3ST_2_Orbitrap.RAW,SYSMHC00019_LA3ST_2_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA3ST,2,Human ,in vivo,Synovium,,,Lyme arthritis,disease duration 0.5 year,class II,"DRB1_0301,DRB1_1501",27726376,SYSMHC00019,native,immunoaffinity,L243,7-10 grams ,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA3ST_3_Orbitrap.RAW,SYSMHC00019_LA3ST_3_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA3ST,3,Human ,in vivo,Synovium,,,Lyme arthritis,disease duration 0.5 year,class II,"DRB1_0301,DRB1_1501",27726376,SYSMHC00019,native,immunoaffinity,L243,7-10 grams ,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA3ST_4_Orbitrap.RAW,SYSMHC00019_LA3ST_4_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA3ST,4,Human ,in vivo,Synovium,,,Lyme arthritis,disease duration 0.5 year,class II,"DRB1_0301,DRB1_1501",27726376,SYSMHC00019,native,immunoaffinity,L243,7-10 grams ,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA4ST_1_Orbitrap.RAW,SYSMHC00019_LA4ST_1_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA4ST,1,Human ,in vivo,Synovium,,,Lyme arthritis,disease duration 1.6 years,class II,"DRB1_1101,DRB1_1302",27726376,SYSMHC00019,native,immunoaffinity,L243,7-10 grams ,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA4ST_2_Orbitrap.RAW,SYSMHC00019_LA4ST_2_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA4ST,2,Human ,in vivo,Synovium,,,Lyme arthritis,disease duration 1.6 years,class II,"DRB1_1101,DRB1_1302",27726376,SYSMHC00019,native,immunoaffinity,L243,7-10 grams ,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA4ST_3_Orbitrap.RAW,SYSMHC00019_LA4ST_3_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA4ST,3,Human ,in vivo,Synovium,,,Lyme arthritis,disease duration 1.6 years,class II,"DRB1_1101,DRB1_1302",27726376,SYSMHC00019,native,immunoaffinity,L243,7-10 grams ,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA4ST_4_Orbitrap.RAW,SYSMHC00019_LA4ST_4_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA4ST,4,Human ,in vivo,Synovium,,,Lyme arthritis,disease duration 1.6 years,class II,"DRB1_1101,DRB1_1302",27726376,SYSMHC00019,native,immunoaffinity,L243,7-10 grams ,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA5PB_1_Orbitrap.raw,SYSMHC00019_LA5PB_1_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA5PB,1,Human ,in vivo,Blood,PBMC,,Lyme arthritis,disease duration 4 years,class II,"DRB1_0301,DRB1_0305",27726376,SYSMHC00019,native,immunoaffinity,L243,4.2×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA5PB_2_Orbitrap.raw,SYSMHC00019_LA5PB_2_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA5PB,2,Human ,in vivo,Blood,PBMC,,Lyme arthritis,disease duration 4 years,class II,"DRB1_0301,DRB1_0305",27726376,SYSMHC00019,native,immunoaffinity,L243,4.2×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA5PB_3_Orbitrap.raw,SYSMHC00019_LA5PB_3_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA5PB,3,Human ,in vivo,Blood,PBMC,,Lyme arthritis,disease duration 4 years,class II,"DRB1_0301,DRB1_0305",27726376,SYSMHC00019,native,immunoaffinity,L243,4.2×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA5PB_4_Orbitrap.raw,SYSMHC00019_LA5PB_4_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA5PB,4,Human ,in vivo,Blood,PBMC,,Lyme arthritis,disease duration 4 years,class II,"DRB1_0301,DRB1_0305",27726376,SYSMHC00019,native,immunoaffinity,L243,4.2×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA5PB_5_Orbitrap.raw,SYSMHC00019_LA5PB_5_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA5PB,5,Human ,in vivo,Blood,PBMC,,Lyme arthritis,disease duration 4 years,class II,"DRB1_0301,DRB1_0305",27726376,SYSMHC00019,native,immunoaffinity,L243,4.2×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA5SF_1_Orbitrap.raw,SYSMHC00019_LA5SF_1_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA5SF,1,Human ,in vivo,,synovial fluid mononuclear cells,,Lyme arthritis,disease duration 4 years,class II,"DRB1_0301,DRB1_0305",27726376,SYSMHC00019,native,immunoaffinity,L243,3.4×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA5SF_2_Orbitrap.raw,SYSMHC00019_LA5SF_2_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA5SF,2,Human ,in vivo,,synovial fluid mononuclear cells,,Lyme arthritis,disease duration 4 years,class II,"DRB1_0301,DRB1_0305",27726376,SYSMHC00019,native,immunoaffinity,L243,3.4×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA5SF_3_Orbitrap.raw,SYSMHC00019_LA5SF_3_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA5SF,3,Human ,in vivo,,synovial fluid mononuclear cells,,Lyme arthritis,disease duration 4 years,class II,"DRB1_0301,DRB1_0305",27726376,SYSMHC00019,native,immunoaffinity,L243,3.4×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA5SF_4_Orbitrap.raw,SYSMHC00019_LA5SF_4_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA5SF,4,Human ,in vivo,,synovial fluid mononuclear cells,,Lyme arthritis,disease duration 4 years,class II,"DRB1_0301,DRB1_0305",27726376,SYSMHC00019,native,immunoaffinity,L243,3.4×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA5SF_5_Orbitrap.raw,SYSMHC00019_LA5SF_5_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA5SF,5,Human ,in vivo,,synovial fluid mononuclear cells,,Lyme arthritis,disease duration 4 years,class II,"DRB1_0301,DRB1_0305",27726376,SYSMHC00019,native,immunoaffinity,L243,3.4×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA5ST_1_Orbitrap.RAW,SYSMHC00019_LA5ST_1_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA5ST,1,Human ,in vivo,Synovium,,,Lyme arthritis,disease duration 4 years,class II,"DRB1_0301,DRB1_0305",27726376,SYSMHC00019,native,immunoaffinity,L243,7-10 grams ,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA5ST_2_Orbitrap.RAW,SYSMHC00019_LA5ST_2_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA5ST,2,Human ,in vivo,Synovium,,,Lyme arthritis,disease duration 4 years,class II,"DRB1_0301,DRB1_0305",27726376,SYSMHC00019,native,immunoaffinity,L243,7-10 grams ,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA5ST_3_Orbitrap.RAW,SYSMHC00019_LA5ST_3_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA5ST,3,Human ,in vivo,Synovium,,,Lyme arthritis,disease duration 4 years,class II,"DRB1_0301,DRB1_0305",27726376,SYSMHC00019,native,immunoaffinity,L243,7-10 grams ,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA5ST_4_Orbitrap.RAW,SYSMHC00019_LA5ST_4_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA5ST,4,Human ,in vivo,Synovium,,,Lyme arthritis,disease duration 4 years,class II,"DRB1_0301,DRB1_0305",27726376,SYSMHC00019,native,immunoaffinity,L243,7-10 grams ,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA6PB_QEp.raw,SYSMHC00019_LA6PB_QEp_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA6PB_QE,1,Human ,in vivo,Blood,PBMC,,Lyme arthritis,disease duration 0.83 year,class II,"DRB1_0103,DRB1_0301",27726376,SYSMHC00019,native,immunoaffinity,L243,8.0×107,10%,Q-Exactive,Waters noAcquity UPLC ,no,DDA,HCD,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA6ST_1_Orbitrap.raw,SYSMHC00019_LA6ST_1_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA6ST,1,Human ,in vivo,Synovium,,,Lyme arthritis,disease duration 0.83 year,class II,"DRB1_0103,DRB1_0301",27726376,SYSMHC00019,native,immunoaffinity,L243,15 grams,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA6ST_2_Orbitrap.raw,SYSMHC00019_LA6ST_2_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA6ST,2,Human ,in vivo,Synovium,,,Lyme arthritis,disease duration 0.83 year,class II,"DRB1_0103,DRB1_0301",27726376,SYSMHC00019,native,immunoaffinity,L243,15 grams,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA7SF_QEp.raw,SYSMHC00019_LA7SF_QEp_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA7SF_QE,1,Human ,in vivo,,synovial fluid mononuclear cells,,Lyme arthritis,disease duration 0.83 year,class II,"DRB1_0403,DRB1_1501",27726376,SYSMHC00019,native,immunoaffinity,L243,5.9×107,10%,Q-Exactive,Waters noAcquity UPLC ,no,DDA,HCD,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA7ST_1_Orbitrap.raw,SYSMHC00019_LA7ST_1_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA7ST,1,Human ,in vivo,Synovium,,,Lyme arthritis,disease duration 0.83 year,class II,"DRB1_0403,DRB1_1501",27726376,SYSMHC00019,native,immunoaffinity,L243,14.5 grams,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA7ST_2_Orbitrap.raw,SYSMHC00019_LA7ST_2_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA7ST,2,Human ,in vivo,Synovium,,,Lyme arthritis,disease duration 0.83 year,class II,"DRB1_0403,DRB1_1501",27726376,SYSMHC00019,native,immunoaffinity,L243,14.5 grams,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA8SF_1_QEp.raw,SYSMHC00019_LA8SF_1_QEp_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA8SF_QE,1,Human ,in vivo,,synovial fluid mononuclear cells,,Lyme arthritis,disease duration 0.75 year,class II,"DRB1_0401,DRB1_1001",27726376,SYSMHC00019,native,immunoaffinity,L243,6.2×107,10%,Q-Exactive,Waters noAcquity UPLC ,no,DDA,HCD,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA8SF_2_QEp.raw,SYSMHC00019_LA8SF_2_QEp_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA8SF_QE,2,Human ,in vivo,,synovial fluid mononuclear cells,,Lyme arthritis,disease duration 0.75 year,class II,"DRB1_0401,DRB1_1001",27726376,SYSMHC00019,native,immunoaffinity,L243,6.2×107,10%,Q-Exactive,Waters noAcquity UPLC ,no,DDA,HCD,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_LA8ST_QEp.raw,SYSMHC00019_LA8ST_QEp_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_LA8ST_QE,1,Human ,in vivo,Synovium,,,Lyme arthritis,disease duration 0.75 year,class II,"DRB1_0401,DRB1_1001",27726376,SYSMHC00019,native,immunoaffinity,L243,17 grams,5%,Q-Exactive,Waters noAcquity UPLC ,no,DDA,HCD,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA2PB_1_Orbitrap.raw,SYSMHC00019_RA2PB_1_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA2PB,1,Human ,in vivo,Blood,PBMC,,rheumatoid arthritis,disease duration 3 years,class II,"DRB1_0101,DRB1_0401",27726376,SYSMHC00019,native,immunoaffinity,L243,6.3×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA2PB_2_Orbitrap.raw,SYSMHC00019_RA2PB_2_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA2PB,2,Human ,in vivo,Blood,PBMC,,rheumatoid arthritis,disease duration 3 years,class II,"DRB1_0101,DRB1_0401",27726376,SYSMHC00019,native,immunoaffinity,L243,6.3×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA2PB_3_Orbitrap.raw,SYSMHC00019_RA2PB_3_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA2PB,3,Human ,in vivo,Blood,PBMC,,rheumatoid arthritis,disease duration 3 years,class II,"DRB1_0101,DRB1_0401",27726376,SYSMHC00019,native,immunoaffinity,L243,6.3×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA2PB_4_Orbitrap.raw,SYSMHC00019_RA2PB_4_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA2PB,4,Human ,in vivo,Blood,PBMC,,rheumatoid arthritis,disease duration 3 years,class II,"DRB1_0101,DRB1_0401",27726376,SYSMHC00019,native,immunoaffinity,L243,6.3×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA2PB_QEp.raw,SYSMHC00019_RA2PB_QEp_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA2PB_QE,1,Human ,in vivo,Blood,PBMC,,rheumatoid arthritis,disease duration 3 years,class II,"DRB1_0101,DRB1_0401",27726376,SYSMHC00019,native,immunoaffinity,L243,6.3×107,10%,Q-Exactive,Waters noAcquity UPLC ,no,DDA,HCD,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA2SF_1_Orbitrap.raw,SYSMHC00019_RA2SF_1_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA2SF,1,Human ,in vivo,,synovial fluid mononuclear cells,,rheumatoid arthritis,disease duration 3 years,class II,"DRB1_0101,DRB1_0401",27726376,SYSMHC00019,native,immunoaffinity,L243,8.7×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA2SF_2_Orbitrap.raw,SYSMHC00019_RA2SF_2_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA2SF,2,Human ,in vivo,,synovial fluid mononuclear cells,,rheumatoid arthritis,disease duration 3 years,class II,"DRB1_0101,DRB1_0401",27726376,SYSMHC00019,native,immunoaffinity,L243,8.7×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA2SF_3_Orbitrap.raw,SYSMHC00019_RA2SF_3_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA2SF,3,Human ,in vivo,,synovial fluid mononuclear cells,,rheumatoid arthritis,disease duration 3 years,class II,"DRB1_0101,DRB1_0401",27726376,SYSMHC00019,native,immunoaffinity,L243,8.7×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA2SF_4_Orbitrap.raw,SYSMHC00019_RA2SF_4_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA2SF,4,Human ,in vivo,,synovial fluid mononuclear cells,,rheumatoid arthritis,disease duration 3 years,class II,"DRB1_0101,DRB1_0401",27726376,SYSMHC00019,native,immunoaffinity,L243,8.7×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA2SF_5_Orbitrap.raw,SYSMHC00019_RA2SF_5_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA2SF,5,Human ,in vivo,,synovial fluid mononuclear cells,,rheumatoid arthritis,disease duration 3 years,class II,"DRB1_0101,DRB1_0401",27726376,SYSMHC00019,native,immunoaffinity,L243,8.7×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA2SF_QEp.raw,SYSMHC00019_RA2SF_QEp_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA2SF_QE,1,Human ,in vivo,,synovial fluid mononuclear cells,,rheumatoid arthritis,disease duration 3 years,class II,"DRB1_0101,DRB1_0401",27726376,SYSMHC00019,native,immunoaffinity,L243,8.7×107,10%,Q-Exactive,Waters noAcquity UPLC ,no,DDA,HCD,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA2ST_QEp.raw,SYSMHC00019_RA2ST_QEp_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA2ST_QE,1,Human ,in vivo,Synovium,,,rheumatoid arthritis,disease duration 3 years,class II,"DRB1_0101,DRB1_0401",27726376,SYSMHC00019,native,immunoaffinity,L243,7-10 grams ,5%,Q-Exactive,Waters noAcquity UPLC ,no,DDA,HCD,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA3ST_1_Orbitrap.RAW,SYSMHC00019_RA3ST_1_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA3ST,1,Human ,in vivo,Synovium,,,rheumatoid arthritis,disease duration 7 years,class II,"DRB1_0101,DRB1_0401",27726376,SYSMHC00019,native,immunoaffinity,L243,7-10 grams ,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA3ST_2_Orbitrap.RAW,SYSMHC00019_RA3ST_2_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA3ST,2,Human ,in vivo,Synovium,,,rheumatoid arthritis,disease duration 7 years,class II,"DRB1_0101,DRB1_0401",27726376,SYSMHC00019,native,immunoaffinity,L243,7-10 grams ,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA3ST_3_Orbitrap.RAW,SYSMHC00019_RA3ST_3_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA3ST,3,Human ,in vivo,Synovium,,,rheumatoid arthritis,disease duration 7 years,class II,"DRB1_0101,DRB1_0401",27726376,SYSMHC00019,native,immunoaffinity,L243,7-10 grams ,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA3ST_4_Orbitrap.RAW,SYSMHC00019_RA3ST_4_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA3ST,4,Human ,in vivo,Synovium,,,rheumatoid arthritis,disease duration 7 years,class II,"DRB1_0101,DRB1_0401",27726376,SYSMHC00019,native,immunoaffinity,L243,7-10 grams ,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA4PB_1_Orbitrap.raw,SYSMHC00019_RA4PB_1_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA4PB,1,Human ,in vivo,Blood,PBMC,,rheumatoid arthritis,disease duration 1 year,class II,"DRB1_0401,DRB1_1501",27726376,SYSMHC00019,native,immunoaffinity,L243,3.0×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA4PB_2_Orbitrap.raw,SYSMHC00019_RA4PB_2_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA4PB,2,Human ,in vivo,Blood,PBMC,,rheumatoid arthritis,disease duration 1 year,class II,"DRB1_0401,DRB1_1501",27726376,SYSMHC00019,native,immunoaffinity,L243,3.0×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA4PB_3_Orbitrap.raw,SYSMHC00019_RA4PB_3_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA4PB,3,Human ,in vivo,Blood,PBMC,,rheumatoid arthritis,disease duration 1 year,class II,"DRB1_0401,DRB1_1501",27726376,SYSMHC00019,native,immunoaffinity,L243,3.0×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA4SF_1_Orbitrap.raw,SYSMHC00019_RA4SF_1_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA4SF,1,Human ,in vivo,,synovial fluid mononuclear cells,,rheumatoid arthritis,disease duration 1 year,class II,"DRB1_0401,DRB1_1501",27726376,SYSMHC00019,native,immunoaffinity,L243,3.6×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA4SF_2_Orbitrap.raw,SYSMHC00019_RA4SF_2_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA4SF,2,Human ,in vivo,,synovial fluid mononuclear cells,,rheumatoid arthritis,disease duration 1 year,class II,"DRB1_0401,DRB1_1501",27726376,SYSMHC00019,native,immunoaffinity,L243,3.6×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA4SF_3_Orbitrap.raw,SYSMHC00019_RA4SF_3_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA4SF,3,Human ,in vivo,,synovial fluid mononuclear cells,,rheumatoid arthritis,disease duration 1 year,class II,"DRB1_0401,DRB1_1501",27726376,SYSMHC00019,native,immunoaffinity,L243,3.6×107,10%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA5ST_1_Orbitrap.raw,SYSMHC00019_RA5ST_1_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA5ST,1,Human ,in vivo,Synovium,,,rheumatoid arthritis,disease duration 3 years,class II,"DRB1_0801,DRB1_1501",27726376,SYSMHC00019,native,immunoaffinity,L243,9.4 grams,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA5ST_2_Orbitrap.raw,SYSMHC00019_RA5ST_2_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA5ST,2,Human ,in vivo,Synovium,,,rheumatoid arthritis,disease duration 3 years,class II,"DRB1_0801,DRB1_1501",27726376,SYSMHC00019,native,immunoaffinity,L243,9.4 grams,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA5ST_3_Orbitrap.raw,SYSMHC00019_RA5ST_3_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA5ST,3,Human ,in vivo,Synovium,,,rheumatoid arthritis,disease duration 3 years,class II,"DRB1_0801,DRB1_1501",27726376,SYSMHC00019,native,immunoaffinity,L243,9.4 grams,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00019_RA5ST_4_Orbitrap.raw,SYSMHC00019_RA5ST_4_Orbitrap_c.mzXML,SYSMHC00019_Wangq_161024_Costello_USA_RA5ST,4,Human ,in vivo,Synovium,,,rheumatoid arthritis,disease duration 3 years,class II,"DRB1_0801,DRB1_1501",27726376,SYSMHC00019,native,immunoaffinity,L243,9.4 grams,5%,Orbitrap XL,Waters noAcquity UPLC ,no,DDA,CID,"Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN.",52 min,0.5 µL/min,"150 µm × 10 cm, 1.7 µm 130 Å BEH C18, Waters Corp",C18,linear gradient of buffer B from 2% to 40% over 52 min 
SYSMHC00020_carone_K151230_001_Mtbsynpep_THP1.mzXML,SYSMHC00020_carone_K151230_001_Mtbsynpep_THP1.mzXML,SYSMHC00020_carone_161024_aebersold_switzerland_Mtb_synpep_hlathp1,1,Mycobacterium tuberculosis,,,,,,predicted to bind class I,class I,"A02,A24,B15,B35,C03",,SYSMHC00020,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00020_carone_Y150824_001_synpMHCI_DDA.mzXML,SYSMHC00020_carone_Y150824_001_synpMHCI_DDA.mzXML,SYSMHC00020_carone_161024_aebersold_switzerland_Mtb_synpep_ottenhof,1,Mycobacterium tuberculosis,,,,,,predicted to bind class I,class I,"A0201,A0301,B0702,E",,SYSMHC00020,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00020_carone_Y150825_002_synpMHCI_4uL_DDA.mzXML,SYSMHC00020_carone_Y150825_002_synpMHCI_4uL_DDA.mzXML,SYSMHC00020_carone_161024_aebersold_switzerland_Mtb_synpep_ottenhof,2,Mycobacterium tuberculosis,,,,,,predicted to bind class I,class I,"A0201,A0301,B0702,E",,SYSMHC00020,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00021_carone_Y150824_001_synpMHCI_DDA.mzXML,SYSMHC00021_carone_Y150824_001_synpMHCI_DDA.mzXML,SYSMHC00021_carone_161024_aebersold_switzerland_EBV_synpep,1,Epstein-Barr virus,,,,,,predicted to bind class I,class I,"A02,B07",,SYSMHC00021,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00021_carone_Y150825_002_synpMHCI_4uL_DDA.mzXML,SYSMHC00021_carone_Y150825_002_synpMHCI_4uL_DDA.mzXML,SYSMHC00021_carone_161024_aebersold_switzerland_EBV_synpep,2,Epstein-Barr virus,,,,,,predicted to bind class I,class I,"A02,B07",,SYSMHC00021,synthetic,,,,,Triple-TOF 5600,no-LC Ultra HPLC (Eksigent),yes,DDA,CID,2-32% ACN,120,,,,
SYSMHC00022_140218_DK_SynPepLibrary_HLA-I_1pmol_25cm90min1s_msms1.RAW,SYSMHC00022_140218_DK_SynPepLibrary_HLA-I_1pmol_25cm90min1s_msms1_c.mzXML,SYSMHC00022_kowalewskid_161024_rammensee_germany_HLAI_synpep,1,human,,,,,,,class I,"A01,A02,A03,A24,B07,B13,B15,B18,B35,B44,B51",,SYSMHC00022,synthetic,,,,,Orbitrap XL,Ultimate3000 RSLCno,no,DDA,CID,2-32% ACN,120,,,,
SYSMHC00023_20140304_EXQ6_MiBa_SA_MM12-HLAp-1.raw,SYSMHC00023_20140304_EXQ6_MiBa_SA_MM12-HLAp-1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM12-HLAp-1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,B080101,C070101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140304_EXQ6_MiBa_SA_MM12-HLAp-2.raw,SYSMHC00023_20140304_EXQ6_MiBa_SA_MM12-HLAp-2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM12-HLAp-2,3,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,B080101,C070101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140304_EXQ6_MiBa_SA_MM3-HLAp-1.raw,SYSMHC00023_20140304_EXQ6_MiBa_SA_MM3-HLAp-1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM3-HLAp-1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140304_EXQ6_MiBa_SA_MM3-HLAp-2.raw,SYSMHC00023_20140304_EXQ6_MiBa_SA_MM3-HLAp-2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM3-HLAp-2,3,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140304_EXQ6_MiBa_SA_MM4-HLAp-1.raw,SYSMHC00023_20140304_EXQ6_MiBa_SA_MM4-HLAp-1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM4-HLAp-1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140304_EXQ6_MiBa_SA_MM4-HLAp-2.raw,SYSMHC00023_20140304_EXQ6_MiBa_SA_MM4-HLAp-2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM4-HLAp-2,3,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140305_EXQ6_MiBa_SA_MM5-HLAp-1.raw,SYSMHC00023_20140305_EXQ6_MiBa_SA_MM5-HLAp-1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM5-HLAp-1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A01,A25,B08,B18",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140305_EXQ6_MiBa_SA_MM5-HLAp-2.raw,SYSMHC00023_20140305_EXQ6_MiBa_SA_MM5-HLAp-2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM5-HLAp-2,3,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A01,A25,B08,B18",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140305_EXQ6_MiBa_SA_MM8-HLAp-1.raw,SYSMHC00023_20140305_EXQ6_MiBa_SA_MM8-HLAp-1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM8-HLAp-1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,A030101,B070201,B080101,C070101,C070201",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140305_EXQ6_MiBa_SA_MM8-HLAp-2.raw,SYSMHC00023_20140305_EXQ6_MiBa_SA_MM8-HLAp-2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM8-HLAp-2,3,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,A030101,B070201,B080101,C070101,C070201",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140306_EXQ6_MiBa_SA_MM12-HLAp-1.raw,SYSMHC00023_20140306_EXQ6_MiBa_SA_MM12-HLAp-1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM12-HLAp-1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,B080101,C070101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140306_EXQ6_MiBa_SA_MM12-HLAp-2.raw,SYSMHC00023_20140306_EXQ6_MiBa_SA_MM12-HLAp-2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM12-HLAp-2,4,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,B080101,C070101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140306_EXQ6_MiBa_SA_MM3-HLAp-1.raw,SYSMHC00023_20140306_EXQ6_MiBa_SA_MM3-HLAp-1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM3-HLAp-1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140306_EXQ6_MiBa_SA_MM3-HLAp-2.raw,SYSMHC00023_20140306_EXQ6_MiBa_SA_MM3-HLAp-2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM3-HLAp-2,4,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140306_EXQ6_MiBa_SA_MM4-HLAp-1.raw,SYSMHC00023_20140306_EXQ6_MiBa_SA_MM4-HLAp-1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM4-HLAp-1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140306_EXQ6_MiBa_SA_MM4-HLAp-2.raw,SYSMHC00023_20140306_EXQ6_MiBa_SA_MM4-HLAp-2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM4-HLAp-2,4,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140306_EXQ6_MiBa_SA_MM5-HLAp-1.raw,SYSMHC00023_20140306_EXQ6_MiBa_SA_MM5-HLAp-1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM5-HLAp-1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A01,A25,B08,B18",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140306_EXQ6_MiBa_SA_MM5-HLAp-2.raw,SYSMHC00023_20140306_EXQ6_MiBa_SA_MM5-HLAp-2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM5-HLAp-2,4,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A01,A25,B08,B18",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140306_EXQ6_MiBa_SA_MM8-HLAp-1.raw,SYSMHC00023_20140306_EXQ6_MiBa_SA_MM8-HLAp-1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM8-HLAp-1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,A030101,B070201,B080101,C070101,C070201",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20140306_EXQ6_MiBa_SA_MM8-HLAp-2.raw,SYSMHC00023_20140306_EXQ6_MiBa_SA_MM8-HLAp-2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_MM8-HLAp-2,4,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,A030101,B070201,B080101,C070101,C070201",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_1_A.raw,SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_1_A_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM15_1_A,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A030101,A680101,B270502,B350301,C020202,C040101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_1_B.raw,SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_1_B_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM15_1_B,3,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A030101,A680101,B270502,B350301,C020202,C040101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_2_A.raw,SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_2_A_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM15_2_A,5,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A030101,A680101,B270502,B350301,C020202,C040101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_2_B.raw,SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_2_B_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM15_2_B,7,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A030101,A680101,B270502,B350301,C020202,C040101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_3_A.raw,SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_3_A_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM15_3_A,9,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A030101,A680101,B270502,B350301,C020202,C040101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_4_A.raw,SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_4_A_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM15_4_A,13,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A030101,A680101,B270502,B350301,C020202,C040101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_4_B.raw,SYSMHC00023_20141208_QEp7_MiBa_SA_HLA-I-p_MM15_4_B_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM15_4_B,15,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A030101,A680101,B270502,B350301,C020202,C040101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_1_A_1.raw,SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_1_A_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM15_1_A_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A030101,A680101,B270502,B350301,C020202,C040101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_1_B_1.raw,SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_1_B_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM15_1_B_1,4,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A030101,A680101,B270502,B350301,C020202,C040101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_2_A_1.raw,SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_2_A_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM15_2_A_1,6,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A030101,A680101,B270502,B350301,C020202,C040101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_2_B_1.raw,SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_2_B_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM15_2_B_1,8,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A030101,A680101,B270502,B350301,C020202,C040101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_3_A_1.raw,SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_3_A_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM15_3_A_1,10,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A030101,A680101,B270502,B350301,C020202,C040101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_3_B_1.raw,SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_3_B_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM15_3_B_1,12,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A030101,A680101,B270502,B350301,C020202,C040101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_4_A_1.raw,SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_4_A_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM15_4_A_1,14,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A030101,A680101,B270502,B350301,C020202,C040101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_4_B_1.raw,SYSMHC00023_20141210_QEp7_MiBa_SA_HLA-I-p_MM15_4_B_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM15_4_B_1,16,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A030101,A680101,B270502,B350301,C020202,C040101",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141212_QEp7_MiBa_SA_HLA-I-p_MM16_1_A.raw,SYSMHC00023_20141212_QEp7_MiBa_SA_HLA-I-p_MM16_1_A_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM16_1_A,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,A240201,B070201,B080101,C070101,C070201",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141212_QEp7_MiBa_SA_HLA-I-p_MM16_1_B.raw,SYSMHC00023_20141212_QEp7_MiBa_SA_HLA-I-p_MM16_1_B_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM16_1_B,3,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,A240201,B070201,B080101,C070101,C070201",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141212_QEp7_MiBa_SA_HLA-I-p_MM16_2_A.raw,SYSMHC00023_20141212_QEp7_MiBa_SA_HLA-I-p_MM16_2_A_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM16_2_A,5,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,A240201,B070201,B080101,C070101,C070201",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141212_QEp7_MiBa_SA_HLA-I-p_MM16_2_B.raw,SYSMHC00023_20141212_QEp7_MiBa_SA_HLA-I-p_MM16_2_B_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM16_2_B,7,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,A240201,B070201,B080101,C070101,C070201",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141212_QEp7_MiBa_SA_HLA-I-p_MM16_3_A.raw,SYSMHC00023_20141212_QEp7_MiBa_SA_HLA-I-p_MM16_3_A_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM16_3_A,9,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,A240201,B070201,B080101,C070101,C070201",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141212_QEp7_MiBa_SA_HLA-I-p_MM16_3_B.raw,SYSMHC00023_20141212_QEp7_MiBa_SA_HLA-I-p_MM16_3_B_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM16_3_B,11,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,A240201,B070201,B080101,C070101,C070201",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141213_QEp7_MiBa_SA_HLA-I-p_MM16_1_A_1.raw,SYSMHC00023_20141213_QEp7_MiBa_SA_HLA-I-p_MM16_1_A_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM16_1_A_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,A240201,B070201,B080101,C070101,C070201",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141213_QEp7_MiBa_SA_HLA-I-p_MM16_2_A_1.raw,SYSMHC00023_20141213_QEp7_MiBa_SA_HLA-I-p_MM16_2_A_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM16_2_A_1,6,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,A240201,B070201,B080101,C070101,C070201",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141213_QEp7_MiBa_SA_HLA-I-p_MM16_2_B_1.raw,SYSMHC00023_20141213_QEp7_MiBa_SA_HLA-I-p_MM16_2_B_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM16_2_B_1,8,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,A240201,B070201,B080101,C070101,C070201",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141213_QEp7_MiBa_SA_HLA-I-p_MM16_3_A_1.raw,SYSMHC00023_20141213_QEp7_MiBa_SA_HLA-I-p_MM16_3_A_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM16_3_A_1,10,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,A240201,B070201,B080101,C070101,C070201",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141213_QEp7_MiBa_SA_HLA-I-p_MM16_3_B_1.raw,SYSMHC00023_20141213_QEp7_MiBa_SA_HLA-I-p_MM16_3_B_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM16_3_B_1,12,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,"A010101,A240201,B070201,B080101,C070101,C070201",27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MM21_1.raw,SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MM21_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM21_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MM21_2.raw,SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MM21_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM21_2,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MM21_3.raw,SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MM21_3_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM21_3,3,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MMf_18_1.raw,SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MMf_18_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_18_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MMf_18_2.raw,SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MMf_18_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_18_2,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MMf_18_3.raw,SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MMf_18_3_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_18_3,3,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MMf_4_1.raw,SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MMf_4_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_4_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MMf_4_2.raw,SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MMf_4_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_4_2,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MMf_4_3.raw,SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MMf_4_3_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_4_3,3,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MMf_5_1.raw,SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MMf_5_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_5_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MMf_5-2.raw,SYSMHC00023_20141214_QEp7_MiBa_SA_HLA-I-p_MMf_5-2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_5-2,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141215_QEp7_MiBa_SA_HLA-I-p_MMf_1_1.raw,SYSMHC00023_20141215_QEp7_MiBa_SA_HLA-I-p_MMf_1_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_1_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141215_QEp7_MiBa_SA_HLA-I-p_MMf_1_2.raw,SYSMHC00023_20141215_QEp7_MiBa_SA_HLA-I-p_MMf_1_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_1_2,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141215_QEp7_MiBa_SA_HLA-I-p_MMf_15_1.raw,SYSMHC00023_20141215_QEp7_MiBa_SA_HLA-I-p_MMf_15_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_15_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141215_QEp7_MiBa_SA_HLA-I-p_MMf_16_1.raw,SYSMHC00023_20141215_QEp7_MiBa_SA_HLA-I-p_MMf_16_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_16_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141215_QEp7_MiBa_SA_HLA-I-p_MMf_16_2.raw,SYSMHC00023_20141215_QEp7_MiBa_SA_HLA-I-p_MMf_16_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_16_2,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141215_QEp7_MiBa_SA_HLA-I-p_MMf_7_1.raw,SYSMHC00023_20141215_QEp7_MiBa_SA_HLA-I-p_MMf_7_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_7_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141215_QEp7_MiBa_SA_HLA-I-p_MMf_7-2.raw,SYSMHC00023_20141215_QEp7_MiBa_SA_HLA-I-p_MMf_7-2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_7-2,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141216_QEp7_MiBa_SA_HLA-I-p_MMf_10_1.raw,SYSMHC00023_20141216_QEp7_MiBa_SA_HLA-I-p_MMf_10_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_10_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141216_QEp7_MiBa_SA_HLA-I-p_MMf_10_2.raw,SYSMHC00023_20141216_QEp7_MiBa_SA_HLA-I-p_MMf_10_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_10_2,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141216_QEp7_MiBa_SA_HLA-I-p_MMf_2_1.raw,SYSMHC00023_20141216_QEp7_MiBa_SA_HLA-I-p_MMf_2_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_2_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141216_QEp7_MiBa_SA_HLA-I-p_MMf_2_2.raw,SYSMHC00023_20141216_QEp7_MiBa_SA_HLA-I-p_MMf_2_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_2_2,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141216_QEp7_MiBa_SA_HLA-I-p_MMf_3_1.raw,SYSMHC00023_20141216_QEp7_MiBa_SA_HLA-I-p_MMf_3_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_3_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141216_QEp7_MiBa_SA_HLA-I-p_MMf_3_2.raw,SYSMHC00023_20141216_QEp7_MiBa_SA_HLA-I-p_MMf_3_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_3_2,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141216_QEp7_MiBa_SA_HLA-I-p_MMf_6_1.raw,SYSMHC00023_20141216_QEp7_MiBa_SA_HLA-I-p_MMf_6_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_6_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141216_QEp7_MiBa_SA_HLA-I-p_MMf_6_2.raw,SYSMHC00023_20141216_QEp7_MiBa_SA_HLA-I-p_MMf_6_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_6_2,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141217_QEp7_MiBa_SA_HLA-I-p_MMf_13_1.raw,SYSMHC00023_20141217_QEp7_MiBa_SA_HLA-I-p_MMf_13_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_13_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141217_QEp7_MiBa_SA_HLA-I-p_MMf_13_2.raw,SYSMHC00023_20141217_QEp7_MiBa_SA_HLA-I-p_MMf_13_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_13_2,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141217_QEp7_MiBa_SA_HLA-I-p_MMf_17_1.raw,SYSMHC00023_20141217_QEp7_MiBa_SA_HLA-I-p_MMf_17_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_17_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141217_QEp7_MiBa_SA_HLA-I-p_MMf_17_2.raw,SYSMHC00023_20141217_QEp7_MiBa_SA_HLA-I-p_MMf_17_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_17_2,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MM_12_1.raw,SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MM_12_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM_12_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MM_12_2.raw,SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MM_12_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM_12_2,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MM_20_1.raw,SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MM_20_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM_20_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MM_20_2.raw,SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MM_20_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MM_20_2,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MMf_11_1.raw,SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MMf_11_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_11_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MMf_11_2.raw,SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MMf_11_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_11_2,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MMf_12_1.raw,SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MMf_12_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_12_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MMf_12_2.raw,SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MMf_12_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_12_2,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MMf_19_1.raw,SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MMf_19_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_19_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MMf_19_2.raw,SYSMHC00023_20141218_QEp7_MiBa_SA_HLA-I-p_MMf_19_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-I-p_MMf_19_2,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class I,,27869121,SYSMHC00023,native,immunoaffinity,W6/32 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141220_QEp7_MiBa_SA_HLA-II-p_MM15_1_1.raw,SYSMHC00023_20141220_QEp7_MiBa_SA_HLA-II-p_MM15_1_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM15_1_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141220_QEp7_MiBa_SA_HLA-II-p_MM15_1.raw,SYSMHC00023_20141220_QEp7_MiBa_SA_HLA-II-p_MM15_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM15_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141220_QEp7_MiBa_SA_HLA-II-p_MM15_2_1.raw,SYSMHC00023_20141220_QEp7_MiBa_SA_HLA-II-p_MM15_2_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM15_2_1,4,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141220_QEp7_MiBa_SA_HLA-II-p_MM15_2.raw,SYSMHC00023_20141220_QEp7_MiBa_SA_HLA-II-p_MM15_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM15_2,3,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141220_QEp7_MiBa_SA_HLA-II-p_MM15_3_1.raw,SYSMHC00023_20141220_QEp7_MiBa_SA_HLA-II-p_MM15_3_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM15_3_1,6,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141220_QEp7_MiBa_SA_HLA-II-p_MM15_3.raw,SYSMHC00023_20141220_QEp7_MiBa_SA_HLA-II-p_MM15_3_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM15_3,5,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141220_QEp7_MiBa_SA_HLA-II-p_MM15_4_1.raw,SYSMHC00023_20141220_QEp7_MiBa_SA_HLA-II-p_MM15_4_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM15_4_1,8,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141220_QEp7_MiBa_SA_HLA-II-p_MM15_4.raw,SYSMHC00023_20141220_QEp7_MiBa_SA_HLA-II-p_MM15_4_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM15_4,7,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MM16_1_1.raw,SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MM16_1_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM16_1_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MM16_1.raw,SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MM16_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM16_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MM16_2_1.raw,SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MM16_2_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM16_2_1,4,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MM16_2.raw,SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MM16_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM16_2,3,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MM16_3_1.raw,SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MM16_3_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM16_3_1,6,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MM16_3.raw,SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MM16_3_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM16_3,5,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MM21_1.raw,SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MM21_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM21_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MM21.raw,SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MM21_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM21,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MMf_16_1.raw,SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MMf_16_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_16_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MMf_16.raw,SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MMf_16_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_16,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MMf_18_1.raw,SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MMf_18_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_18_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MMf_18.raw,SYSMHC00023_20141221_QEp7_MiBa_SA_HLA-II-p_MMf_18_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_18_,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_1_1.raw,SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_1_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_1_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_1.raw,SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_1,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_13_1.raw,SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_13_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_13_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_13.raw,SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_13_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_13,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_15_1.raw,SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_15_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_15_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_15.raw,SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_15_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_15_,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_4_1.raw,SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_4_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_4_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_4.raw,SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_4_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_4,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_7_1.raw,SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_7_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_7_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_7.raw,SYSMHC00023_20141222_QEp7_MiBa_SA_HLA-II-p_MMf_7_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_7,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_10_1.raw,SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_10_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_10_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_10.raw,SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_10_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_10,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_11_1.raw,SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_11_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_11_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_11.raw,SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_11_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_11,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_2_1.raw,SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_2_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_2_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_2.raw,SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_2_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_2,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_3_1.raw,SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_3_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_3_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_3.raw,SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_3_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_3,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_5_1.raw,SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_5_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_5_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_5.raw,SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_5_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_5,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_6_1.raw,SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_6_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_6_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_6.raw,SYSMHC00023_20141224_QEp7_MiBa_SA_HLA-II-p_MMf_6_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_6,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MM12_141226122233.raw,SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MM12_141226122233_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM12_141226122233,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MM12.raw,SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MM12_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM12,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MM20_141226211948.raw,SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MM20_141226211948_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM20_141226211948,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MM20.raw,SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MM20_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MM20,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MMf_12_1.raw,SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MMf_12_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_12_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MMf_12.raw,SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MMf_12_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_12,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MMf_17_1.raw,SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MMf_17_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_17_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MMf_17.raw,SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MMf_17_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_17_,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MMf_19_1.raw,SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MMf_19_1_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_19_1,2,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MMf_19.raw,SYSMHC00023_20141225_QEp7_MiBa_SA_HLA-II-p_MMf_19_c.mzXML,SYSMHC00023_bassanim_161205_Mann_Germany_HLA-II-p_MMf_19_,1,Human,In vivo,Skin,Melanoma,,Metastatic,,class II,,27869121,SYSMHC00023,native,immunoaffinity,HB-145 ,,,Q-Exactive HF,"no-LC, Proxeon Biosystems, Thermo",no,DDA,HCD,2-30% ACN,90,250 nL/min,"75um x 50cm, 1.9um C18-AQ",,
